Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  09-SEP-2019A Multiple-Dose Clinical Study to Evaluate the Safety, Tolerability,
Pharmacokinetics and QTc Effect of MK-8189 in Participants With 
Schizophrenia and Healthy Participants
PRODUCT: MK-8189  1
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A multiple -dose clinical stud y to evaluate the safet y, tolerability , 
pharmacokinetics and QTc effect of MK -8189 in participants with schizophrenia and healthy  
participants .
Protocol Number: 007-06
Compound Numb er:MK-8189
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND 118,986
Approval Date: 09 September 2019Â 
Â  059Y88
PRODUCT: MK-8189  2
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:DateÂ 
Â  059Y88
PRODUCT: MK-8189  3
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 06 09-Sep-2019 Outdated protocol template language needed to be deleted from the contraception 
inclusion criteria to fix discrepancies and redundancies with the new language added in 
Amendment 05.
Amendment 05 15-Aug-2019 Updated Panel D to include 20 participants with schizophrenia, ECG Holter monitoring 
and an increase to a maximum dose of 48 mg. 
Amendment 04 27- Sep-2018 Addition of Panel D to evaluate the safet y, tolerability  and pharmacokinetics (PK) of MK -
8189 as monotherap y at doses up to 36 mg in healthy  participants.
Amendment 03 06- Aug-2018 Addition of Panel C to evaluate the safet y, tolerability  and pharmacokinetics (PK) of MK -
8189 as add- on therapy .
Amendment 02 19-Jul-2018 The additional assessments included in Protocol 007 Amendment 02 are to enhance safety  
monitoring based on consultation with a health authority . Medications permitted during 
the antipsy chotic washout period and trial were added and additional protocol 
clarifications were made throughout.
Amendment 01 28-Jun-2018 The protocol was amended to allow subjects to begin their washout as an outpatient if the 
investigator deems it appropr iate for a participant, the caf feine consumption restriction 
was updated on PK/ECG Holter day s as it is not considered to impact the QTc/PK 
analysis or the PK of MK -8189 and Panel B eligibility  was updated to include evaluation 
of the screening laboratory  values. Additional changes were included to improve study  
logistics, clarify  protocol language andcorrect t ypographical errors.
Original Protocol 17-May-2018 Not applicableÂ 
Â  059Y88
PRODUCT: MK-8189  4
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 06
Overall Rationale for the Amendments:
Outdated contraception protocol template language needed to be deleted from the inclusion criteria to fix discrepancies and
redundan cieswith the new language added in Amendment 05 .
Summary of Changes Table:
Section # and Name Description of Change Brief Rationale  
5.1.2 Panel B, Panel 
C and Panel D 
(Participants with 
Schizophrenia) 
Inclusion CriteriaThe following language was removed from inclusion #24: 
a.If the participant is a female with reproductive potential, she must 
demonstrate a serum Î² -human chorionic gonadotropin (Î² -hCG) 
level consistent with the nongravid state at the prestudy  (screening) 
visit and agree to use (and/or have their partner use) 2 a cceptable 
methods of birth control beginning at the prestudy (screening) visit, 
throughout the stud y (including washout intervals between 
treatment periods/panels) and until 2 weeks after the last dose of 
study  drug in the last treatment period. Acceptable methods of birth 
control are defined in Appendix 5.
b.If the participant is a postmenopausal female: she is without menses 
for at least 1 year and has a FSH value in the postmenopausal range 
upon prestudy  (screening) evaluation.
c.If the participant is a surg ically  sterile female: she is status post 
hysterectom y, oophorectomy  or tubal ligation. Note: I nformation 
regarding the procedure may be based on the participantâ€™s recall of 
her medical history , and details of the recall must be captured 
appropriatel y within the site's source documents.This section contained language 
that was discrepant andredundant
to the updated contraception 
language presented in Appendix 5.
The contraception language in 
Appendix 5 is based upon Clinical
Trial Facilitation Group (CTFG)
recommendations and aligns with 
TransCelerate Common Protocol 
Template (CPT) guidelines for 
contraception which takes into 
account feedback from health 
authori ties and regulators 
regarding acceptable contraception 
requirements.Â 
Â  059Y88
PRODUCT: MK-8189  5
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Section # and Name Description of Change Brief Rationale  
2.2.2. Prec linical and 
Clinical StudiesIn the Clinical Study  summary , the number of discontinuations due to 
AE in the Phase 1 studies was updated from 8 to 9.The change reflects the true 
number of discontinuations 
throughout the Phase 1 program.Â 
Â  059Y88
PRODUCT: MK-8189  6
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 17
1.3 Schedule of Activities (SoA) ................................................................................ 19
2 INTRODUCTION .......................................................................................................... 29
2.1 Study Rationale ....................................................................................................29
2.2 Background .......................................................................................................... 29
Pharmaceutical and Therapeutic Background ............................................. 30
Preclinical and Clinical Studies ...................................................................30
Ongoing Clinical .......................................................................................... 35
2.3 Benefit/Risk Assessment ...................................................................................... 37
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 38
4 STUDY DESIGN ............................................................................................................ 39
4.1 Overall Design ......................................................................................................39
4.2 Scientific Rationale for Study Design ................................................................ .41
Rationale for Endpoints ............................................................................... 42
4.2.1.1 Safety  Endpoints ................................................................................ 42
4.2.1.2 Pharmacokinetic Endpoints ............................................................... 43
4.2.1.3 Pharmacod ynamic Endpoints ............................................................. 44
4.2.1.4 Planned Exploratory  Biomarker Research ......................................... 44
4.2.1.4.1 Planned Genetic Anal ysis........................................................ 44
4.2.1.5 Future Biomedical Research .............................................................. 45
Rationale for the Use of Comparator/Placebo ............................................. 45
Rationale for Suicidal Ideation and Be havior Monitoring ........................... 45
4.3 Justification for Dose ........................................................................................... 45
Starting Dose for This Study ........................................................................46
Maximum Dose/Exposure for This Study ................................................... 46
Rationale for Dose Interval and Study Design ............................................ 47
4.4 Beginning and End of Study Definition ............................................................. 48
Clinical Criteria for Early Study Termination ............................................. 49
5 STUDY POPULATION ................................................................................................ 49
5.1 Inclusion Criteria ................................................................................................ .49
Panel A (Healthy  Participants) Inclusion Criteria .......................................49Â 
Â  059Y88
PRODUCT: MK-8189  7
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panel B, Panel C and Panel D (Participants with Schizophrenia) 
Inclusion Criteria ......................................................................................... 51
5.2 Exclusion Criteria ................................................................................................ 53
Panel A (Healthy  Participants) Exclusion Criteria ......................................53
Panel B, Panel C, and Panel D (Participants with Schizophrenia) 
Exclusion Criteria ........................................................................................ 56
5.3 Lifestyle Considerations ...................................................................................... 60
Meals and Dietary Restrictions ....................................................................60
5.3.1.1 Diet Restrictions................................................................................. 60
5.3.1.2 Fruit Juice Restrictions ......................................................................60
Caffeine, Alcohol, and Tobacco Restrictions .............................................. 61
5.3.2.1 Caffeine Restrictions .......................................................................... 61
5.3.2.2 Alcohol Restrictions ........................................................................... 61
5.3.2.3 Tobacco Restrictions .......................................................................... 61
Activity  Restrictions .................................................................................... 61
5.4 Screen Failures .....................................................................................................62
5.5 Participant Replacement Strategy ......................................................................62
6 STUDY INTERVENTION ............................................................................................ 62
6.1 Study Intervention(s) Administered ...................................................................63
6.2 Preparation/Handling/Storage/Accountability ................................................. 64
Handling, Storage, and Accountability ........................................................ 64
6.3 Measures to Minimize Bias: Randomization and Blind ing.............................. 65
Intervention Assignment.............................................................................. 65
Stratification ................................................................................................ .66
Blinding........................................................................................................66
6.4 Study Intervention Compliance .......................................................................... 66
6.5 Concomitant Therapy .......................................................................................... 66
Rescue Medications and Supportive Care ................................................... 67
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 67
6.7 Intervention After the End of the Study ............................................................ 68
6.8 Clinical Supplies Disclosure ................................................................................ 68
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAW AL............................................................................................................ 68
7.1 Discontinuation of Study Intervention ............................................................... 68
7.2 Participant Withdrawal From the Study ........................................................... 69
7.3 Lost to Follow -up................................................................................................ .69
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 70
8.1 Administrative and General Procedures ........................................................... 71Â 
Â  059Y88
PRODUCT: MK-8189  8
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Informed Consent ......................................................................................... 71
8.1.1.1 General Informed Consent ................................................................ .71
8.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 71
Inclusion/Exclus ion Criteria ........................................................................71
Participant Identification Card .....................................................................72
Medical Hi story ........................................................................................... 72
Prior and Concomitant Medications Review ............................................... 72
8.1.5.1 Prior Medications ............................................................................... 72
8.1.5.2 Concomitant Medications ..................................................................72
Washout from Antipsy chotics ......................................................................72
Assignment of Screening Number ............................................................... 73
Assignment of Treatment/Randomization Number .....................................73
Study  Intervention Administration .............................................................. 73
8.1.9.1 Timing of Dose Administration ......................................................... 73
Discontinuation and Withdrawal ................................................................ .73
8.1.10.1 Withdrawal From Future Biomedical Researc h................................ 74
Participant Blinding/Unblinding ..................................................................74
Domiciling ...................................................................................................75
Calibration of Equipment ............................................................................. 75
8.2 Efficacy/Immunogenicity Assessments .............................................................. 75
8.3 Safety Assessments ............................................................................................... 75
Physical Examinations ................................................................................. 76
Body Mass Index (BMI) .............................................................................. 76
Vital Signs....................................................................................................76
8.3.3.1 Resting Vital Signs ............................................................................ 76
8.3.3.2 Body Temperature ............................................................................. 76
8.3.3.3 Orthostatic Vital Signs.......................................................................77
Electrocardiograms ...................................................................................... 77
Pregnancy  Testing ........................................................................................ 78
Clinical Safety  Laboratory  Assessments ..................................................... 78
Suicidal I deation and Behavior Monitoring ................................................. 79
8.3.7.1 Clinical Assessments for Suicidal I deation and Behavior 
Monitoring ......................................................................................... 79
Monitoring for Extrap yramidal Sy mptoms .................................................. 80
Assessment of Neurops ychological Effects ................................................. 80
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 80Â 
Â  059Y88
PRODUCT: MK-8189  9
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 81
Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......83
Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...83
Regulatory  Reporting Requirements for SAE ............................................. 83
Pregnancy  and Exposure During Breastfeeding .......................................... 83
Disease -related Events and/or Disease -related Outcomes Not Qualify ing 
as AEs or SAEs ............................................................................................ 84
Events of Clinical I nterest (ECI s)................................................................ 84
8.5 Treatment of Overdose ........................................................................................ 85
8.6 Pharmacokinetics................................................................................................ .85
Blood Collection for Plasma MK- 8189 ....................................................... 85
Urine Collection for MK -8189 and metabolite profiling ............................. 85
8.7 Pharmacodynamics .............................................................................................. 85
8.8 Biomarkers ........................................................................................................... 85
Planned Genetic Anal ysis Sample Collection .............................................. 85
8.9 Future Biomedical Research Sample Collection ............................................... 86
8.10 Visit Requirements ............................................................................................... 86
Screening......................................................................................................86
Treatment Period .......................................................................................... 86
Discontinued Participants Continuing to be Monitored in the Study .......... 87
Poststudy ......................................................................................................87
8.11 Critical Procedures Based on Study Objectives: Timing of Procedure .......... 87
8.12 Study Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ............................................................................................ 89
9 STATISTICAL ANALYSIS PLAN ............................................................................. 90
9.1 Statistical Analysis Plan Summary.....................................................................90
9.2 Responsibility for Analyses ................................................................................. 91
9.3 Hypotheses/Estimation ........................................................................................ 91
9.4 Analysis E ndpoints ............................................................................................... 91
9.5 Analysis Populations ............................................................................................ 92
9.6 Statistical Methods ............................................................................................... 92
9.7 Interim Analyses ..................................................................................................94
9.8 Multiplicity ........................................................................................................... 94
9.9 Sample Size and Power Calculations ................................................................ .94
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................95
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........95
Code of Conduct for Clinical Trials ............................................................. 95Â 
Â  059Y88
PRODUCT: MK-8189  10
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Financial Disclosure ..................................................................................... 97
Data Protection ............................................................................................. 97
10.1.3.1 Confidentiality  of Data ......................................................................98
10.1.3.2 Confidentiality  of Participant Records ............................................... 98
10.1.3.3 Confidentiality  of IRB/IEC I nformation ............................................ 98
Publication Policy ........................................................................................ 98
Compliance with Study  Registration and Results Posting Requirements ...99
Compliance with Law, Audit, and Debarmen ............................................. 99
Data Qualit y Assurance ............................................................................. 100
Source Documents ..................................................................................... 100
Study  and Site Closure ............................................................................... 101
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 102
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. 104
Definition of AE ........................................................................................ 104
Definition of SAE ...................................................................................... 105
Additional Events Reported in the Same Manner as SAE ......................... 106
Recording AE and SAE ............................................................................. 106
Reporting of AE, SAE, and Other Reportable Safety  Events to the 
Sponsor ......................................................................................................110
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ......................................... 111
10.5 Appendix 5: Contraceptive Guidance .............................................................. 112
Definitions ..................................................................................................112
Contraception Requirements ......................................................................113
10.6 Appendix 6: Collection and Management of Specimens for Fu ture 
Biomedical Research .......................................................................................... 114
10.7 Appendix 7: Country -specific Requirements .................................................. 119
10.8 Appendix 8: 12- Lead Electrocardiogram Abnormality Criteria .................. 120
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values .....122
10.10 Appendix 10: Blood Volume Table ..................................................................123
10.11 Appendix 11: General (Full) Neurological Exam ........................................... 124
10.12 Appendix 12: Targeted Neurological Exam .................................................... 131
10.13 Appendix 13: Abbreviations ............................................................................. 133
11 REFERENCES............................................................................................................. 134Â 
Â  059Y88
PRODUCT: MK-8189  11
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
LIST OF TABLES
Table 1 Study  Interventions .......................................................................................... 63
Table 2 Panel A (health y participants) and Panel B (participants with 
schizophrenia: monotherapy) Sample Allocation Schedule ............................ 65
Table 3 Panel C (participants with schizophrenia; add -on therapy ) Sample 
Allocation Schedule ......................................................................................... 65
Table 4 Panel D (participants with schizophrenia: monotherap y) Sample 
Allocation Schedule ......................................................................................... 65
Table 5 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safet y Events ................................................................................. 82
Table 6 Protocol -required Safet y Laboratory  Assessments ........................................102Â 
Â  059Y88
PRODUCT: MK-8189  12
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
LIST OF FIGURES
Figure 1 Study  Schema Panel A: Healthy  Participants (Japanese and non -Japanese) ...17
Figure 2 Study  Schema Panel B: Participants with Schizophrenia (monotherapy ).......17
Figure 3 Study  Schema Panel C: Participants with Schizophrenia (add -on therapy )....18
Figure 4 Study  Schema Panel D: Participants with Schizophrenia (monotherap y).......18Â 
Â  059Y88
PRODUCT: MK-8189  13
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A multiple -dose clinical stud y to evaluate the safety, tolerability , 
pharmacokinetics and QTc effect of MK -8189 in participants with schizophrenia and health y 
participants.
Short Title: MK-8189 m ultiple -dose clinical study  in participants with schizophrenia and 
healthy participants.
Acronym: MDCS
Hypot heses, Objectives ,and Endpoints :
The following objectives will be evaluated in participants with schizophrenia and healthy 
participants.
Primary  Objectives Primary  Endpoints
-To evaluate the safet y and tolerability of 
rising multiple once -daily  oral doses of MK -
8189 in participants with schizophrenia, as 
monotherap y and as add -on  therap y,  and 
healthy  Japanese and non -Japanese 
participants -Adverse experiences, laboratory  safet y 
tests, ECGs, and vital signs 
Secondary  Objectives Secondary  Endpoints
-To estimate the pharmacokinetics for MK -
8189 following multiple once -daily oral 
doses in participants with schizophrenia, as 
monotherap y and as add -on therap y, and in 
healthy Japanese and non -Japanese 
participants-AUC0 -24, Cmax, C24hr, Tmax, CL , Vd 
and apparent t1/2
Tertiary /Exploratory  Objectives Tertiary /Exploratory  Endpoints
-To evaluate the effect of MK -8189 
concentrations on QTc interval and other 
ECG parameters-QTc, PR and RR intervals, heart rate, 
QRS duration, T wave morphology , 
presence of U waves and outlier 
assessmentÂ 
Â  059Y88
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
7RLQYHVWLJDWHWKHUHODWLRQVKLSEHWZHHQ
JHQHWLFSRO\PRUSKVDQGWKH3.DQG
SKDUPDFRG\QDPLFVRI0.*HQHWLFYDULDWLRQLQ PD\EHDQDO\]HGIRUDVVRFLDWLRQZLWKDQ\ODERUDWRU\RUFOLQLFDOGDWDFROOHFWHGLQWKLVVWXG\*HUPOLQHJHQHWLFYDULDWLRQLQ
7RH[SORUHWKHUHODWLRQVKLSEHWZHHQJHQHWLF
YDULDWLRQDQGUHVSRQVHWRWKHWUHDWPHQWVDGPLQLVWHUHGDQGPHFKDQLVPVRIGLVHDVH9DULDWLRQDFURVVWKHKXPDQJHQRPHPD\EHDQDO\]HGIRUDVVRFLDWLRQZLWKFOLQLFDOGDWDFROOHFWHGLQWKLVVWXG\*HUPOLQHJHQHWLFYDULDWLRQ
2YHUDOO'HVLJQ
6WXG\3KDVH 3KDVH
3ULPDU\3XUSRVH 7UHDWPHQW
,QGLFDWLRQ 7UHDWPHQWRI6FKL]RSKUHQLD
3RSXODWLRQ +HDOWK\SDUWLFLSDQWV DQGSDUWLFLSDQWV ZLWKVFKL]RSKUHQLD 
RUVFKL]RDIIHFWLYHGLVRUGHU
6WXG\7\SH ,QWHUYHQWLRQDO
,QWHUYHQWLRQ0RGHO 3DUDOOHO
7KLVLVDVLQJOHV LWHVWXG\
7\SHRI&RQWURO 3ODFHER
6WXG\%OLQGLQJ 'RXEOHEOLQG
0DVNLQJ 1R0DVNLQJ
(VWLPDWHG'XUDWLRQRI6WXG\ 7KH6SRQVRUHVWLPDWHVWKDWWKHVWXG\ ZLOOUHTXLUH
DSSUR[LPDWHO\ PRQWKVIURPWKHWLPHWKHILUVWSDUWLFLSDQWVLJQVWKHLQIRUPHGFRQVHQWXQWLOWKHODVWSDUWLFLSDQWÂ¶VODVWVWXG\UHODWHGWHOHSKRQHFDOORUYLVLW
 <CCI
CCI
CCI
PRODUCT: MK-8189  15
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Number of Partic ipant s:
Approximately  64participants will be allocated/randomized .
Intervention Groups and Du ration :
Intervention 
GroupsIntervention 
Group 
NameDrugDose 
StrengthDose 
FrequencyRoute 
of 
Admin .Regimen/ 
Treat ment 
Period/ 
Vaccination 
RegimenUse
Active
Panel A, 
Panel B
Panel C and 
Panel DMK-
81894 mg QD OralPanels A, B and 
C:
1 tablet 
Days 1-3, 
2 tablets Day s 4-
6, 
3 tablets Days 7-
9, 
4 tablets Days 10 -
12, 5 tablets Days 
13-15, 6 tablets 
Days 16-18
Panel D :
2 tablets 
Days 1 -3, 
4 tablets 
Day 4 -6,
6 tablets 
Days 7 -9,
9 tablets 
Days 10- 12,
12 tablets 
Days 13 -15Experimental 
Treatment
Placebo
Panel A, 
Panel B
Panel C and 
Panel DPlacebo 0mg QD OralPanels A, B and 
C:
1 tablet 
Days 1-3, 
2 tablets Day s 4-
6, 
3 tablets Days 7-
9, 
4 tablets Days 10-
12, 5 tablets Days 
13-15, 6 tablets 
Days 16-18
Panel D :
2 tablets 
Days 1 -3, 
4 tablets 
Day 4 -6,
6 tablets 
Days 7 -9,
9 tablets 
Days 10-12,
12 tablets 
Days 13 -15Placebo 
Matched to 
Experimental 
TreatmentÂ 
Â  059Y88
PRODUCT: MK-8189  16
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Total 
Number2intervention groups
Duration of 
ParticipationPanel A (health y Japanese and non -Japanese participants): Each participant 
will participate in the study  for approximately  8 weeks from the time the 
participant signs the Informed Consent F orm (I CF) through t he final 
contact. After a screening phase of approximately 4 weeks, each participant 
will receive assigned intervention for approximately  18days. After the end 
of treatment ,each participant will be followed for 2weeks.
Panel B and Panel C (participants with schizophreni a; monotherap y and 
add-on therapy ,respectively ): Each participant will participate in the study  
for approximately  8 weeks from the time the particip ant signs the ICF 
through the final contact. After a screening phase of approximately  4weeks
(which may  include a washout phase (Panel B only) of at least 5 day s from 
the participantâ€™s standard of care medication )each participant will receive
assigned intervention for approximately  18days. After the end of treatment ,
each participant will be followed for 2weeks.
Panel D ( participants with schizophrenia ; monotherap y):Each participant 
will participate in the study  for approximately  7.5 weeks from the time the 
participant signs the Informed Consent Form (I CF) through t he final 
contact. After a screening phase of approximately 4 weeks (which may  
include a washout phase of at least 5 day s from the participantâ€™s standard of 
care medication) , each participant will receive assigned intervention for 1 5
days. After the end of treatment, each participant will be followed for 2 
weeks.
Study Governance Committees:
Steering Committee No
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Insert Other Oversight Committee No
Study  governance considerations are outlined in Appendix 1.
Study  Accepts Healthy  Volunteers : Yes
A list of abbreviations used in this document can be found in Appendix 13.Â 
Â  059Y88
PRODUCT: MK-8189  17
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
1.2 Schema
The study  design is depicted in Figure 1,Figure 2,Figure 3and Figure 4 .
Figure 1Study  Schema Panel A: Healthy  Participants (Japanese and non -Japanese)
Figure 2Study  Schema Panel B: Participants with Schiz ophreni a(monotherap y)
Â 
Â  059Y88
PRODUCT: MK-8189  18
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Figure 3Study  Schema Panel C: Participants with Schizophrenia (add -on therapy )
Figure 4Study  Schema Panel D: Participants with Schizophrenia (monotherap y)
Â 
Â  059Y88
PRODUCT: MK-8189  19
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
1.3 Schedule of Activities (SoA)
Panels A, B and C
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718192021~27
Administrative Procedures
Informed Consent X
Informed Consent for 
Future Biomedical 
ResearchX
Inclusion/Exclusion 
CriteriaXRecheck 
clinical status 
before 1stdose 
of study 
intervention
Participant 
Identification CardX
Medical History 
(includes psychiatric 
history and substance 
usage)XSubstances: 
drugs, alcohol, 
tobacco (Panel 
A only) , and 
caffeine
Prior/Concomitant 
Medication Review       X----------------------------------------------------------------------------------------------------------------------------- ------- X
Assignment of 
Screening NumberX
Washout from 
Antipsychotics â€“ Panel 
B onlyX XDiscontinue 
medication at 
least 5 days or 
at least 3 half -
lives
(whichever is 
longer) prior 
to Day -1Â 
Â  059Y88
PRODUCT: MK-8189  20
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panels A, B and C
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718192021~27
Assignment of 
Allocation Number 
(Randomization )XMay occur on 
Day -1 if 
required for 
Holter
MK-8189/Placebo 
AdministrationX X X X X X X X X X X X X X X X X XSee 
Section s 8.1.9 
and6.3.1
Standard MealsaXXXXXXXXXXXXXXXXXXXXX
Confinement in ClinicbX------------------------------------------------------------------------------------------------------------- X
Follow -up Phone Call â€“
Panel B onlyXMay occur 5 -7 
days after 
discharge.
Safety Procedures
Full Physical Exam X XmX X
Height X
Weight X XmX X
Full Neurological Exam X Xm
Targeted Neurological 
ExamX X X X X X X XCom plete 
predose on 
dosing days or 
anytime on 
non-dosing
days;
Days 2, 5, 11: 
Panel A only
Vital Signs (heart rate, 
blood pressure)c X X X X X X X X X X X X X X X XDays 2, 5: 
Panel A only
Orthostatic Vital Signs 
(heart rate, blood 
pressure)dX X X X X X X X X X X X X X X XDays 2, 5: 
Panel A onlyÂ 
Â  059Y88
PRODUCT: MK-8189  21
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panels A, B and C
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718192021~27
Vital Signs (respiratory 
rate, temperature)X X X X X XCom plete 
predose;
Day 5: 
Panel A only
12-lead Safety ECG
(Panels A and B only)e X X X X X X X X X XDays 2, 5: 
Panel A only
24-hour Holter ECG & 
Extraction (Panels A 
and B only)fX X X X X X X
12-lead Safety ECG 
(Panel C only)g X X X X X X X X X X
Serum Î² -Human 
Chorionic 
Gonadotropin
(Î²-hCG; WOCBP only)X X
Urine Pregnancy test 
(WOCBP only)h Xm
Serum Follicle 
Stimulating Hormone 
(FSH; WONCBP only)X
HIV, hepatitis B and C 
Screen (per site SOP)X
Urine Drug Screen 
(per site SOP)i X X
Laboratory Safety Tests 
(hematology , urinalysi s,
chemistry )X XmX X X XCollected 
predose after 
~8 hour fast
Columbia Suicide 
Severity Rating Scale 
(C-SSRS) -
Baseline VersionXÂ 
Â  059Y88
PRODUCT: MK-8189  22
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panels A, B and C
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718192021~27
Columbia Suicide 
Severity Rating Scale 
(C-SSRS) -Since Last 
Assessment VersionjXmX X X X XCom plete 
predose
Barnes Akathisia 
Rating Scale (BARS)j, k XmX X X XCom plete 
predose
Abnorm al Involuntary 
Movement Scale 
(AIMS)j, kXmX X X XCom plete 
predose
Simpson Angus Scale 
(SAS)j, k XmX X X XCom plete 
predose
Bond and Lader Visual 
Analog Scale (VAS)j XmX X X X X X XDays 2, 5, 11: 
Panel A only.
Com plete 
predose
Brief Ps ychiatric Rating 
Scale (BPRS; 
PanelsBand C only)jX XmX X X XCom plete 
predose
AE/SAE review       X----------------------------------------------------------------------------------------------------------------------------- -------- X
Biom arkers
Blood for Genetic 
AnalysisnXCollect 
predose from 
enrolled 
participants 
only; See 
Section 8.8
Pharm acokinetics
Blood for Plasma 
MK-8189 and/or 
Metabolites assaylX X X X X X X X X XÂ 
Â  059Y88
PRODUCT: MK-8189  23
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
a.Meals should be given at approximately the same time every day starting on Day -1 (time -matched to postdose meals) through Day 20.  Breakfast will be given at ~1 hour postdose, lunch given at ~4 
hours postdose, a snack given at ~8 hours postdose and dinner at ~12 hours postdose.  All meals will follow the completion of all specified procedures at that timepoint.
b.Panel A will be confined minimally from Day - 2 through Day 21.  Panel B will be confined within a week of starting their antipsychotic washout period through Day 21; minimally subjects will be 
confined from Day -6 through Day 21. Panel C will be confined mini mally from Day -1 through Day 21.
c.Single HR and BP measurements will be obtained at all postdose timepoints.  On the following days, specific timepoints are noted:    
ï‚· Day -1:  Triplicate measurements time-matched to 8 hour post dose vital sign   
ï‚· Day 2 and Day 5: 8 hours post -dose (Panel A only)
ï‚· Day 8, Day 11, Day 14 and Day 17:  8 hours post -dose
ï‚· Day 10, Day 12, Day 13, Day 15, Day 16 and Day 18: 10 and 16 hours postdose
d.Orthostatic assessments in HR and BP will follow semi recumbent vital sign assessments.  Subjects should be standing for appr oximately 3 minutes prior to the orthostatic assessments.   Orthostatic 
HR and BP measurements will be obtained on: 
ï‚· Day -1: Time -matched to 8 hour post dose orthostatic vital sign .  
ï‚· Day 2 and Day 5: 8 hours post -dose (Panel A only).
ï‚· Day 8, Day 11, Day 14 and Day 17:  8 hours post -dose 
ï‚· Day 10, Day 12, Day 13, Day 15, Day 16 and Day 18: 10 and 16 hours postdose 
e.For Panels A and B, single12 -lead safety ECG measurements will be at all postdose timepoints. On the following days, specific timepoints are noted: 
ï‚· Day 1: Triplicate measurements within 2 hours prior to dosing.
ï‚· Day 2 and Day 5: 8 hours post -dose (Panel A only).
ï‚· Day 8, Day 11, Day 14 and Day 17: 8, 10 and 16 hours post- dose
f.For Panels A and B, c ontinuous (24 -hour) Holter ECG measurements will be performed from approximately 30 minutes prior to dose administration and until 24 hours post -dose. 
ECG data will be extracted on:
ï‚· Day -1(baseline measurement) :  time matched to dosing days at the following timepoints: 2, 6, 8, 10, 12, 16 and 24 hour s
ï‚· Day 7, Day 10, Day 13 and Day 16: predose, 2, 6, 8, 10, 12, 16 and 24 hours post -dose.
ï‚· Day 18: 2, 6, 8, 10, 12, 16, 24, 36 and 48 hours post -dose.
ï‚· If a subject discontinues study treatment at a dose of 12 mg or higher, an attempt should be made to collect 24 -hour Holter data through 48 hours following their last dose.
g.For Panel C, triplicate 12 -lead safety ECG measurements will be taken 1 -2 minutes apart at all timepoints.  On the following days, specific timepoints are noted:
ï‚· Day 1: within 2 hours prior to dosing
ï‚· Day 9, Day 12,  Day 13, Day 15, Day 16 and Day 18: 8, 10, 16 and 24 hours post -dose
h.In the e vent the urine pregnancy test is positive or cannot be confirmed negative, a serum pregnancy test will be required.
i.Screening UDS is mandatory; any additional UDS are conducted per site SOP. UDS prior to randomization will be done on the day of admission.
j.Scheduled assessments are completed predose on dosing days and at any time on non-dosing days.  
k.Additional BARS, AI MS and SAS assessments will be conducted when observed or reported c omplaints of dystonia and/or akathisia occur.
l.MK-8189 plasma PK sample collection (note: when time point coincides with Holter extraction, the PK sample will be collected as soon as possible after Holter extraction but must collected after any 
vital sign assessments ): 
ï‚· Panel A and B and C: Day 1 and Day 4:  pre -dose.  
ï‚· Panel A and B: Day 7, Day 10, Day 13 and Day 16: predose, 2, 6, 8, 10, 12, 16 and 24 hours post -dose  
ï‚· Panel C: Day 9, Day 12, Day 15; predose, 2, 6, 8, 10, 12, 16 and 24 hours post -dose. 
ï‚· Panel A and B and C:  Day 18:  2, 6, 8, 10, 12, 16, 24, 36 and 48 hours post -dose  
ï‚· Optional sample when signs of dystonia and/or akathisia occur
ï‚· If a subject discontinue s study treatment at a dose of 12 mg or higher, an attempt should be made to collect PK samples through 48 hours following th eir last dose.
ï‚· Leftover main study plasma will be stored for future biomedical research if the participant consents to future biomedical research .
m.In Panels A and B, assessments will be done on Day -2. In Panel C, assessments will be done on Day -1.
n. This sample will be drawn for CYP2C9 and for planned analysis of the association between genetic variants in DNA and drug response. I f the I RB/IEC does not approve of the planned analysis of the 
association between DNA variation and drug response, or if there is a local law or regulation prohibiting the same, data anal ysis will be limited to CYP2C9. Leftover extracted DNA will be stored for 
future biomedical research if the participant signs the future biomedical research consent.Â 
Â  059Y88
PRODUCT: MK-8189  24
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panel D
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718 ~24
Administrative Procedures
Informed Consent X
Informed Consent for 
Future Biomedical 
ResearchX
Inclusion/Exclusion 
CriteriaXRecheck clinical status 
before 1stdose of study 
intervention
Participant 
Identification CardX
Medical History 
(includes psychiatric 
history and substance 
usage)XSubstances: drugs, alcohol,  
and caffeine
Prior/Concomitant 
Medication ReviewX----------------------------------------------------------------------------------------------------------------------------X
Assignment of 
Screening NumberX
Washout from 
AntipsychoticsX XDiscontinue medication at 
least 5 days or at least 3 
half-lives (whichever is 
longer) prior to Day -1
Assignment of 
Allocation Number 
(Randomization)XMay occur on Day -1 if 
required for Holter
MK-8189/Placebo 
AdministrationX X X X X X X X X X X X X X XSee 
Sections 8.1.9 and 6.3.1
Standard MealsaXXXXXXXXXXXXXXXXXX
Confinement in 
Clinicb X------------------------------------------------------------------------------------------- X
Follow -upPhone Call XÂ 
Â  059Y88
PRODUCT: MK-8189  25
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panel D
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718 ~24
Safety Procedures
Full Physical Exam X X X X
Height X
Weight X X X X
Full Neurological 
ExamX X
Targeted Neurological 
Examc X X X X X X X
Vital Signs (heart rate, 
blood pressure)d X X X X X X X X X X X X X X X X X X X
Orthostatic Vital 
Signs (heart rate, 
blood pressure)eX X X X X X X X X X X X X X X X X X X
Vital Signs 
(respiratory rate, 
temperature)cX X X X X X X X
12-lead Safety ECGfX X X X X X X X X
24-hour Holter ECG 
& Extractiong X X X X X X X X
Serum Î² -Human 
Chorionic 
Gonadotropin
(Î²-hCG; WOCBP 
only)X X
Urine Pregnancy test 
(WOCBP only)h X
Serum Follicle 
Stimulating Hormone 
(FSH; WONCBP 
only)X
HIV, hepatitis B and 
C Screen (per site 
SOP)XÂ 
Â  059Y88
PRODUCT: MK-8189  26
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panel D
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718 ~24
Urine Drug Screen 
(per site SOP)i X X
Laboratory Safety 
Tests (hematology, 
urinalysis, chemistry)cX X X X X X XCollected after ~8 hour 
fast
Columbia Suicide 
Severity Rating Scale 
(C-SSRS) -
Baseline VersionX
Columbia Suicide 
Severity Rating Scale 
(C-SSRS) -Since Last 
Assessment VersioncX X X X X X
Barnes Akathisia 
Rating Scale (BARS)c, X X X X X X
Abnorm al Involuntary 
Movement Scale 
(AIMS)c, jX X X X X X
Simpson Angus Scale 
(SAS)c, j X X X X X X
Bond and Lader 
Visual Analog Scale 
(VAS)cX X X X X X X
Brief Psychiatric 
Rating Scale (BPRS)X X X X X X X
AE/SAE review X-------------------------------------------------------------------------------------------------------------------------- XÂ 
Â  059Y88
PRODUCT: MK-8189  27
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panel D
Study Period ScreeningWash -
outPost-
studyNotes
Scheduled Day Screening -6-2-1123456789101112131415161718 ~24
Biom arkers
Blood for Genetic 
Analysism XCollect predose from 
enrolled participants only ;
See Section 8.8
Pharm acokinetics
Blood for Plasma 
MK-8189  and/or 
Metabolites assaykX X X X X X
Urine for potential 
MK-8189 and 
metabolite profilinglXÂ 
Â  059Y88
PRODUCT: MK-8189  28
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
a.Meals should be given at approximately the same time every day starting on Day -1 (time -matched to postdose meals) through Day 17.  Breakfast will be given at ~1 hour postdose, lunch given at ~4 
hours postdose, a snack given at ~8 hours postdose and dinner at ~12 hours postdose.  All meals will follow the completion o f all specified procedures at that timepoint.
b.Participants will be confined minimally from Day -1 until Day 18 procedures are complete. 
c.Scheduled assessments are completed predose on dosing days and at any time on non -dosing days.  
d. Single HR and BP measurements will be obtained at all postdose timepoints.  On the following days, specific timepoints are noted:   
ï‚· Day -1:  Triplicate measurements time -matched to 8, 10, 16 hours post dose vital sign  
ï‚· Day 1, Day 2, Day 5, Day 8, Day 11, Day 14: 8 hours post -dose
ï‚· Day 3, Day 6, Day 7, Day 9, Day 10, Day 12, Day 13, Day 15 and Day 17: 8, 10 and 16 hours postdose
e.Orthostatic assessments in HR and BP will follow semi -recumbent vital sign assessments.  Subjects should be standing for ap proximately 3 minutes prior to the orthostatic assessments.   Orthostatic 
HR and BP measurements will be obtained on: 
ï‚· Day -1: Time -matched to 8, 10, 16 hours post dose orthostatic vital sign.  
ï‚· Day 1, Day 2, Day 5, Day 8, Day 11, Day 14: 8 hours post -dose
ï‚· Day 3, Day 6, Day 7, Day 9, Day 10, Day 12, Day 13, Day 15 and Day 17: 8, 10 and 16 hours postdose
f.Single 12-lead safety ECG measurements will be taken at all postdose timepoints.  On the following days, specific timepoints are noted:
ï‚· Day 1: Triplicat e measurements within 2 hours of dosing
ï‚· Day 2, Day 5, Day 8, Day 11, and Day 14: 8, 10, 16 and 24 hours post -dose
g. Continuous (24 -hour) Holter ECG measurements will be performed from approximately 30 minutes prior to dose administration and until 24 hour s post -dose.  
ECG data will be extracted on:
ï‚· Day -1 (baseline measurement):  time matched to dosing days at the following timepoints: 2, 6, 8, 10, 12, 16 and 24 hours
ï‚· Day 1, Day 4, Day 7, Day 10 and Day 13: predose, 2, 6, 8, 10, 12, 16 and 24 hours post-dose.
ï‚· Day 15: 2, 6, 8, 10, 12, 16, 24, 36 and 48 hours post -dose.
ï‚· If a subject discontinues study treatment at a dose of 16 mg or higher, an attempt should be made to collect 24 -hour Holter data through 48 hours following their last dose.
h.In the ev ent the urine pregnancy test is positive or cannot be confirmed negative, a serum pregnancy test will be required.
i.Screening UDS is mandatory; any additional UDS are conducted per site SOP. UDS prior to randomization will be done on the day of admission .
j.Additional BARS, AI MS and SAS assessments will be conducted when observed or reported complaints of dystonia and/or akathisia occur. 
k.MK-8189 plasma PK sample collection: 
ï‚· Day 1, Day 4, Day 7, Day 10 and Day 13: predose, 2, 6, 8, 10, 12, 16 and 24 hours post -dose. 
ï‚· Day 15:  2, 6, 8, 10, 12, 16, 24, 36 and 48 hours post -dose  
ï‚· Optional sample when signs of dystonia and/or akathisia occur.
ï‚· If a subject discontinues study treatment at a dose of 16 mg or higher, an attempt should be made to collect PK s amples through 48 hours following their last dose.
ï‚· Leftover main study plasma will be stored for future biomedical research if the participant consents to future biomedical res earch.
l. Spot collection between 8 -12 hr postdose at the 48 mg dose only.  Participants should void prior to dose administration.
m. This sample will be drawn for CYP2C9 and for planned analysis of the association between genetic variants in DNA and drug response. I f the I RB/IEC does not approve of the planned analysis of 
the ass ociation between DNA variation and drug response, or if there is a local law or regulation prohibiting the same, data analysi s will be limited to CYP2C9. Leftover extracted DNA will be 
stored for future biomedical research if the participant signs the futu re biomedical research consent.Â 
Â  059Y88
PRODUCT: MK-8189  29
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
2 INTRODUCTION
2.1 Study Rationale
This study  will evaluate safet y, tolerability and pharmacokinetics (PK) of multiple oral doses 
of MK -8189, an inhibitor of phosphodiesterase 10A (PDE10A), in healthy  participants and 
participants with schizophrenia at doses that are higher than those explo red in the previous 
multiple -ascending dose study  (MK -8189 PN003 -06).  Initially  this protocol was intended to 
evaluate doses up to and including doses of 24 mg.  However, doses up to 24 mg have been 
generall y well tolerated in Panel A and B, and thus this amendment will allow the safet y and 
tolerability  assessment of doses up to and including 48 mg.  This study  will also evaluate the 
effect of MK -8189 on QTc.  
The clinical dose of MK -8189 is currentl y unknown; however, 12 mg has demonstrated 
antipsy chotic activity  in acute exacerbation of schizophrenia and was generally  well 
tolerated.  Based on data from the current protocol as well as the potential for increased 
efficacy  at higher doses of MK -8189, doses of MK -8189 as high as 24 mg are being 
considered f or evaluation in Phase 2. Therefore, the current study , which will evaluate doses 
up to 48 mg of MK -8189 as monotherap y and up to 24 mg of MK -8189 as add- on therapy , 
would support safet y and tolerability margins for doses as high as 24 mg or 16 mg, when 
given as monotherap y or as adjunct therap y, respectively.   Therefore, these data would 
potentially  support dosing in the presence of intrinsic and extrinsic factors which may  
increase MK -8189 exposure (e.g. CYP3A inhibition).  In addition, if titration to 
supratherapeutic doses is achievable , this trial could support robust characterization of the 
effect of MK -8189 on QTc, which would depend on determination of the final clinical dose. 
Inclusion of health y Japanese subjects will support the global clinical d evelopment in Japan.
It is recognized that an undesirable propert y of some non -antiarrh ythmic drugs is their ability  
to delay  cardiac repolarization leading to increased risk of development of life -threateni ng 
cardiac arrh ythmias such as Torsade de Pointes (TdP) and possibly  other ventricular 
tachyarrh ythmias. The potential effect ofadrug oncardiac repolarization can be measured as 
prolongation oftheQT interval onECG recordings. There is in general aqualitative
relationship between substantial QT prolongation and the riskofTdP.   The current trial will 
evaluate in arigorous manner theimpact of administration ofMK-8189 on the QTc interval ,
to determine the risk of cardiac repolarization prolongation. While MK -8189 data to date do 
not suggest a QT prolongation risk, in fact, many  antipsy chotics are known to prolong QT. 
As MK -8189 is expected to be used as adjunct therap y, the QTc effect of MK -8189 will be 
an important assessment in the present study .
2.2 Background
Refer to the Investigatorâ€™s Brochur e (IB)/approved labeling for detailed background 
information on MK -8189 .Â 
Â  059Y88
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
3KDUPDFHXWLFDODQG7KHUDSHXWLF%DFNJURXQG
0.LVDSRWHQWDQGVHOHFWLYHLQKLELWRURI3'($WKDWLVEH LQJGHYHORSHGDVDQRYHO
WKHUDSHXWLFIRUWKHWUHDWPHQWRIVFKL]RSKUHQLD7KH3'($HQ] \PHPHWDEROLFDOO\
LQDFWLYDWHVWKHXELTXLWRXVVHFRQGPHVVHQJHUVF\FOLFDGHQRVLQH PRQRSKRVSKDWHF$03DQG
F\FOLFJXDQRVLQHPRQRSKRVSKDWHF*03>%HQGHU$7DQG%HDYR -$@ DQG LV
KLJKO\H[SUHVVHGLQWKHWDUJHWQXFOHXVRIWKHFRUWLFRVWULDWDOS DWKZD\WKHVWULDWXP >6HHJHU7
)HWDO@3UHFOLQLFDOSKDUPDFR ORJ\VWXGLHVGHPRQVWUDWH WKDW3'($LQKLELWLRQ
LQFUHDVHVF$03F*03VLJQDOLQJLQSDWKZD\VWKDWKDYHEHHQDVVRFL DWHGZLWKXQGHUO\LQJ
SDWKRORJ\JOXWDPDWHDVZHOODVFOLQLFDOO\YDOLGDWHGWKHUDSHXW LFVGRSDPLQH'UHFHSWRU
DQWDJRQLVWVIRUVFKL]RSKUHQLD(QKDQFHGVLJQDOLQJLQWKHVHSD WKZD\VLVK\SRWKHVL]HGWR
UHVWRUHEHKDYLRUDOLQKLELWLRQWKDWLVLPSDLUHGLQVFKL]RSKUHQLD >*UDXHU60HWDO@
>6FKPLGW&-HWDO@3'($LQKLELWRUVPD\SRWHQWLDOO \EHDQDOWHUQDWLYHWUHDWPHQW
DVPRQRWKHUDS\DQGRUDGMXQFWWUHDWPHQWLQVFKL]RSKUHQLDSDWLHQ WVZKRKDYHLQDGHTXDWH
UHVSRQVHWRILUVWOLQHDW\SLFDODQWLSV\FKRWLF$$3WUHDWPHQW
3UHFOLQLFDODQG&OLQLFDO6WXGLHV
3UHFOLQLFDO7ULDOV
 <CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 <CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 <CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 <CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 <CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
$GGLWLRQDOGDWDIRU3 FDQEHIRXQGLQWKH0. ,%
2QJRLQJ&OLQLFDO
 <CCI
CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 <CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 %HQHILW5LVN$VVHVVPHQW
,WFDQQRWEHJXDUDQWHHGWKDWSDUWLFLSDQWVLQFOLQLFDOVWXGLHVZ LOOGLUHFWO\EHQHILWIURP
WUHDWPHQWGXULQJSDUWLFLSDWLRQDVFOLQLFDOVWXGLHVDUHGHVLJQH GWRSURYLGHLQIRUPDWLRQDERXW
WKHVDIHW\DQGHIIHFWLYHQHVVRIDQLQYHVWLJDWLRQDOPHGLFLQH
$GGLWLRQDOGHWDLOVUHJDUGLQJVSHFLILFEHQHILWVDQGULVNVIRUSD UWLFLSDQWVSDUWLFLSDWLQJLQWKLV
FOLQLFDOVWXG\PD\ EHIRXQGLQWKHDFFRPSDQ\LQJ,%DQG,&)GRFX PHQWV
 <CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 +<327+(6,62%-(&7,9(6$1'(1'32,176 
7KHIROORZLQJREMHFWLYHVZLOOEHHYDOXDWHGLQSDUWLFLSDQWVZLWK VFKL]RSKUHQLDDQGKHDOWK\
SDUWLFLSDQWV
2EMHFWLYHV (QGSRLQWV
3ULPDU\
Â‡ 7RHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RI
ULVLQJPXOWLSOHRQFHGDLO\RUDOGRVHVRI0.LQSDUWLFLSDQWVZLWKVFKL]RSKUHQLDDVPRQRWKHUDS\DQGDVDGGRQWKHUDS\ DQGKHDOWK\-DSDQHVHDQGQRQ-DSDQHVHSDUWLFLSDQWVÂ‡ $GYHUVHH[SHULHQFHVODERUDWRU\VDIHW\
WHVWV(&*VDQGYLWDOVLJQV
6HFRQGDU\
Â‡ 7RHVWLPDWHWKHSKDUPDFRNLQHWLFV IRU
0.IROORZLQJPXOWLSOHRQFHGDLO\RUDOGRVHVLQSDUWLFLSDQWV ZLWKVFKL]RSKUHQLDDVPRQRWKHUDS\DQGDVDGGRQWKHUDS\ DQGLQKHDOWK\-DSDQHVHDQGQRQ-DSDQHVHSDUWLFLSDQWVÂ‡ $8&&PD[&KU7PD[&/
9GDQGDSSDUHQWW
7HUWLDU\([SORUDWRU\
Â‡ 7RHYDOXDWHWKHHIIHFWRI0.
FRQFHQWUDWLRQVRQ47FLQWHUYDO DQGRWKHU(&*SDUDPHWHUVÂ‡ 47F35DQG55LQWHUYDOVKHDUWUDWH
456GXUDWLRQ7ZDYHPRUSKRORJ\SUHVHQFHRI8ZDYHVDQGRXWOLHUDVVHVVPHQW
Â‡ 7RLQYHVWLJDWHWKHUHODWLRQVKLSEHWZHHQ
JHQHWLFSRO\PRUSKVDQGWKH3.
DQGSKDUPDFRG\QDPLFVRI0.*HQHWLFYDULDWLRQLQ PD\EHDQDO\]HGIRUDVVRFLDWLRQZLWKDQ\ODERUDWRU\RUFOLQLFDOGDWDFROOHFWHGLQWKLVVWXG\Â‡ *HUPOLQHJHQHWLFYDULDWLRQLQ
Â‡ 7RH[SORUHWKHUHODWLRQVKLSEHWZHHQ
JHQHWLFYDULDWLRQDQGUHVSRQVHWRWKHWUHDWPHQWVDGPLQLVWHUHGDQGPHFKDQLVPVRIGLVHDVH 9DULDWLRQDFURVVWKHKXPDQJHQRPHPD\EHDQDO\]HGIRUDVVRFLDWLRQZLWKFOLQLFDOGDWDFROOHFWHGLQWKLVVWXG\Â‡ *HUPOLQHJHQHWLFYDULDWLRQ
 <CCI
CCI
CCI
PRODUCT: MK-8189  39
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
4 S TUDY DESIGN
4.1 Overall Design
Specific procedures to be performed during the study, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
This is a four -panel, randomized , placebo -controlled, parallel -group, multiple -dose, double -
blinded, safet y, tolerability , PK and QTc study  of MK-8189 in participants with 
schizophrenia and healthy  participants. 
Panel A will enroll up to 16 healthy  participants (8 Japanese and 8 non- Japanese) and 
Panel B will enroll up to 16 participants with schizophrenia or schizoaffective disorder to 
ensure at least 12 completers per group.  Panel C will enroll up to 12 participants with 
schizophrenia /schizoaffective disorder and Panel D will enroll up to 20 participants with 
schizophrenia ;participants may  be replaced at the discretion of the Sponsor in consultation 
with the principal investigator.  P articipants will be randomized to MK -8189 or matched-
placebo in a ratio of 3:1(Panels A, B and C) and 3:2 (Panel D) according to a computer
generated allocation schedule ; within Panel A ,6 Japanese and 6 non -Japanese will be 
random ized to MK -8189 and 2 Japanese and 2 non -Japanese will be randomized to receive 
placebo according to the computer generated allocation schedule.   
Participants with s chizophreni ain Panel B and Panel D will be washed off their antipsy chotic 
medication .  The washout may  start with a down titration of the antipsy chotic treat ment 
during the screening phase per direction of the investigator .  Participants in Panel B and 
Panel D should not receive antipsy chotics for at least 5 day sor 3 half -lives (whichever is 
longer) prior to Day  -1 Holter assessments. If deemed appropriate b y the investigator, a 
participant may  begin their washout as an outpatient, but should be confined within a week of 
starting the washout and minimally  beginning on Day  -6.  In Panel C, part icipants with 
schizophrenia 
will remain on their study  permitted atypical antipsy chotic (AAP) .
Panels A, B and C: Beginning on Day  1, participants randomized to MK -8189 will begin to 
receive MK -8189 QD and will be titrated from 4 mg to 24 mg over the course of an 18 day  
treatment period as follows: 1 x 4 mg tablet Day s 1-3,  2 x 4 mg tablets Day s 4-6, 3x 4 mg 
tablets Day s 7-9, 4 x 4 mg tablets Day s 10-12 , 5 x 4 mg tablets Day s 13-15 and 6 x 4 tablets 
Days 16-18. Participants randomized to placebo will receive the same number of tablets 
matching the 4 mg tablet of MK -8189 as the active group. Dose titration decisions for each 
participant will occur, a fter 3 day s of dosing per dose level, jointly  between the investigator 
and Sponsor. 
Panel D: Beginning on Day  1, participants randomized to MK -8189 will begin to receive  
MK-8189 QD and will be titrated from 8mg to 48 mg over the course of a 1 5day treat ment 
period as follows: 2 x 4 mg tablets Day s 1-3, 4 x 4 mg tablets Day s 4-6, 6 x 4 mgtablets 
Days 7-9,9 x4 mg tablets Day s 10-12and 12 x 4 mg tablets Day s 13-15.  Participants 
randomized to placebo will receive the same number of tablets matching the 4 mg tablet of Â 
Â  059Y88
PRODUCT: MK-8189  40
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
MK-8189 as the active group. Dose titration decisions for each participant will occur, after 3 
days of dosing per dose level , jointly  between the investi gator and Sponsor .
In Panel D , asmall cohort (n=4) will initially be dosed with 8 mg to confirm tolerability  prior 
to dosing the remainder of the cohort.  Tolerability will be assessed following the second 
dose of 8 mg before the remainder of the panel is dosed; depending on tolerability , the 
remainder of the panel may i)be dosed starting with 8 mg , ii) asmall cohort of the remainder 
of the panel may  bedosed starting with 8 mg, or iii) the starting dose may  be adjusted 
downward to 4 mg . The decision on how to proceed will be made b y the principal
investigator jointly with the Sponsor and documented in a protocol clarification letter .  If any 
of the panel begins dosing at 4 mg, the following titration schedule may be followed: 
1 x 4 mg tablets Days 1 -3, 2x 4 mg tablets Day s 4-6, 4 x 4 mg tablets Days 7-9, 6 x 4 mg 
tablets Day s 10-12 and 12x4 mg tablets Day 13 -15.    
If a participant does not tolerate escalation to the next dose, the participant may be titrated 
down to the previous dose (Panel A, B, C or D) or intermediate dose (Panel D ).In addition, 
as discussed above, if the initial dosing cohort of Panel D orsubsequent dosing cohort(s) 
does not tolerate the starting dose of 8 mg, subjects may be down -titrated to 4 mg.  If 
appropriate medical care necessitates a down -dose, the investigator may  do so independent of 
consultation with the Sponsor. If the participant tolerates continued dosing following down -
titration, the participant may continue in the trial at that dose until study completion or may  
be re -challenged at a higher dose. Re -challenges  are onl y to occur on regularly scheduled 
dose titration day s, i.e. Day  4, Day 7, Day  10, etc. and will not extend the participantâ€™s time 
in the study .Participants will be followed for approximately  2 weeks after the last study  
treatment dose.
Panel A , health y participants, will be confined to the clinical research unit ( CRU )beginning 
on Day  -2through Day  21.
Participants with schizophrenia in Panel B and Panel D have a risk to experience 
exacerbations in psychotic sy mptoms both during the washout period as well as during the 
MK-8189 treatment period. To mitigate this risk, only participants with schizophrenia in the 
non-acute phase of their illness, with the onset of the first episode being no less than 2 y ears 
prior to study  entry , will be recruited for stud
y. 
Panel B and Panel D , participants with schizophrenia ,will be confined to the CRU within a 
week of beginning their antipsy chotic medication washout and for at least the last 5 d ays of 
their washout ( i.e.confinement will begin on Day  -6 or earlier) and during the MK -8189 
treatment to provide an enhanced level of participant supervision. If needed ,rescue 
medication will be provided to treat withdrawal symptoms (see Section 6.5.1) . Participants
showing exacerbations in psy chotic s ymptoms during the washout period will be 
re-evaluated for participation and referred for additional treatment as indicated.
Panel C , participants with schizophrenia ,will be confined to the CRU beginning on Day  -1 
through Day  21.Â 
Â  059Y88
PRODUCT: MK-8189  41
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
The safet y and tolerability of MK -8189 will be monitored by  clinical assessment of AE, 
repeated measurements of ECGs and VS, phy sical and neurological examinations, and 
standard laboratory  tests (hematology , chemistry , urinaly sis). In addition, extrapy ramidal 
symptoms (EPS) of dy stonia and akathisia will be monitored along wi th psy chological 
effects using rating scale s.
All participants in Panel s A,B and D will have 24 -hour Holter recordings on Day  -1,which 
will be considered baseline , and throughout the dosing period as specified in the SoA .  Blood 
sampling for PK will follow each ECG extraction time.  I n addition, 24 -hour Holter 
recordings and blood sampling for PK will be conducted for 2 a dditional day s following the 
participantâ€™ s last dose.   In the case a participant has down- dosed or does not dose escalate 
and continues in the study, the participant will not repeat the 24- hour Holter monitoring and 
PK sampling at the given dose level . Inthe case of participant discontinuation at a dose of 
12mg or higher , an attempt should be made to collect 24 -Holter and matched PK 
measurements for 48 hours following the participantâ€™ s last dose .  Panel C will not have 
Holter assessments but will have 12 -lead ECG evaluations with coinciding PK samples at 
specified timepoints as per the So A.
After completion of the MK -8189 treatment ,participants with schizophrenia in Panel B and 
Panel D will resume the use of their own antipsy chotic medication following collection of the
last PK sample; Panel B: Day 18, 48- hour postdose PK sample ( Day 20)and Panel D: the
Day 15, 48- hour postdose PK sample (Day  17).  Participants in Panel sB and D will remain 
domiciled through Day  21 (Panel B) and Day  18 (Panel D)   All par ticipants willbe followed 
for approximately  2weeks after the last stud ytreatment dose .
Because this is a Phase 1 assessment of MK-8189 in humans, the pharmacokinetic (PK) , 
pharmacod ynamic, and safet y profiles of the compound are sti ll being elucidated. This 
protocol is therefore written with flexibility  to accommodate the inherent dy namic nature of 
Phase 1 clinical studies. Refer to 
Section 8.12 for examples of modifications permitted within 
the protocol parameters.
4.2 Scientific Ration ale for Study Design
Initiall y a3-Panel design was selected such that MK- 8189 could be evaluated in both health y 
Japanese and non -Japanese participants (Panel A) and participants with schizophrenia as 
monotherap y (Panel B) and as add -on therapy (Panel C). At the time of study  initiation, 
12mg was considered the likely  clinical dose and c haracterization of high erdose (>12mg)
safet y, tolerabilit y and PK of MK -8189 in healthy participant s could enable a determination 
of the safet y/tolerability  margin in this population, which is needed to understand the 
potential forhealth y participant s to participate in future Phase 1 cl inical studies that require 
supratherapeutic doses or exposure .  However, i f dose escalation above 12 mg in health y 
participant s was poorl y tolerated, high dose safet y data in participant s with schizophrenia 
would be used to understand the safety /tolerability margin in the target population , including 
evaluation of the effect of higher doses of MK -8189 on QTc. Panel C of this study  will 
provide safet y data in a small number of participants to support the evaluation of doses 
higher than 12 mg of MK -8189 in the setting of add- ontherapy  in a planned Phase 2 study .Â 
Â  059Y88
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
$WKSDQHOLVEHLQJDGGHG3DQHO'WRWKHFXUUHQWSURWRFRODVSUHOL PLQDU\GDWDIURP3DQHO$
DQG%RIWKHRQJRLQJ VWXG\VXJJHVWWKDW0.LVJHQHUDOO\ZHO OWROHUDWHGLQKHDOWK\
SDUWLFLSDQWVDQGSDUWLFLSDQWVZLWKVFKL]RSKUHQLDXSWRDQGLQFOX GLQJGRVHVRIPJ6LQFH
WKHFOLQLFDOGRVHPD\EHDVKLJKDVPJ3DQHO'ZLOOHYDOXDW HWKHVDIHW\DQGWROHUDELOLW\RI
0.DWGRVHVXSWRLQFOXGLQJ PJLQSDUWLFLSDQWV ZLWKVFKL] RSKUHQLDWRSURYLGHD
FOLQLFDOPDUJLQWRWKHPJGRVH7KLV PDUJLQPD\EHQHHGHGWR FRYHUH[SRVXUHLQFUHDVHV
UHVXOWLQJIURPSRWHQWLDOHIIHFWVRILQWULQVLFDQGH[WULQVLFIDF WRUVRQ0.3.LQIXWXUH
WULDOV:KLOH0.ZDVJHQHUDOO\ZHOOWROHUDWHGLQERWKKHD OWK\SDUWLFLSDQWVDQG
SDUWLFLSDQWVZLWKVFKL]RSKUHQLDWKHVFKL]RSKUHQLDSRSXODWLRQZ DVVHOHFWHGIRUHYDOXDWLRQLQ
3DQHO'DVSUHOLPLQDU\GDWDVXJJHVWWKDWH[SRVXUHVPD\EHJUHDW HULQWKHSDWLHQWSRSXODWLRQ
'RVHVZLOOEHWLWUDWHGXSWRPJ3DQHOV$%DQG&DQG P J3DQHO'RI0.WR
LPSURYHWROHUDELOLW\DQG PLQLPL]H(36VHH6HFWLRQDQGDPD WFKHGSODFHERFRQWUROZLOO
EHLQFOXGHGWRUHGXFHELDVZLWKUHJDUGVWRWKHSDWLHQWUHSRUWLQ JDQGLQYHVWLJDWRUDVVHVVPHQWRI
$(V ,QDGGLWLRQ LQFOXVLRQRIDSODFHERFRKRUWZLOODOVRFRQWURO IRUSRWHQWLDOELDVLQWURGXFHG
E\VWXG\SURFHGXUHVDQGWRLQFUHDVHWKHSRZHUWRH[FOXGHPRGHVW 47FHIIHFWVLQDVWXG\ZLWK
DUHODWLYHO\VPDOOVDPSOHVL]H
,Q3DQHO$ 3DQHO%DQG3DQHO' +ROWHUPRQLWRULQJIRUKRXUSHU LRGVDQG(&*LQWHUYDO
H[WUDFWLRQDWSUHVSHFLILHGWLPHSRLQWVIRUUHYLHZE\DEOLQGHG F HQWUDOUHDGHUZLOOEHLQFOXGHG
WRVXSSRUWWKHULJRURXVHYDOXDWLRQRI47HIIHFWLQDFFRUGDQFHZ LWKWKH47ZKLWHSDSHU
>*DUQHWW&HWDO@5HSOLFDWH(&*VWULSOLFDWHH[WUDFW HGIURPKRXU+ROWHUWUDFLQJV
DQGDFHQWUDOL]HGFRUHODERUDWRU\WRDVVHVV47FLQWHUYDOZLOOU HGXFHYDULDELOLW\
3KDUPDFRNLQHWLFVZLOODOVREHHYDOXDWHGRQ+ROWHUGD\VWRVXSSR UWDFRQFHQWUDWLRQ47F
DQDO\VLV DOORZLQJIRUFKDUDFWHUL]DWLRQRIWKHH[SRVXUH47FUHODW LRQVKLSDWDPXOWLSOHDERYH
H[SHFWHGWKHUDSHXWLFFRQFHQWUDWLRQV,Q3DQHO &OHDGWULSOL FDWH(&*VDQG3.ZLOOEH
HYDOXDWHGDWWLPHSRLQWVH[SHFWHGWRFRLQFLGHZLWKSHDNFRQFHQWU DWLRQV DWGRVHVÂ•PJWR
PRQLWRUVDIHW\DQGWRH[SORUHWKH47FFRQFHQWUDWLRQUHODWLRQVKL SLQWKHVHWWLQJRIDGGRQ
WKHUDS\3DQHO&
5DWLRQDOHIRU(QGSRLQWV
 6DIHW\(QGSRLQWV6DIHW\DQGWROHUDELOLW\ZLOOEHDVVHVVHGWKURXJKRXWWKHVWXG\E \PRQLWRULQJSDUWLFLSDQWV IRU
FOLQLFDO$(V DVZHOODVWKURXJKWKHFRQGXFWRISK\VLFDODQGQHXU RORJLFDOH[DPLQDWLRQV
OHDG(&*V96DQGODERUDWRU\ VDIHW\WHVWV ,QDGGLWLRQ VFDOH VZLOOEHLQFOXGHGWRHYDOXDWH
(36DQGJHQHUDOZHOOEHLQJ
$SUHOLPLQDU\H[SRVXUHUHVSRQVHPRGHOEDVHGRQGDWDIURPWKH0$ 'VWXG\3ZKLFK
HYDOXDWHGGRVHV IRXQGQRUHODWLRQVKLSEHWZHHQ0.FRQFHQWU DWLRQVDQG
47F)LQWHUYDOVRUKHDUWUDWH+5,QDGGLWLRQSUHFOLQLFDOGDWD GRQRWVXJJHVWDULVNRI
SURORQJHGFDUGLDFUHSRODUL]DWLRQ$V47FLVDSKDU PDFRG\QDPLF 3 'HQGSRLQWRIWKLVVWXG\
WKLVHQGSRLQW LVIXUWKHUGLVFXVVHGXQGHU6HFWLRQ +RZHYHU DVGRVHVDUHEHLQJ
HVFDODWHG LQWKLVWULDODERYHGRVHVSUHYLRXVO\HYDOXDWHGWKHVD IHW\(&*V ZLOOEHFRQGXFWHG
DURXQGWKHWLPHRISHDNSODVPDFRQFHQWUDWLRQV
 <CCI
PRODUCT: MK-8189  43
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
As EPS are associated with antipsy chotics and have been observed in the MK-8189 clinical 
program, t he Barnes Akathisia Rating Scale ( BARS ), Abnormal Involuntary Movement 
Scale (AIMS) and Sim pson Angus Scale (SAS) will be used to quantify  any EPS observed in 
the trial .The BARS is an akathisia rating scale with objective and subjective measures and 
an overall rating from 0to 5.A score of 0presents no evidence for akathisia , a score of 3 is 
moderate akathisia and a score of 5 is severe akathisia . The AIMS evaluates 12 items and 
uses a 5 -point scale to assess abnormal movement in 3 areas (orofacial, extremities, trunk).
The S AS evaluates 10 items and uses a 5 -point scale to measure s ymptoms of parkinsonism 
or parkinsonian side effects (including rigidit y, tremor, akinesia, and salivation).   
In case moderate EPS symptoms in an individual participant persist ,the dose will not be 
further up titrated for this participant . Participants with severe EPS sy mptoms will be 
discontinued if not attenuated with dose reduction , dose titration and/or medical 
management. 
To monitor the psy chological well -being ,the Bond and Lader Visual Analogue Scale (VAS ) 
will be used in all participants. Inparticipants with schizophrenia ,the Brief Psy chiatric 
Rating Scale (BPRS )will be used.  The BPRS is rating scale to measure psy chiatric 
symptoms such as depression ,anxiety ,hallucinations and unusual behavior in a range of 
psychotic and affective sy mptom s.The BPRS ha sbeen used in clinical research as a tool to 
measure treatment effects and are effective scales to monitor the general well -being of the 
psychiatric patients. The BPRS consists of 18 symptom constructs and takes 20 -30 minutes 
for the interview and scoring. The rater should enter a number ranging from 1 (not present) to 
7 (extremely  severe). 0 is entered if the item is not assessed. Participants who experience 
severe psychosis during the study  will be discontinued and referred for additional treatment 
asindicated.
TheColumbia Suicide Severit yRating Scale (C -SSRS) will be administered to monitor 
mood and suicidal ideation and behavior in all trial participants (see Section 4.2.3).
All dose titration decisions will be made jointly  by the investigator and the Sponsor. Each 
dose titration decision for each individual participant will occur after 3 days of dosing per 
dose level .However, if a participant needs to be discontinued or have a dose reduction based 
on safet y/tolerability , the princ ipal investigator may do so independent of consultation with 
the Sponsor.
4.2.1.2 Pharmacokinetic Endpoints
An objective of this study is to characterize the PK of MK -8189, particularly  at higher doses 
which have not been previously  evaluated. Therefore, individua l plasma concentration and 
actual sample collection times of MK -8189 will be used to drive the PK parameter values 
AUC0 -24, Cmax, Tmax , C24hr , CL, Vd and apparent t1/2 .Â 
Â  059Y88
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
 3KDUPDFRG\QDPLF(QGSRLQWV
$Q H[SORUDWRU\REMHFWLYHRIWKLVWULDOLVWRHYDOXDWHHIIHFWVRI DVXSUDWKHUDSHXWLFGRVHRI
0.RQ47FLQWHUYDO7KHSRWHQWLDOHIIHFWRIDGUXJRQFDUG LDFUHSRODUL]DWLRQFDQEH
PHDVXUHGDVSURORQJDWLRQRIWKH47LQWHUYDORQ(&*UHFRUGLQJV 7KHUHLV LQJHQHUDO D
TXDOLWDWLYHUHODWLRQVKLSEHWZHHQVXEVWDQWLDO47SURORQJDWLRQDQ GWKHULVNRI7G37KH
UDWLRQDOHIRUWKHHQGSRLQWLVWKXVWRGHPRQVWUDWHWKDW0. GRHVQRWPHDQLQJIXOO\
SURORQJLH!PVHFWKH47FLQWHUYDO
,Q3DQHOV $ % DQG'HOHFWURFDUGLRJUDPGDWD HJ4745655 DQG 35 LQWHUYDOVZLOOEH
REWDLQHGZLWKDGLJLWDO+ROWHUGHYLFHDWHDFKGRVHOHYHOEHJLQ QLQJZLWKWKHPJGRVHLQ
3DQHOV$DQG%DQGWKHPJGRVHLQ3DQHO'$KRXU+ROWHUZ LOODOVREHFRQGXFWHGRQ
'D\VXFKWKDW(&*GDWDFDQEH H[WUDFWHGDWWLPHSRLQWVWLPHPD WFKHGWRSRVWGRVH
DVVHVVPHQWV DVVSHFLILHGLQWKH6R$
 3ODQQHG([SORUDWRU\%LRPDUNHU5HVHDUFK 3ODQQHG*HQHWLF$QDO\VLV*HQHWLFYDULDWLRQPD\LPSDFWDSDUWLFLSDQWÂ¶VUHVSRQVHWRWKHUDS \VXVFHSWLELOLW\WRVHYHULW\
DQGSURJUHVVLRQRIGLVHDVH9DULDEOHUHV SRQVHWRWKHUDS\PD\EH GXHWRJHQHWLFGHWHUPLQDQWV
WKDWLPSDFWGUXJDEVRUSWLRQGLVWULEXWLRQPHWDEROLVPDQGH[FU HWLRQPHFKDQLVPRIDFWLRQRI
WKHGUXJGLVHDVHHWLRORJ\DQGRUPROHFXODUVXEW\SHRIWKHGLV HDVHEHLQJWUHDWHG7KHUHIRUH
ZKHUHORFDOUHJXODWLRQVDQG,5%,(&DOORZDVDPSOHZLOOEHFRO OHFWHGIRU'1$DQDO\VLV
IURPFRQVHQWLQJSDUWLFLSDQWV
'1$VDPSOHVZLOOEHXVHGIRUUHVHDUFKUHODWHGWRWKHVWXG\LQWH UYHQWLRQVWKHGLVHDVHXQGHU
VWXG\DQGUHODWHGGLVHDVHV7K H\PD\DOVREHXVHGWRGHYHORSW HVWVDVVD\VLQFOXGLQJ
GLDJQRVWLFWHVWVUHODWHGWRWKHGLVHDVHXQGHUVWXG\UHODWHGGL VHDVHVDQGVWXG\LQWHUYHQWLRQV
*HQHWLFUHVHDUFKPD\FRQVLVWRIWKHDQDO\VLVRIRUPRUHFDQGL GDWHJHQHVRUWKHDQDO\VLVRI
JHQHWLFPDUNHUVWKURXJKRXWWKHJHQRPH>RUDQDO\VLVRIWKHHQWLU HJHQRPH@DVDSSURSULDWH
'1$VDPSOHVZLOOEHDQDO\]HGIRUYDULDWLRQDFURVVWKHHQWLUHJH QRPH$QDO\VHVPD\EH
FRQGXFWHGLILWLVK\SRWKHVL]HGWKDWWKLVPD\KHOSIXUWKHUXQGH UVWDQGWKHFOLQLFDOGDWD
7KHVDPSOHVPD\EHDQDO\]HGDVSDUWRIDPXOWLVWXG\DVVHVVPHQW RIJHQHWLFIDFWRUVLQYROYHG
LQWKHUHVSRQVHWRXQGHUVWDQGVWXG\GLVHDVHRUUHODWHGFRQGLWLR QV
,QDGGLWLRQWRVWXG\LQJYDULDWLRQDFURVVWKHKXPDQJHQRPHSRO\ PRUSKVRI ZLOO
VSHFLILFDOO\EHLQYHVWLJDWHGIRUDVVRFLDWLRQZLWKWKH3.DQG3' RI0.*HQHWLF
YDULDWLRQ PD\EHDQDO\]HGIRUDVVRFLDWLRQZLWKDQ\ODERUDWRU\ RUFOLQLFDOGDWD
FROOHFWHGLQWKLVVWXG\
 <CCI
CCI
PRODUCT: MK-8189  45
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
4.2.1.5 Future Biomedical Research
The Sponsor will conduc t future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measureme nt of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therape utic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect time. The 
details of this future biomedical r esearch substudy  are presented in Appendix 6.
Rationale for t he Use of Comparator/Placebo
Amatched placebo- control will be included to reduce bias with regards to the participant
reporting and investigator assessment of AEs.  In addition, inclusion of a placebo cohort will 
also control for potential bias introduced b y study procedures and to increase the power to 
exclude modest QTc effects in a study  with a relatively  small sample size.
Rationale for Suicidal Ideation and Behavior Monitori ng
Prospective assessment of suicidal ideation and behavior will be performed in this study  
using the C -SSRS. This assessment is being conducted in compliance with the 2012 FDA 
guidance requiring prospective assessment in cl inical trials conducted under Investigational 
New Drug (IND) applications and trials that ar e intended for submission in a New Drug 
Application to the Neurology  or Ps ychiatr y Divisions of the FDA or biologics license 
application, as well as assessment in trials that fall within the guida nce for other reasons 
(e.g., central nervous s ystem active/penetrant compounds, and known mechanisms or 
indications for which suicidal ideation/behavior has been previously identified as a potential 
concern).
4.3 Justification for Dose
The methods used in cal culating doses and estimated exposures are detail ed in Sections 4.3.1 
and 4.3.2.Â 
Â  059Y88
352'8&7 0. 
35272&2/$0(1'0(1712 
0.),1$/35272&2/ 6(3
6WDUWLQJ'RVHIRU7KLV6WXG\
$PJVWDUWLQJGRVHZLWKWKH&5WDEOHWIRUPXODWLRQKDVEHHQVK RZQWREHZHOOWROHUDWHGLQ
SUHYLRXVFOLQLFDOWULDOVLQVFKL]RSKUHQLDLQFOXGLQJWKH0$'VWX G\3DVZHOODVWKH32&
VWXG\36LQFHWKHVDIHW\DQGWROHUDELOLW\SURILOHLQKHD OWK\SDUWLFLSDQWVDQGSDUWLFLSDQWV
ZLWKVFKL]RSKUHQLDLVVLPLODUDPJGRVHKDVEHHQVHOHFWHGIR UWKHFXUUHQWSURWRFROLQ3DQHOV
$%DQG& $VKLJKHUGRVHVDUHEHLQJSURSRVHGIRU3KDVHLWL VLPSRUWDQWWRH[SORUH
RSWLPL]HGWLWUDWLRQVFKHGXOHVWKHUHIRUH3DQHO'ZLOOH[SORUHD VWDUWLQJGRVHRIPJ
,QLWLDWLQJWKHGRVHDWPJLVVXSSRUWHGE\WKHWROHUDELOLW\RE VHUYHGLQ3DQHO$3DQHO%DQG
3DQHO&,QDGGLWLRQWKHDYHUDJHUHFHSWRURFFXSDQF\LQFUHDVHIUR PWRPJLV
DSSUR[LPDWHO\ ZLWKDODUJHGHJUHHRIRYHUODSEHWZHHQGRVHVVHH ILJXUH
EHORZLQVHFWLRQWKXVWKHWROHUDELOLW\LVH[SHFWHGWRE HVLPLODUEHWZHHQWKHWZRVWDUWLQJ
GRVHV$VGHVFULEHGLQWKHVWXG\GHVLJQ6HFWLRQDVPDOO FRKRUWQ ZLOOLQLWLDOO\EH
GRVHGZLWKPJWRFRQILUPWROHUDELOLW\SULRUWRGRVLQJWKHUHPD LQGHURIWKHFRKRUW
0D[LPXP'RVH([SRVXUHIRU7KLV6WXG\
$VGHVFULEHGLQ6HFWLRQSUHYLRXVWULDOVKDYHGHPRQVWUDWH GWKDW0.KDVEHHQ
JHQHUDOO\ZHOOWROHUDWHGXSWRGRVHVRIPJLQKHDOWK\SDUWLF LSDQWVDQGXSWRPJLQ
SDUWLFLSDQWVZLWKVFKL]RSKUHQLDGRVHVXSWRPJKDYHEHHQHYD OXDWHGDVPRQRWKHUDS\DQG
GRVHVXSWRPJKDYHEHHQHYDOXDWHGDVDGGRQWKHUDS\'DWDI URPWKHSUHVHQWWULDO
LQGLFDWHGRVHVXSWRPJDUHJHQHUDOO\ZHOOWROHUDWHGDVPRQRW KHUDS\LQKHDOWK\
SDUWLFLSDQWVDQGSDUWLFLSDQWVZLWKVFKL]RSKUHQLD
)ROORZLQJDWLWUDWLRQVFKHGXOHIURPPJWRPJRYHUGD\V WKH$8&ZDVIRXQGWR
EHDSSUR[LPDWHO\ ,I3.UHPDLQVGRVHSURSRUWLRQDOXSWRPJ WKHSUHGLFWHG
H[SRVXUHPDUJLQWRWKH$8&IRUDPJGRVHDVGHULYHGIURP WKHFKURQLFWR[LFRORJ\
VWXGLHVZRXOGEH 7KH3.SURILOHIRU0.LVVLPLODUZKHQ DGPLQLVWHUHGDV
PRQRWKHUDS\RUDVDGG RQWKHUDS\%ULHIVXPPDULHVRIWKHFKUR QLFWR[LFRORJ\VWXGLHV
VXSSRUWLQJGRVHHVFDODWLRQDUHSURYLGHGEHORZ
,QWKHPRQWKUDWVWXG\GRVHVRIDQGPJNJGD\ ZHUHHYDOXDWHG7ZR
KLJKGRVHPJNJGD\IHPDOHUDWVZHUHIRXQGGHDGVWXG\ZH HNDQGVWXG\ZHHN
ZLWKDFXWHWXEXODUQHFURVLVZLWKDQGZLWKRXWWXEXODUPLQHUDOL] DWLRQ7KHUHIRUHWKH
PJNJGD\GRVHZDVFRQVLGHUHGWKHQRREVHUYHGDGYHUVHHIIHFWOH YHO12$(/IRUWKLVVWXG\
$8&KU  SURYLGLQJDQH[SRVXUHPDUJLQRI RYHUWKHSUHGLFW HG
VXSUDWKHUDSHXWLFH[SRVXUHRI DWWKHPJGRVH
,QWKHPRQWKPRQNH\VWXG\GRVHVRIRU PJNJGD\RI0.
ZHUHDGPLQLVWHUHG5HQDOWXEXODUGHJHQHUDWLRQZDVREVHUYHGLQW KHKLJKGRVHJURXS
PJNJGD\7KH12$(/IRUWDUJHWRUJDQWR[LFLW\LV PJNJGD\
$8&KU SURYLGLQJD RYHUWKHSUHGLFWHGVXSUDWKHUDSHXWLF H[SRVXUH
RI DWWKHPJGRVH
7KHHIIHFWVRI0.RQPHDVXUHVRIFDUGLDFFRQGXFWLRQDQGUHS RODUL]DWLRQZHUHDVVHVVHG
LQERWKLQYLWURK(5*FXUUHQW>,.U@HYDOXDWLRQDQG LQYLYRDQHVWKHWL]HGJXLQHDSLJVDQG
FRQVFLRXVWHOHPHWHUHGPRQNH\PRGHOV0.LQKLELWHGK(5*FX UUHQWZLWKDQ,&
 <CCI
CCI
CCI
CCI
CCICCI
CCI CCI
CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0.),1$/35272&2/ 6(3
YDOXHRI SURYLGLQJODUJHPDUJLQV WRWKHSURMHFWHGPHGLDQXQER XQG
&PD[IRUHIILFDF\PJGRVHLQKXPDQV,QDQDQHVWKHWL]HGJXL QHDSLJVWXG\0.
KDGQRHIIHFWVRQ+5DQG(&*SDUDPHWHUV$YHUDJHSHDNSODVPDFRQFH QWUDWLRQVRI
0.PHDVXUHGGXULQJWKHPLQLQIXVLRQVRIDQGPJ NJZHUHDQG
UHVSHFWLYHO\7KXVWKH12(/12$(/LQWKLVVWXG\ZDV SURYLGL QJDQ
H[SRVXUHPDUJLQRI UHODWLYHWRWKHSURMHFWHGFOLQLFDO&PD[DWW KHPJGRVHRI
,QDWHOHPHWU\VWXG\LQPRQNH\VVLQJOHRUDOGRVHVRIDQG PJNJZHUHHYDOXDWHGDQG
WHVWDUWLFOHUHODWHGGRVHLQGHSHQGHQWLQFUHDVHVLQ+5EORRGSU HVVXUH%3DQGWKHUDWH
FRUUHFWHG47LQWHUYDOZHUHREVHUYHG,QDVHFRQGVWXG\ DWORZHURUDOGRVHVRIDQG
PJNJWKHUHZHUHQRWHVWDUWLFOHUHODWHGHIIHFWV7KXVWK HQRREVHUYHGHIIHFWOHYHOZDVD
VLQJOHRUDOGRVHRIPJNJSURYLGLQJH[SRVXUHPDUJLQVRI RI WKHSURMHFWHGFOLQLFDO
&PD[RI $QXPEHURIVWXGLHVZHUHFRQGXFWHGWRGHWHUPLQHWKHXQG HUO\LQJFDXVH
VHH0.,%IRUDGGLWLRQDOGHWDLOV7KHJHQHUDOFRQFOXVLRQ IURPWKHVHVWXGLHVZDVWKDW
LQFUHDVHVLQ+5%3DQG47LQWHUYDOOLNHO\RFFXUGXHWRDVWUHV VLQGXFHGUHOHDVHRI
HSLQHSKULQHVXEVHTXHQWWR3'($WDUJHWHQJDJHPHQWLQFRQVFLRXV UKHVXVPRQNH\VDQG
WKHUHIRUHWKHVHFKDQJHVLQ47+5DQG%3DUHQRWUHOHYDQWWRKXP DQV
7KHUHIRUHSUHFOLQLFDOGDWDVXSSRUWGRVHHVFDODWLRQWRPJLQ WKHFXUUHQWVWXG\,QDGGLWLRQ
GXULQJWKH VWXG\VDIHW \DQGWROHUDELO LW\ZLOOEHFDUHIXOO\DVVH VVHGLQFOXGLQJVFDOHVWRDVVHVV
G\VWRQLD'RVHHVFDODWLRQPD\EHVWRSSHGEDVHGRQWROHUDELOLW\
5DWLRQDOHIRU'RVH,QWHUYDO DQG6WXG\'HVLJQ
7R PLWLJDWH WKH ULVN RI (36 DQWLSV\FKRWLF WUHDWPHQW LV JHQHUDOO\ LQLWLDW HG XVLQJGRVH
WLWUDWLRQVFKHGXOHVLQ ZKLFK WKH GRVH LVJUDGXDOO\ LQFUHDVHG ZKLOH PRQLW RULQJ IRU
IUHTXHQF\DQG VHYHULW\ RI (36 V\PSWRPV 7KH GRVH WLWUDWLRQ VWHSV LQ3DQHO $%DQG&RI
WKH FXUUHQW VWXG\ DUH EDVHG RQGRVHWLWUDWLRQSDUDGLJPVXVHGLQSULRU0.VWXGLHV
ZKLFKKDYHEHHQJHQHUDOO\ZHOOWROHUDWHG $VGRVHVDVKLJKDVPJDUHSODQQHGWREH
HYDOXDWHGLQ3KDVH3DQHO'ZLOOH[SORUHDQRSWLPL]HGWLWUDWL RQVFKHPHWRVKRUWHQWKHWLPHWR
UHDFKWKHLQWHQGHGWKHUDSHXWLFGRVHZKLOHPLQLPL]LQJWKHSRWHQW LDOIRU$(V7KH0. 
SURJUDPLQLWLDOO\EDVHGLWVWLWUDWLRQVWUDWHJ\RQFXUUHQWSUDFWLF HRIWLWUDWLRQVFKHGXOHVIRU
DQWLSV\FKRWLFVDQGRQLQIRUPDWLRQDYDLODEOHRQGRVHWLWUDWLRQVFKHGXO HVZLWKRWKHU
LQYHVWLJDWLRQDO3'($LQKLELWRUV'RVHWLWUDWLRQRIDQWLSV\FKRWLFV LVXVXDOO\GRQHHYHU\RU
GD\V>-DQVVHQ3KDUPDFHXWLFDO/WG@>1RYDUWLV3KDUPDFHXWLFDOV @>863UHVFULELQJ
,QIRUPDWLRQ@>3IL]HU@>(OL/LOO\@>863UHVFULE LQJ,QIRUPDWLRQ@
+RZHYHUIRUFRPSRXQGVZLWKDORQJHUKDOIOLIHVXFKDVRODQ]DSLQHW  KRXUVDQG
DULSLSUD]ROHW KRXUVDVORZHUGRVHWLWUDWLRQLVUHFRPPHQGHG>' HSDUWPHQWRI3XEOLF
+HDOWK@)ROORZLQJDGPLQLVWUDWLRQRI0.DVDQLPPHGLDWH UHOHDVHGRVHIRUP
0.KDVDKDOIOLIHRI FRPSDUDEOHWRTXHWLDSLQHDQG]LSUDVLGRQ HDQGGRVH
WLWUDWLRQRQFHHYHU\GD\VLVDQWLFLSDWHGWREHDGHTXDWHWRSUHYHQW(3 6$(VLHG\VWRQLD
DQGDNDWKLVLDRUWRDOORZ(36WRDWWHQXDWHEHIRUHWKHQH[WWLWUDWLRQVWHS 7KHGRVHWLWUDWLRQ
VFKHGXOHVIRUDOO3DQHOVDUHGHVFULEHGLQ6HFWLRQDQG6HFWL RQ$VGHVFULEHGLQ6HFWLRQ
DQDOWHUQDWHGRVHWLWUDWLRQVFKHGXOHUHJLPHQLVSURYLGHGI RU3DQHO'LILWLVIRXQGWKDWD
VWDUWLQJGRVHRIPJDVFRPSDUHGWRPJLVQRWZHOOWROHUDW HG,QWKLVDOWHUQDWHWLWUDWLRQ
VFKHGXOHDODUJHUILQDOWLWUDWLRQVWHSRIIROGPJWRP JDVFRPSDUHGWRWKHSUHYLRXV
 <CCI CCI
CCI CCI
CCI
CCI
CCICCI
CCI
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
WLWUDWLRQVWHSRIIROGPJWRPJZLOORFFXU7KLVL VVXSSRUWHGVLQFHDWWKHKLJKHU
HQGRIWKHGRVHHVFDODWLRQWKHIODWSRUWLRQRIWKHGRVHHQ]\PH UHFHSWRURFFXSDQF\LV
DSSURDFKHGDQGWKHUHI RUHRQO\VPDOOFKDQJHVLQSKDUPDFRG \QDPLFUHVSRQVHZRXOGEH
DQWLFLSDWHG VHHILJXUHEHORZ
 %HJLQQLQJDQG(QGRI 6WXG\'HILQLWLRQ
7KHRYHUDOOVWXG\EHJLQVZKHQWKHILUVWSDUWLFLSDQWVLJQVWKH, &)7KHRYHUDOOVWXG\HQGV
ZKHQWKHODVWSDUWLFLSDQWFRPSOHWHVWKHODVWVWXG\UHODWHGWHOH SKRQHFDOORUYLVLWZLWKGUDZV
IURPWKHVWXG\RULVORVWWRIROORZXSLHWKHSDUWLFLSDQWLV XQDEOHWREHFRQWDFWHGE\WKH
LQYHVWLJDWRU
3ULRUWRDILQDOGHFLVLRQRQFRQWLQXDWLRQRUWHUPLQDWLRQRIWKH VWXG\ D VWXG\PD\ EHSDXVHG
GXULQJUHYLHZRIQHZO\DYDLODEOHSUHFOLQLFDOFOLQLFDOVDIHW\S KDUPDFRNLQHWLF
SKDUPDFRG\QDPLFHIILFDF\RUELRORJLFGDWDRURWKHULWHPVRIL QWHUHVWSULRUWRDILQDO
GHFLVLRQRQFRQWLQXDWLRQRUWHUPLQDWLRQRIWKHVWXG\,WPD\EH QHFHVVDU\WRNHHSWKHVWXG\
RSHQIRUJDWKHULQJUHYLHZLQJRIDGGLWLRQDOVXSSRUWLYHGDWDWRR SWLPDOO\FRPSOHWHWKH
REMHFWLYHVRIWKHVWXG\,IQHFHVVDU\WKHDSSURSULDWHDPHQGP HQWVWRWKHSURWRFRODQGRU
DSSURSULDWHFRPPXQLFDWLRQVZLOOEHJHQHUDWHG,IWKHGHFLVLRQ KDVEHHQPDGHWRHQGWKH
VWXG\IROORZLQJWKLVUHYLHZSHULRGWKHVWXG\HQGZLOOEHGHILQ HGDVWKHGDWHRIWKH6SRQVRU
GHFLVLRQDQGWKLVHQGRIVWXG\GDWHVXSHUVHGHVWKHGHILQLWLRQV RXWOLQHGDERYH 7KH&RPSHWHQW
$XWKRULW\LHVDQG,QVWLWXWLRQDO5HYLHZ%RDUGV,QGHSHQGHQW(W KLFV&RPPLWWHHV
>,5%V,(&V@ZLOOEHDSSULVHGRIWKHPD[LPXPGXUDWLRQRIWKH VWXG\EH\RQGWKHODVW
SDUWLFLSDQWRXWDQGWKHMXVWLILFDWLRQIRUNHHSLQJWKHVWXG\RSH Q

 <CCI
PRODUCT: MK-8189  49
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Clinical Criteria f orEarly Study Termination
There are no pres pecified criteria for terminating the study  early.
5 STUDY POPULATION
Health yJapanese and non -Japanese and schizophrenic male and female participants , with an 
attempt to enroll approximately 40% of female participants (in each panel) ,between the ages 
of 18and 60 years(inclusive) will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Panel A (Healthy Participants) Inclusion Criteria
Participants are eligible to be included in the study onl y if all o f the following criteria apply:
1.Is in good health based on medical history, ph ysical examination, vital sign (VS) 
measurements and 12-lead safet yECGs performed prior to randomization. Appendix 8
provides a table of the 12 -Lead Electrocardiogram Abnormality Criteria.
2.Is in good health based on laboratory  safet y tests obtained at the screening visit. 
Appendix 2 provides a table of laboratory safet y tests to be performed. Appendix 9 
provides an algorithm for the assessment of out of range laboratory values.
3.Have a Bod y Mass Index (BMI) >18.5 and â‰¤ 35kg/m2, inclusive, and total body  weight 
of  > 50kg (110 lbs) at the screening visit . See Section 8.3.2 for criteria on rounding to 
the nearest whole number. BMI = weight (kg)/height (m)2.
4.Have no clinically  signifi cant abnormalit y on the 12 -lead safet y ECG performed at the 
pre-trial (screening) visit and/or prior to randomization . The assessment p rior to 
randomization is based on the mean of the triplicate measures. Note:  The QTcF duration 
must be <450 msec for males and <470 msec for females, the QRS duration <120 msec 
and the PR interval <200 msec. Repeat 12-lead safety  ECGs may  be performed in 
participants whose parameters are , per investigator discretion, minimally  outside the 
designated range. Appendix 8 provides a table of the 12- Lead Electrocardiogram 
Abnormality  Criteria.
5.Have a normal resting blood pressure (systolic blood pressure is â‰¥90 mm Hg and 
â‰¤140 mmHg; diastolic blood pressure is 
â‰¥60 mmHg and â‰¤90 mmHg) and normal resting 
heart rate ( â‰¥45 beats per minute [bpm] and â‰¤100 bpm) in the semi -recumbent position at 
the pre- trial (screening) visit and/or prior t o randomization (up to the time -matched 
8hour assessment) . Repeat evaluations may  be done if the values for a participant are, 
per investigator discretion, minimally  outside the designated range. The assessment prior 
to randomization is based on the mean of the triplicate measures.Â 
Â  059Y88
PRODUCT: MK-8189  50
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Demographics
6.Participant is Male or Female .
7.Participant is from 18yearsto 60yearsof age inclusive, at the time of signing the 
informed consent.
     Female Particip ants
d.If the participant is a female with reproductive potential, she must demonstrate a 
serum Î² -human chorionic gonadotropin (Î² -hCG) level consistent with the nongravid 
state at the prestud y (screening) visit and agree to use (and/or have their partner use) 
2 acceptable methods of birth control beginning at the prestud y (screening) visit, 
throughout the study (including washout intervals between treatment periods/panels) 
and until 2 weeks after the last dose of stud y drug in the last treatment period. 
Acceptable methods of birth control are defined in Section 5.3.1.
e.If the participant is a postmenopausal female: she is without menses for at least 1 year 
and have a follicle stimulating hormone (FSH) value in the postmenopausal range 
upon prestudy  (screening) evalu ation.
f.If the participant is a surgically  sterile female: she is status post hy sterectomy , 
oophorectom y or tubal ligation. Note: Information regarding the procedure may  be 
based on the participantâ€™s recall of her medical history, and details of the recall must 
be captured appropriatel y within the site's source documents.
Japanese Participants
a.If the participant is of Japanese descent , both biological pa rents and all biological 
grandparents must be born in Japan.  Adequate documentation to verify  the descent 
should be obtained and kept with source documents .  While 2ndand 3rdgeneration 
Japanese are acceptable for enrollment, preference should be given to enrollment of 
subjects who were born in Japa n.
Informed Consent
8.The participant provides written informed consent for the stud y. The participant may  also 
provide consent for future biomedical research. However, the participant may  participate 
in the main study  without participating in future biomedi cal research.
Additional Categories
9.Is willing to comply  with the study  restrictions (see Section 5.3for a complete summary  
of study  restrictions).Â 
Â  059Y88
PRODUCT: MK-8189  51
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Panel B ,Panel C and Panel D (Participants with Schizophreni a) Inclusion 
Criteria
Participants are eligibl e to be included in the study onl y if all of the following criteria appl y:
10.Is in good health based on laboratory  safet y tests obtained at the screening visit. 
Appendix 2 provides a table of laboratory safet y tests to be performed. Appendix 9 
provides an algorithm for the assessment of out of range laboratory  values.
11.Have a Bod y Mass Index (BMI) >18.5 and â‰¤ 40 kg/m2, inclusive, and total body  weight 
of>50 kg (110 lbs) at the screening visit . See Section 8.3.2 for criteria on rounding to 
the nearest whol e number. BMI = weight (kg)/height (m)2.
12.Have no clinically  significant abnormalit y on 12-lead safet y ECG performed at the pre -
trial (screening) visit and/or prior to randomization. 
The assessment prior to 
randomization is based on the mean of the triplica te measures. Note:  The QTcF duration 
must be <450 msec for males and <470 msec for females, the QRS duration <120 msec 
and the PR interval <200 msec. Repeat 12-lead safety  ECGs may  be performed in 
participants whose parameters are , per investigator discre tion, minimally  outside the 
designated range. Appendix 8 provides a table of the 12- Lead Electrocardiogram 
Abnormality  Criteria.
13.Have a normal resting blood pressure (sy stolic blood pressure is â‰¥90 mm Hg and â‰¤140 
mmHg; diastolic blood pressure is â‰¥60 mmHg and â‰¤90 mmHg) and normal resting heart 
rate ( â‰¥45 beats per minute [bpm] and â‰¤100 bpm) in the semi- recumbent position at the 
pre-trial (screening) visit and/or prior to randomization. Repeat evaluations may  be done 
if the values for a participant are, per investigator discretion, minimally outside the 
designated range. The assessment prior to randomization is based on the mean of the 
triplicate measures. For Panel C and Panel D , participants may be included if values are 
outside the normal range but considered not clinically  significant per investigator 
discretion.
14.Meetsdiagnostic criteria for schizophrenia or schizoaffective disorder according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM -5)criteria with the onset of 
the first episode being no less than 2 years prior to screening and monotherapy  with 
antipsy chotics for treatment should be indicated .
15.Has a total Brief Ps ychiatric Rating Scale (BPRS) score of < 48 with a BPRS score < 4 
for #10(hostility ) and #14(uncooperativeness) at the screening visit .
16.Isin the non -acute phase of their illness and clinically  stable for 3 months prior to 
screening as demonstrated by :
a.no clinically  significant change in dose of prescribed antipsy chotic medication, or 
clinically  significant change in antipsy chotic medication to treat s ymptoms of 
schizophrenia for two months prior to screening;Â 
Â  059Y88
PRODUCT: MK-8189  52
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
b.no increase in level of psychiatric care due to worsening of s ymptoms of 
schizophrenia for three months prior to screening .
17.Has a history  of receiving and tolerating antips ychotic medication within the usual dose 
range emplo yed for schizophrenia .
18.Hasa stable living situation in which the patient or a contact person can be reached b y 
the investigator i f there is a need for follow up.
19.Participants with hy pothy roidism, diabetes, high blood pressure, chronic respiratory  
conditions or other mild forms of these medical conditions could be considered as 
candidates for study  enrollment if their condition is stable and the p rescribed dose and 
regimen of medication is stable for at least 3 months prior to screening and there are no 
expected changes in co- medication during the study . 
20.Hasregular bowel movements and, in the opinion of the investigator, no clinically  
significant diarrhea or constipation.
21.Panels B and D : Participant is able to discontinue the use of all antips ychotic medication 
at least 5 day s prior to the start of the treatment period and during the study period. 
Demographics
22.Participant is Male or Female .
23.Participant is from 18yearsto 60yearsof age inclusive, at the time of signing the 
informed consent.
Female Participants
24. A female participant is eligible to participate if she is not pregnant or breastfeeding, 
and at least one of the following condition s applies: 
â€¢Is not a WOCBP
OR
â€¢Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate 
of <1% per year), with low user dependency , or be abstinent from heterosexual 
intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent 
basis), as described in Appendix 5 during the intervention period and for at least 14 days
after the last dose of study intervention. The investigator should evaluate the potential for 
contraceptive method failure (ie, non compliance, recentl y initiated) in relationship to the 
first dose of study  intervention.
â€¢A WOCBP must have a negative highly  sensitive pregnancy  test (serum as required b y 
local regulations) within 24 hours before the first dose of study intervention.Â 
Â  059Y88
PRODUCT: MK-8189  53
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
â€¢Addi tional requirements for pregnancy  testing during and after stud y intervention are 
located in Appendix 2.
â€¢The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy .
Informed Consent
25.The participant provides written informed consent for the stud y. The participant may also 
provide consent for future biomedical research. However, the participant may  participate 
in the main study  without participating in future biomedical research.
Additional Categories
26.Is willing to comply  with the study  restrictions (see Section 5.3for a complete summary  
of study  restrictions).
5.2 Exclusion Criteria
Panel A (Healthy Participants) Exclusion Criteria
Participants are excluded from the study if an y of the following criteria apply:
Medical Conditions
1.Has a history  of clinically  diagnosed depression, anxiety  disorder, or any  history  of 
psychiatric disorders having required drug treatment or hospi talization. Participant s who 
have had situational depression more than 5 y ears before the start of the study  may  be 
enrolled in the study  at the discretion of the investigator. 
2.Has a history  of stroke, chronic seizures, or major neurological disorder. 
3.Has a history  of dystonic reaction to antips ychotic, anti -emetic or related medication
4.Is at imminent risk of self -harm, based on clinical interview and responses on the 
C-SSRS , or of harm to others in the opinion of the investigator.  Participant s must be 
excluded if they  report suicidal ideation with intent, with or without a plan or method 
(e.g., positive response to item 4 or 5 in assessment of suicidal ideation on the C -SSRS) 
in the past 5 y ears or suicidal behavior in  their lifetime. 
5.Is a woman of ch ildbearing potential ( WOCBP )who has a positive serum pregnancy  test 
at the screening visit or a positive urine pregnancy test within 48 hours before the first 
dose of study  intervention. If the urine test is positive or cannot be confirmed as negative, 
a serum pregnancy  test will be required. Â 
Â  059Y88
PRODUCT: MK-8189  54
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
6.Has a history  of clinically  significant endocrine, gastrointestinal, cardiovascular, 
hematological, hepatic, immunological, renal, respiratory , genitourinary , or major 
neurological (including stroke and chronic seizu res) abnormalities or diseases. 
Participants with a remote history  of uncomplicated medical events ( e.g., uncomplicated 
kidney  stones, as defined as spontaneous passage and no recurrence in the last 5 y ears, or 
childhood asthma) may  be enrolled in the stud y at the discretion of the investigator.
7.Is mentally  or legall y incapacitated, has significant emotional problems at the time of 
prestudy  (screening) visit or expected during the conduct of the study or has a history of 
clinically  significant ps ychiatric d isorder of the last 5 y ears. Participants who have had 
situational depression may  be enrolled in the study at the discretion of the investigator.
8.Has an y clinicall y significant abnormal laboratory, VS, phy sical examination, or 12-lead 
safet yECG findings a t screening or changes from baseline that may  interfere with the 
interpretation of PK or safety parameters or ,in the opinion of the investigator ,would 
make the participant inappropriate for entry  into this study .
9.Has a history  of cancer (malignancy ).
Exceptions: (1) Participants with adequatel y treated nonmelanomatous skin carcinoma or 
carcinoma in situ of the cervix may participate in the study ; (2) Participants with other 
malignancies which have been successfull y treated â‰¥10 y ears prior to the prestu dy 
(screening) visit where, in the judgment of both the investigator and treating ph ysician, 
appropriate follow -up has revealed no evidence of recurrence from the time of treatment 
through the time of the prestudy  (screening) visit (except those cancers id entified at the 
beginning of this exclusion criteria); or (3) Participants, who, in the opinion of the study 
investigator, are highl y unlikely  to sustain a recurrence for the duration of the study.
10.Has a clinicall y significant history or presence of sick s inus sy ndrome, first, second, or
third degree atrioventricular (AV) block, m yocardial infarction, pulmonary congestion, 
cardiac arrh ythmia, prolonged QTc interval, or conduction abnormalities.
11.Has h istory  of repeated or frequent sy ncope, vasovagal episodes , or epileptic seizures.
12.Has a family  history  of sudden death.
13.Has a history  of an y illness that, in the opinion of the study investigator, might confound 
the results of the study or poses an additional risk to the participant by their participation 
in the study .
14.Participant has an estimated creatinine clearance (CrCl) â‰¤ 80 mL /min based on the 
Cockcroft -Gault (CG) Equation.
Cockcroft -Gault Equation: 
ClCr=(140-age[yr ])(body wt [kg])
(72)(serum creat [mg/dL])Â 
Â  059Y88
PRODUCT: MK-8189  55
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
When creatinine is measure d in micromole/litre, u sethis formul a:
ClCr=(140-age[ yr])(bo dy wt[kg])
(72)(serum creatinine [mic romol/L] x 0.0113)
For females, multiple the result by 0.85.
At the discretion of the investigator a measured creatinine clearance, as determined by a 
24-hour urine collection, may  be used in place of, or in conjunction with, the estimate of 
the creatinine clearance.
Participants who have a measured creatinine clearance of up to 10% below 80 mL /min 
may be enrolled in the study  at the discretion of t he investigator.
15.Has a history  of significant multiple and/or severe allergies ( e.g., food, drug, latex 
allergy ), or has had an anaphy lactic reaction or significant intolerability  (i.e., systemic 
allergic reaction) to prescription or non -prescription drugs or food.
16.Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
17.Had major surgery , donated or lost 1 unit of blood (approximately  500 mL) within 
4weeks prior to the prestudy  (screening) visit.
Prior/Concomitant Therapy
18.Is unable to refrain from or anticipates the use of any  medication, including prescription 
and nonprescription drugs or herbal remedies ,beginning approximately  2 weeks (or 5 
half-lives) prior to administration of the initial dose of study drug, throughout the study 
(including washout intervals between treatment periods), until the poststudy visit. There 
may be certain medications that are permitted (see Section 6.5).
Prior/Concurrent Clinical Study Experience
19.Has participated in another investigational study  within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the prestud y (screening) visit. The window will be derived 
from the date of the last visit in the previous study.
Diagnostic Assessments
20.Has history  or presence of risk factors for TdP (e.g., cardiac disease, heart failure, 
hypokalaemia or hypomagnesaemia, hypertrophy , cardiom yopath y, or family history of
long QT s yndrome).  For Panel A, p lasma calcium must be within normal limits at 
screening and serum calcium must be within normal limits prior to dosing.
Other Exclusions 
21.Is a smoker and/or has used nicotine or nicotine -containing products (e.g., nicotine patch 
and electronic cigarette) within 3 months of screening.Â 
Â  059Y88
PRODUCT: MK-8189  56
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
22.Is under the age of legal consent.
23.Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately  
equivalent to: beer [354 mL /12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 
mL/1 ounce]) per day . Participants who consume 4 glasses of alcoholic beverages per day  
may be enrolled at the discretion of the investigator.
24.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day.
25.Is a regular user of cannabis, any  illicit drugs or has a history  of drug (including alcohol) 
abuse within approximately  3 years. Participants must have a negative urine drug screen 
(UDS) prior to randomization.
26.Presents an y concern b y the investigator regarding safe participation in the study o r for 
any other reason the investigator considers the participant inappropriate for participation 
in the study .
27.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff direct ly involved with this study .
Panel B ,Panel C , and Panel D (Participants with Schizophreni a) Exclusion 
Criteria
Participants are excluded from the study if an y of the following criteria apply:
Medical Conditions
28.Has evidence or history  of a primary  DSM -5 axis I psy chiatric diagnosis other than 
schizophrenia or schizoaffective disorder per the allowed DSM -5criteria within one 
month of screening.
29.Has evidence or history  of mental retardation, borderline personality  disorder, anxiety  
disorder, or organic brai n syndrome.
30.Has a history  of neuroleptic malignant s yndrome or moderate to severe tardive dyskinesia 
(TD).
31.Has a substance -induced psy chotic disorder or behavioral disturbance thought to be due 
to substance abuse. 
32.Has a DSM-5 defined substance abuse or de pendence disorder (excluding nicotine and 
caffeine) within three months of screening.
33.Has a history  of seizure disorder bey ond childhood or is receiving treatment with any  
anticonvulsant to prevent seizures. Â 
Â  059Y88
PRODUCT: MK-8189  57
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
34.Has an untreated or uncompensated clinicall y significant renal, endocrine, hepatic, 
respiratory , gastrointestinal, psy chiatric, neurologic, cardiovascular, hematological, 
immunological or cerebrovascular disease, malignance, allergic disease or other chronic 
and/or degenerative process at screening.
35.Has any clinicall y significant abnormal laboratory, VS, phy sical examination, or 12-lead 
safet y ECG findings at screening or changes from baseline that may  interfere with the 
interpretation of PK or safety parameters or ,in the opinion of the investigator ,would 
make the participant inappropriate for entry  into this study .
36.Is at imminent risk of self -harm, based on clinical interview and responses on the 
C-SSRS , or of harm to others in the opinion of the investigator.  Participant s must be 
excluded if they report suicidal ideation with intent, with or without a plan or method 
(e.g., positive response to item 4 or 5 in assessment of suicidal ideation on the C -SSRS) 
in the past 2months or suicidal behavior in  the past 6 months.
37.Is a WOCBP who has a positiv e serum pregnancy  test at the screening visit or a urine 
pregnancy  test within 48 hours before the first dose of study  intervention. If the urine test 
is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 
38.Has a history  of cancer (malignancy ).
Exceptions: (1) Participants with adequatel y treated nonmelanomatous skin carcinoma or 
carcinoma in situ of the cervix may participate in the study ; (2) Participants with other 
malignancies which have been successfull y treated â‰¥10 y ears prior to the prestudy  
(screening) visit where, in the judgment of both the investigator and treating ph ysician, 
appropriate follow -up has revealed no evidence of recurrence from the time of treatment 
through the time of the prestudy  (screening) visit ( except those cancers identified at the 
beginning of this exclusion criteria); or (3) Participants, who, in the opinion of the study 
investigator, are highl y unlikely  to sustain a recurrence for the duration of the study.
39.Has a clinicall y significant histor y or presence of sick sinus syndrome, first, second, or 
third degree atrioventricular (AV) block, m yocardial infarction, pulmonary congestion, 
cardiac arrh ythmia, prolonged QTc interval, or conduction abnormalities.
40.Has history  of repeated or frequent sy ncope, vasovagal episodes, or epileptic seizures.
41.Has a family  history  of sudden death.
42.Has a history  of an y illness that, in the opinion of the study investigator, might confound 
the results of the study or poses an additional risk to the participant by their participation 
in the study .Â 
Â  059Y88
352'8&7 0. 
35272&2/$0(1'0(1712 
0.),1$/35272&2/ 6(3
3DUWLFLSDQWKDVDQHVWLPDWHGFUHDWLQLQHFOHDUDQFH&U&OÂ” P/PLQEDVHGRQWKH
&RFNFURIW*DXOW&*(TXDWLRQ
&RFNFURIW*DXOW(TXDWLRQ
&O&U DJH>\U@ERG\ZW>NJ@
VHUXPFUHDW>PJG/@
:KHQFUHDWLQLQHLVPHDVXUHGLQPLFURPROHOLWUHXVHWKLVIRUPXOD&O&U DJH>\U@ERG\ZW>NJ@
VHUXPFUHDWLQLQH>PLFURPRO /@[
)RUIHPDOHVPXOWLSOHWKHUHVXOWE\$WWKHGLVFUHWLRQRIWKHLQYHVWLJDWRUDPHDVXUHGFUHDWLQLQHFOH DUDQFHDVGHWHUPLQHGE\D
KRXUXULQHFROOHFWLRQPD\EHXVHGLQSODFHRIRULQFRQMXQ FWLRQZLWKWKHHVWLPDWHRI
WKHFUHDWLQLQHFOHDUDQFH
3DUWLFLSDQWVZKRKDYHDPHDVXUHGFUHDWLQLQHFOHDUDQFHRIXSWR EHORZP/PLQ
PD\EHHQUROOHGLQWKHVWXG\DWWKHGLVFUHWLRQRIWKHLQYHVWLJD WRU
+DVDKLVWRU\RIVLJQLILFDQWPXOWLSOHDQGRUVHYHUHDOOHUJLH VHJIRRGGUXJODWH[
DOOHUJ\RUKDVKDGDQDQDSK\ODFWLFUHDFWLRQRUVLJQLILFDQWLQ WROHUDELOLW\LHV\VWHPLF
DOOHUJLFUHDFWLRQWRSUHVFULSWLRQRUQRQSUHVFULSWLRQGUXJVRU IRRG
,VSRVLWLYHIRUKHSDWLWLV%VXUIDFHDQWLJHQKHSDWLWLV&DQW LERGLHVRU+,9
+DGPDMRUVXUJHU\GRQDWHGRUORVWXQLWRIEORRGDSSUR[LP DWHO\P/ZLWKLQ
ZHHNVSULRUWRWKHSUHVWXG\VFUHHQLQJYLVLW
3ULRU&RQFRPLWDQW7KHUDS\+DVUHFHLYHGWUHDWPHQWZLWKFOR]DSLQHIRUVFKL]RSKUHQLDRUWU HDWPHQWZLWKPRQRDPLQH
R[LGDVHLQKLELWRUVZLWKLQPRQWKVRIVFUHHQLQJ3DUWLFLSDQWL Q3DQHO&KDVUHFHLYHGD
WRWDOGDLO\GRVHRIULVSHULGRQH!PJ
+DVUHFHLYHGDSDUHQWHUDOGHSRWDQWLSV\FKRWLFPHGLFDWLRQZLW KLQPRQWKVRISUHWULDO
VFUHHQLQJ
,VXQDEOHWRUHIUDLQIURPWKHXVHRIFRPHGLFDWLRQZLWKDPR GHUDWHRUVWURQJLQKLELWLQJRU
LQGXFLQJHIIHFWRQ DQGRU EHJLQQLQJDSSUR[LPDWHO\ZHHNVRUKDOIOLYHVZKLFKHYHULVORQJHUSULRUWRDGPLQLVWUDWLRQRIWK HLQLWLDOGRVHRIWULDOGUXJ
DQGWKURXJKRXWWKHWULDORULVXQDEOHWRUHIUDLQIURPWKHXVHRI VHQVLWLYHVXEVWUDWHVRI
8QDEOHWRUHIUDLQIURPF\FOLFKRUPRQHUHSODFHPHQWWKHUDS \7KHUHPD\EH
FHUWDLQPHGLFDWLRQVWKDWDUHSHUPLWWHGVHH6HFWLRQ
 <CCI CCI
CCI
PRODUCT: MK-8189  59
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Prior/Concurrent Clinical Study Experience
50.Has participated in another investigational study within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the prestud y (screening) v isit. The window will be derived 
from the date of the last visit in the previous study.
Diagnostic Assessments
51.Has history  or presence of risk factors for TdP (e.g., cardiac disease, heart failure, 
hypokalaemia or hypomagnesaemia, hypertrophy , cardiom yopath y, or family history of 
long QT s yndrome).  Plasma calcium must be in within normal limits at screening and 
serum calcium must be within normal limits prior to dosing.
Other Exclusions 
52.Is under the age of legal consent.
53.Has been inincarceration or imprisonment within three months prior to screening .
54.Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately  
equivalent to: beer [354 mL /12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 
mL/1 ounce ]) per day . Participants who consume 4 glasses of alcoholic beverages per day  
may be enrolled at the discretion of the investigator.
55.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 mg of caffeine ) of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day.
56.Is a regular user of cannabis, any  illicit drugs or has a history  of drug (including alcohol) 
abuse within approximately  3 years. Participants must hav e a negative UDS prior to 
randomization.
57.Presents an y concern b y the investigator regarding safe participation in the study or for 
any other reason the investigator considers the participant inappropriate for participation 
in the study .
58. Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.Â 
Â  059Y88
PRODUCT: MK-8189  60
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
5.3 Lifestyle Considerations
Meals and Dietary Restrictions
5.3.1.1 Diet Restrictions
Fasting requirements for study  procedures, su ch as but not limited to laboratory safet y 
evalua tions are specified in Section 8 .0.
Each stud y drug administration will need to be taken with 240 mL of water after an 8 hour 
fast. Water will be restricted 1 hour prior to and 1 hour after stud y drug admini stration.   
Subjects will remain fasting until 1 hour post dose.
On full PK sampling days and/or24-hour Holter monitoring day s, participants will fast from 
all food and drinks, except water, for at least 8hours prior to study  drug administration until 
1 hour post -dose. Participants will fast from all food and drinks except water between stud y 
drug administration and the first scheduled meal. Meals and snack(s) will be provided b y the 
investigator at time points indicated in the SoA. Participants will fast from all food and 
drinks except water between meals and snacks. The caloric content and composition of meals 
will be the same on each full PK sampling and/or Holter evaluation day in each panel .  Meals 
and snacks will be served after an y coinciding Holter and/or PK procedure. After the Day  15 
(Panel D) or Day  18 (Panel A, Panel B and Panel C) 48-hour post -dose procedures have been 
completed (Day 17 or Day 20, respectivel y for Panel D or Panel A, Panel B, Panel C ), 
subsequent meals and snacks will be unrestricted in caloric content, composition and timing.
Meal and water restrictions on Day  -1 (Panel s A, B and D only) will be time -matched to 
those timepoints on 24- hour Holter/PK day s when treatment is administered.  Similarly , meal 
and water restrictions will be time -matched on Day  19 and Day  20 (Panel A and B) and Day  
16 and Day  17 (Panel D) to 24-hour Holter/PK days when treatment is administered.
On intermediate days, participants will fast from all food and drinks, except water, for at least 
8hours prior to study  drug administration.  Participants will remain fasted until 1 hour
post-dose.  Meals and snacks should be standardized for caloric content, composition and 
timing.   Meals and snacks should be served after any  scheduled ECG procedure.
5.3.1.2 Fruit Juice Restrictions
Participants will refrain from the consumption of grapefruit juice, grapefruits, and grapefruit 
products beginning approximately  2 weeks prior to administration of the initial dose of study  
drug, throughout the study until 48hours follo wing last dose administration.
On full PK sampling and/or Holter days,participants will refrain from the consumption of all 
fruit juices 24 hours prior to study  drug administration .
On intermediate day s,the consumption of all fruits and fruit juices (except for grapefruit, 
grapefruit juices, and grapefruit products) is allowed.Â 
Â  059Y88
PRODUCT: MK-8189  61
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Caffeine, Alcohol ,and Tobacco Restrictions
5.3.2.1 Caffeine Restrictions
Participants will refrain from consumption of caffeinated beverages or xanthine -containing 
products from 12 hours prior to the prestud y and poststudy  visits. 
On full PK sampling and/or Holter days (Panels A and B: Day -1, Day  7, Day  10, Day  13, 
Day 16, Day 18 and Day  19; Panel C: Day  9, Day  12, Day  15 and Day  18; Panel D: Day  -1, 
Day 1,Day 4, Day  7, Day  10, Day  13,Day 15 and Day  16),participants will be permitted to 
consume approximately  2 units of caffeinated beverages or xanthine -containing products 
only betwe en 1 hour and 2 hours post dose .Otherwise, participants will refrain from 
consumption of such products 8 hours prior to study  drug administration until the 24 -hour 
postdose ECG/PK assessment is complete .
On intermediate day s,caffeinated beverag es or xanthine -containing products will be limited 
to no more than 6 units per day  amounts (>6 units: 1 unit = 120 mg of caffeine).
5.3.2.2 Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours prior to the prestudy and 
poststudy  visits. During the in- house period, consumption of alcohol is not allowed.  At all 
other times, alcohol consumption is limited to no more than approximately 3 alcoholic 
beverages or equivalent (1 glass is approximately equivalent to: beer [354 mL /12 ounces], 
wine [118 mL/4 ounces], or distilled spirits [29.5 mL /1 ounce]) per day .
5.3.2.3 Tobacco Restrictions
For Panel A (healthy participants), s moking (and/or the use of nicotine/nicotine -containing 
products) is not permitted during the stud y.
For Panel B , Panel C and Panel D ( participants with schizophreni a), smoking restrictions 
(and if applicable, the use of nicotine/nicotine -containing products) defined by  the CRU w ill 
be followed during the study .
Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity ( i.e., weight lifting, running, 
bicycling, etc.) from the prestudy  (screening) visit until administration of the initial dose of 
study  drug, throughout the study  (including washout intervals between treatment periods) and 
until the poststudy visit.Â 
Â  059Y88
PRODUCT: MK-8189  62
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized in the study . A minimal set of screen failure information 
may be included, as outlined in the electronic case report forms ( eCRF )entry  guidelines. 
Minimal information may include demograph y, screen failure details, eligibility  criteria, and 
anyAEs or SAEs meeting reporting requirements.
5.5 Participant Replacement Strategy
A participant who discontinues from study  intervention orwithdraws from the study in 
Panel A or Pane l Bwill not be replaced.
If a participant discontinues from study  interventi on or withdraws from the study in Panel C
or Panel D ,a replacement participant may  be enrolled if deemed appropriate by  the 
investigator and Sponsor. The replacement participant will generall y receive the same 
intervention or intervention sequence (as appropriate) as the participant being replaced. The 
replacement participant will be assigned a unique treatment/randomization number. The 
study  site should contact the Sponsor for the replacement participantâ€™s 
treatment/randomization number.
The replacement p articipant may  begin dosing at the subsequent dose level for that panel, 
based on investigator and Sponsor review and discussion.
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study  protocol.
Clinical supplies , MK -8189 and matching placebo, will be packaged to support enrollment . 
Clinical supplies will be affixed with a clinical label in accordance with regulatory  
requirements.Â 
Â  059Y88
PRODUCT: MK-8189  63
PROTOCOL/AMENDMENT N O.:007-06 
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
6.1 Study Intervention(s) Administered
The study intervention s to be used in this study areoutlined inTable 1.
Table 1 Study  Intervention s
Arm  
Nam eArm  TypeInter -
vention 
Nam eTypeDose 
FormUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegim en UseIMP/
NIMPSourcing
ActiveExperimental MK-8189 Drug Tablet 4 mg All 
dosage 
levelsOral Panels A, B and 
C: Titration 
period, days 1 -
18
Panel D: 
Titration period, 
days 1 -15Experimental IMP Provided 
centrally
PlaceboPlacebo 
Com paratorMK-8189 Drug Tablet 0 mg All 
dosage 
levelsOral Panels A, B and 
C: Titration 
period, days 1 -
18
Panel D: 
Titration period, 
days 1 -15Experimental IMP Provided 
centrallyÂ 
Â  059Y88
PRODUCT:   MK-8189  64
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
All supplies indicated in Table 1 will be provided per the "Sourcing" row depending upon 
local country  operational requirements. Every  attempt should be made to source these 
supplies from a single lot/batch number. The stud y site is responsible for recording the lot 
number, manufacturer, and expiry  date for an y locally purchased product per local guidelines 
unless otherwise instructed by  the Sponsor.
Refer to Section 8.1.8 for details regarding administration of the study inte rvention.
All placebos were created by  the Sponsor to match the active product.
6.2 Preparation/Handling/Storage/Accountability
Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintai ned during transit for all study intervention received, and an y discrepancies are 
reported and resolved before use of the stud y intervention .
Only  participants enrolled in the study  may  receive study  intervention , and only  authorized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with ac cess limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expiry  date for
any locall y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storag e, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any applicable laws and regulations.Â 
Â  059Y88
PRODUCT:   MK-8189  65
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
6.3 Measures to Minimize Bias: Randomization and Blinding
Intervention Assignment
Participants will be assigned randoml y accor ding to a computer -generated allocation 
schedule in a 3:1 ratio within each Panel .The sample allocation schedules are provided in 
Table 2 ,Table 3 and Table 4.
Table 2 Panel A (health y participants) and Panel B (participants with schizophrenia :
monotherap y)Sample Allocation Schedule
Panel nDays
1-3Days
4- 6Days
7-9Days
10-12Days 
13-15Days 
16-18
Aa12 4 mg 8 mg 12 mg 16 mg 20 mg 24 mg
4 PBO PBO PBO PBO PBO PBO
Bb12 4 mg 8 mg 12 mg 16 mg 20 mg 24 mg
4 PBO PBO PBO PBO PBO PBO
a. Panel A allocation schedule will be stratified to Japanese and non -Japanese participants.  Japanese participants will 
be assigned the lower allocation range (first 8 numbers) and non -Japanese will be assigned the upper allocation 
range (last 8 numbers).  This will allow an equal number of active and placebo within the Japanese and non -Japanese 
participants.
b. Panel B allocation schedule will not be stratified
Table 3 Panel C (participants with schizophrenia ; add- on therapy )Sample Allocation 
Schedule
Panel nDays
1-3Days
4-6Days
7-9Days
10-12Days 
13-15Days 
16-18
C 9 4 mg 8 mg 12 mg 16 mg 20 mg 24 mg
C 3 PBO PBO PBO PBO PBO PBO
Table 4 Panel D ( participants with schizophrenia: monotherap y) Sample Allocation 
Schedule
Panel n Days 1-3 Days 4-6 Days 7-9 Days10-12 Days 13 -15
D 12 8 mg 16 mg 24 mg 36 mg 48 mg
D 8 PBO PBO PBO PBO PBOÂ 
Â  059Y88
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ 6(3
6WUDWLILFDWLRQ
,QWHUYHQWLRQDOORFDWLRQUDQGRPL]DWLRQZLOOEHVWUDWLILHGEDVHG RQHWKQLFLW\IRU3DQHO$
1RVWUDWLILFDWLRQEDVHGRQDJHVH[RURWKHUFKDUDFWHULVWLFVZ LOOEHXVHG IRU3DQHO% 3DQHO&
DQG3DQHO'
%OLQGLQJ
$GRXEOHEOLQGLQJWHFKQLTXHZLOOEHXVHG0.DQGSODFHER ZLOOEHSUHSDUHGDQGRU
GLVSHQVHGLQDEOLQGHGIDVKLRQE\DQXQEOLQGHGSKDUPDFLVWRUTX DOLILHGVWXG\VLWHSHUVRQQHO
7KHSDUWLFLSDQWDQGWKHLQYHVWLJDWRUZKRLVLQYROYHGLQWKHVWX G\LQWHUYHQWLRQDGPLQLVWUDWLRQ
RUFOLQLFDOHYDOXDWLRQRIWKHSDUWLFLSDQWVDUHXQDZDUHRIWKHJ URXSDVVLJQPHQWV
 6WXG\,QWHUYHQWLRQ&RPSOLDQFH$GPLQLVWUDWLRQRIVWXG\PHGLFDWLRQZLOOEHZLWQHVVHGE\WKHLQY HVWLJDWRUDQGRUVWXG\VWDII
 &RQFRPLWDQW7KHUDS\&RQFXUUHQWXVHRIDQ\SUHVFULSWLRQ RUQRQSUHVFULSWLRQPHGLFDWLRQ GXULQJWKHRQJRLQJVWXG\
LHDIWHUUDQGRPL]DWLRQRULQWHUYHQWLRQDOORFDWLRQPXVWILUV WEHGLVFXVVHGEHWZHHQWKH
LQYHVWLJDWRUDQG6SRQVRUSULRUWRDGPLQLVWUDWLRQXQOHVVDSSURS ULDWHPHGLFDOFDUHQHFHVVLWDWHV
WKDWWKHUDS\RUYDFFLQDWLRQVKRXOGEHJLQEHIRUHWKHLQYHVWLJDWR UDQG6SRQVRUFDQFRQVXOW7KH
SDUWLFLSDQWZLOOEHDOORZHGWRFRQWLQXHLQWKHVWXG\LIERWKWK H6SRQVRUDQGWKHLQYHVWLJDWRU
DJUHH
3DUDFHWDPRODFHWDPLQRSKHQDQGDQWDFLGVHJPDJQHVLXPK\GUR[LG HPD\EHXVHGIRUPLQRU
DLOPHQWVZLWKRXWSULRUFRQVXOWDWLRQZLWKWKH6SRQVRU 1RWHIRU SDUWLFLSDQWVLQ3DQHO&WKH
LQYHVWLJDWRUVKRXOGFRQILUPWKHXVHRIDQWDFLGVVKRXOG QRWLQWHUD FWZLWK SDUWLFLSDQWÂ¶V$$3 DV
SHUWKH$$3SUHVFULELQJLQIRUPDWLRQ
)RUSDUWLFLSDQWVZLWKVFKL]RSKUHQLD3DQHO% 3DQHO& DQG3DQHO' PHGLFDWLRQVWRWUHDWPLOG
FKURQLFFRQGLWLRQVVXFKDVK\ SRWK\URLGLVPGLDEHWHV KLJKEORRG SUHVVXUHFKURQLFUHVSLUDWRU\
FRQGLWLRQVRURWKHUPLOGPHGLFDOFRQGLWLRQVDUHDOORZHGGXULQJ WKHVWXG\LIWKHSUHVFULEHG
GRVHDQGUHJLPHQRIPHGLFDWLRQLVVWDEOHIRUDWOHDVWWKUHHPRQ WKVSULRUWRVFUHHQLQJDQGWKHUH
DUHQRH[SHFWHGFKDQJHVLQFRPHGLFDWLRQGXULQJWKHVWXG\0RG HUDWHWRVWURQJLQKLELWRUVRU
LQGXFHUVRI DQGRU DUHQRWDOORZHGDV

,QDGGLWLRQ0.LVDPLOGLQGXFHURI LQ
KXPDQKHSDWRF\WHVDWGUXJFRQFHQWUDWLRQVRIÂ• È0DQGWKHUHIRU HFRPHGLFDWLRQZLWK
VXEVWUDWHVIRU VKRXOGEHDYRLGHG 
)RU3DQHO&RQO\VXEMHFWVZLOOFRQWLQXHWKHXVHRIWKHLUSHUPL WWHG$$3PHGLFDWLRQ LHXVH
RIULVSHULGRQH!PJGD\RUXVHRIFOR]DSLQHLVQRWSHUPLWWHG 
 <CCI CCI CCI
CCI
CCI CCI
PRODUCT:   MK-8189  67
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
For healthy  participants (Panel A) ,no concomitant medication/vaccinations are permitted, 
except for the necessary  treatment of AEs (see also Section 6.5.1 on rescue medication).
Rescue Medications and Supportive Care
For the treatment ofEPS,such asacute dystonia ,all participants may betreated with an
anticholinergic .Ifthesymptoms areunresponsive toanticholinergic treatment, a
benzodiazepine canbeused.
Incase theparticipant presents with signs ofakathisia without signs ofdystonia ,the
participant canbetreated with a Î²-adrenergic blocker .Ifsymptoms do not disappear with
theÎ²-adrenergic blocker ,treatment with ananticholinergic may beused.  An anticholinergic 
may be used as first -line treatment in the case that a Î²-adrenergic blocker is not a preferred 
treatment based on a participantâ€™s medical history  and/or concomitant medication.
Anticholinergics benzodiazepines andÎ²-adrenergic blockers areoften used inthetreatment
ofEPS andareconsidered standard practice .Oral anticholinergic treatment isalso used as
concomitant medication toprevent EPS symptom with antips ychotic medication.
Panel B and Panel D participants will be washed off from their antipsy chotic treatment .  The 
duration of washout period should be at least 5 days or cover at least 3 half -lives of the drug 
(whichever is longer) prior to Day  -1 assessments (this includes any  rescue medication given 
during the washout period) .  During the washout an d treatment period, a benzodiazepine and 
zolpidem may be used to treat withdraw al symptoms . The drugs indicated ab ove should not 
be inhibitors or inducers of CYP3A and CYP2C9 (see Section 6.5 for further details), thus no 
effect on the PK of MK -8189 would be expected during co -administration.   
6.6 Dose Modification (Escalation/Titration/Other)
All dose titration decision s will be made jointly  by the investigator and the Sponsor. Each 
dose titration decision for each individual participant will occur after 3 days of dosing per 
dose level.
Dose titration decisions for each participant will be based on available (as per the SoA) 
safet y variables : VS, 12-lead safet y ECG, laboratory safet y tests ,AEs, C-SSRS , BPRS, and 
EPS evaluations from the previous dose levels . Pharmacoki netic and pharmacod ynamic data 
may be included in the dose titration decisions .
If, as judged b y the Sponsor and investigator, the safet y and tolerability data do not justify 
dose titration, the dose will not be increased as planned. Instead, participants may :
ï‚·Skip a single dose and dosing may  continue at the same dose level or adjusted 
downwards 
ï‚·Receive the same dose level to further explore safety  and tolerability  at that level
ï‚·Receive a lower dose of the study  interventionÂ 
Â  059Y88
PRODUCT:   MK-8189  68
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
ï‚·Dosing may  be stopped
If appropriate medical care necessitates dosing to be stopped or a lower dose given, the
investigator may  do so without consultation with the Sponsor.
Participant discontinuation criteria are outlined in Section 7.
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
The emergency  unblinding call center will use the intervention allocation/randomization 
schedule for the study to unblind participants and to un mask study  intervention identity  . The 
emergency  unblinding call center should only  be used in cases of emergency (see Section 
8.1.11 ). The Sponsor will not provide random code/disclosure envelopes or lists with the 
clinical supplies.
This  study  is blinded but supplies are provided as open label ; therefore, an unblinded 
pharmacist or qualified s tudy site personnel will be used to blind supplies. Study  intervention
identity  (name, strength, or potency ) is included in the label text; random code/disclosure 
envelopes or lists are not provided.
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
Discontinuation of study  intervention does not represent withdrawal from the study .
As certain data on clinical events bey ond study  intervention discontinuation may  be 
important to the study , they  must be coll ected through the participantâ€™s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -specified treatment 
period will still continue to participate in the study as specified in Section 1.3 and Section 
8.1.10, or if available, a protocol clarification lette r.
Participants may  discontinue study  intervention at any  time for any  reason or be discontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study inte rvention by  the 
investigator or the Sponsor if study intervention is inappropriate, the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation a re provided in S ection 8.1. 10.Â 
Â  059Y88
PRODUCT:   MK-8189  69
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
A participant must be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reasons:
â€¢The participant requests to discontinue study  intervention.
â€¢The participantâ€™s treatment assignment has been unblinded by  the investigator, MSD 
subsidiary , or through the emergency  unblinding call center.
â€¢The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor, placed the partic ipant at unnecessary  risk from continued 
administration of study  treatment.
â€¢The participant has a confirmed positive serum pregnancy test.
â€¢The participant has a positive urine drug screen at any time during the course of the 
study .
For participants who are discontinued from study  intervention all applicable discontinuation 
activities will be performed according to Section 8.1.10, or if available, a protocol 
clarification letter.
Discontinuation from study  intervention is â€œpermanent.â€ Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention .
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study  if the participant withdraws consent from the 
study .
If a participant withdraws from the study, the y will no longer receive stud y intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical research, are 
outlined in Section 8.1.10
. The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact the participant 
are outlined in Section 7.3 .
7.3 Lost t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
â€¢The site must attempt to contact the participant and reschedule the missed visit. I fthe 
participant is contacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.Â 
Â  059Y88
PRODUCT:   MK-8189  70
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
â€¢The investigator or designee must make every  effort to regain contact with the participant 
at each missed visit (eg, telephone calls and/or a certified letter to the participantâ€™s last 
known mailing address or locally  equivalent methods). These contact attempts should be 
documented in the participantâ€™s medical record.
â€¢Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines.
8 STUDY ASSESSMENTS AND PROCEDURES
â€¢Study  procedures and their timin g are summarized in the SoA.
â€¢Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
â€¢The investigator is responsible for ensuring that procedures are conducted by 
appropriatel y qualifi ed or trained staff. Delegation of study  site personnel responsibilities 
will be documented in the Investigator Trial File Binder (or equivalent).
â€¢All study -related medica l decisions must be made by  an investigator who is a qualified 
physician .
â€¢All screeni ng evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons f or 
screening failure, as applicable.
â€¢Procedures conducted as part of the participantâ€™s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protoc ol-specified criteria and were performed 
within the time frame defined in the SoA.
â€¢Additional evaluations/testing may  be deemed necessary  by the investigator and or the 
Sponsor for reasons related to participant safet y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accord ance with those regulations.
â€¢The maximum amount of blood collected from each participant over the duration of the 
study will not exceed 500 mL(Appendix 10 ).
â€¢Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues 
with the samples.Â 
Â  059Y88
PRODUCT:   MK-8189  71
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
8.1 Administrative and General Procedures
Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant prior to participating in a clinical 
study or future biomedical r esearch .If there are changes to the participantâ€™s status during the 
study  (eg, health or age of majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place.
8.1.1.1 General Informed Consent
Consent must be documented by  the participantâ€™s dated signature on a consent form along 
with the dated signature of the person conducting the consent discussion.
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committeeâ€™s 
(IRB/IECâ€™s )approval/favorable opinion in advance of use. The participant should be 
informed in a timely  manner if new information becomes available that may be relevant to 
the participantâ€™s willingness to continue participation in the study . The communication of 
this information will be provided and documented via a revised consent form or addendum to 
the original consent form that captures the participantâ€™s dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  qualified designee will explain the future biomedical research 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to the future biomedical research sub study . 
A cop y of the informed consent will be given to the participant.
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator who is a qualified 
physician to ensure that the participant qualifies for the study .Â 
Â  059Y88
PRODUCT:   MK-8189  72
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Participant Identification Ca rd
All participants will be given a pa rticipant identification card identify ing them as participants 
in a research stud y. The card will contain study site contact information (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee wi ll provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a health care provider can obtain information about study 
intervention in emergency situations where t he investigator is not available.
Medical History
A medical history  will be obtained by  the investigator or qualified designee. This should also 
include an y psychiatr ic history  of the participant.
Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qualified designee will review prior medication use, including an y 
protocol -specified washout requirement, and record prior medication taken by  the participant 
within 14 day s before starting the stud yfor Panel A (health y participant s)and within 
3months of starting the study  for Panel B ,Panel C and Panel D (participant s with 
schizophrenia) .  Use of any  prescription or nonprescription medication during the washout 
period of Panel B and Panel D should first be discussed between the inve stigator and 
Sponsor, unless appropriate medical care necessitates that therap y or vaccination should 
begin before the investigator and Sponsor can consult .  Note : medications permitted under 
Section 6.5 of the protocol do not need to be discussed prior to use.
8.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by the participant 
during the stud y.
Washout from Antipsychotics
All participants in Panel B and Panel D will be washed out from their antipsy chotic 
medication prior to Day  -1 Holter assessment.  The washout may  start with a down titration 
of the antipsy chotic treat ment during the screening phase .Â 
Â  059Y88
PRODUCT:   MK-8189  73
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization.Each participant 
will be assigned onl y 1 screening number. Screening numbers must not be re -used for 
different participants.
Any participant who is screened multi ple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.10.1.
Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
Study Intervention Administrati on
Administration of study  medication wi ll be witnessed by  the investigator and/or study  staff.
8.1.9.1 Timing of Dose Administration
MK-8189/ placebo dosing will occur once daily in the morning following an 8 hour fast.  
Participants will receive each oral dose of MK -8189 /placebo with ~ 240mL water.
Discontinuation and Withdrawal
The investigator or study coordinator must notify the Sponsor when a participant has been 
discontinued/withdrawn from the study  and/or intervention. If a participant discontinues for 
any reason at any  time during the course of the study  and/or intervention, the participant may  
be asked to return to the clinic (or be contacted) for a post -study  visit (approximately  14 day s 
after the last dose of study intervention is given) to have the applicable procedures 
conducted. However, the investigator may  decide to perform the poststudy  procedures at the 
time of discontinuation or as soon as possible after discontinuation. If the poststudy  visit 
occurs prior to 14 day s after the last dose of stud y intervention is given, the investigator 
should perform a follow -up telephone call 14 day s after the last dose of study  intervention  to 
determine if an y AEs have occurred since the post -study  clinic visit. Any  AEs that are 
present at the time of discontinuation/withdrawal should be followed in ac cordance with the 
safet y requirements outlined in Section 8.4.Â 
Â  059Y88
PRODUCT:   MK-8189  74
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
8.1.10.1 Withdrawal From Future Biomedical Resear ch
Participants may  withdraw their consent for future biomedical research. Participants may  
withdraw consent at an y time by  contacting the principal inve stigator for the main study . If 
medical records for the main study  are still available, the investigator will contact the 
Sponsor using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently ,the participant's consent for future biom edical r esearch will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility  of the investigator to inform the participant of completion of withdrawal. An y 
analyses in progress at the tim e of request for withdrawal or alread y performed prior to the 
request being received by the Sponsor will continue to be used as part of the overall research 
study  data and results. No new analys es would be generated after the request is received.
In the ev ent that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longer be a l ink between 
the participantâ€™s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed. 
Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NEC ESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the drug used by  a participant and/or the dosage 
administered, he/ she will contact the emergency  unblinding call center by t elephone and 
make a request for emergency  unblinding. As requested by  the investigator or medicall y 
qualified designee , the emergency  unblinding call center will prov ide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contacting the emergency  
unblinding call center to request unblinding of a participantâ€™s treatment assignment, the 
investigator who is qualified phy sician should make re asonable attempts to enter the intensit y
of the AEs observed, th e relation to study  drug , the reason thereof, etc., in the medical chart. 
If it is not possible to record this assessment in the chart prior to the unblinding, the 
unblinding should not be del ayed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may  be unblinded so that the appropriate follow -up medical care can be 
provided to the participant.Â 
Â  059Y88
PRODUCT:   MK-8189  75
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Participants whose treatment assignment has been unblinded by the investigator or medicall y 
qualified designee and/or non study  treating ph ysician must be discontinued from study  
intervention, but should continue to be monitored in the study.
Domicili ng
Participants in Panel A will report to the CRU on Day  -2 prior t o the scheduled day  of stud y 
intervention administration on Day  1.Participants in Panel B and Panel D will be confined to 
the CRU within a week of beginning their antipsychotic washout and at least 6 day s prior to 
treatment with MK -8189 on Day  1. Participants in Panel C will report to the CRU on Day  -1
prior to the scheduled day of stud y intervention administration on Day 1 .All participants in 
Panel A, Panel B and Panel C will remain in the CRU until Day 21 (72 hours following the 
last dose ). Part icipa nts in Panel D will remain in the CRU until Day  18(72 hours following 
the last dose) .At the discretion of the investigator, participants may  be requested to remain in 
the CRU longer .
Participants may  be permitted to leave the unit, for emergency  situations only , during the 
domiciling period at the discretion of the investigator after discussion with the Sponsor. The 
decision how to monitor the participant will be at the discretion of the investigator after 
discussion w ith the Sponsor.
Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or effica cy parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
8.2 Efficacy/Immunogenicity Assessments
There are no direct efficacy or immunogenicity  assessments in this study . 
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood to be drawn over the course of the study  (from prestudy  
to poststudy  visit s), including approximate blood volumes drawn by visit and by  sample t ype 
per particip ant, can be found in Section 10.10.
Planned time points for all safety assessments are provided in the SoA.Â 
Â  059Y88
PRODUCT:   MK-8189  76
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Physical Examinations
A complete ph ysical examination will be conducted by an investigator or medically  qualified 
designee (consistent with local requirements) as per institutional standard . Height and weight 
will also be measured and recorded.
Investig ators should pay  special attention to clinical signs related to previous serious 
illnesses.
Body Mass Index (BMI)
Body Mass Index equals a person's weight in kilograms divided by heig ht in meters squared 
(BMI=kg/m2 ). Bod y Mass Index will be rounded to the nearest whole number according to 
the standard convention of 0.1 -0.4 round down and 0.5 -0.9 round up.
Body weight and height will be obtained with the participantâ€™s shoes off and jacket or coat 
removed.
Vital Signs
â€¢Oral temperature, pulse rate, respiratory rate, and BPwill be assessed at prespecified 
timepoints noted in the SoA (Section 1.3) .
â€¢Blood pressure and pulse measurements will be assessed semi -recumbent with a 
completely  automated device. Manual techniques will be used only  if an aut omated 
device is not available.
8.3.3.1 Resting Vital Signs
Vital Sign Measurements (Heart Rate and Blood Pressure)
Participants should be resting in a semi -recumbent for at least 10 minutes prior to having VS 
measurements obtained. Semi -recumbent will include HR and BP. The correct size of the BP 
cuff and the correct positioning on the participants' arm is essential to increase the accuracy 
of BP measurements.
The predose (baseline) HR and BP will be in triplicate measurements, obtained at least 1 -2 
minutes apart on Day  -1 as p er the SoA . The mean of these measurements will be used as the 
baseline to calculate change from baseline for safety evaluations (and for rechecks, if 
needed). Postdose VS measurements will be single measurements.
8.3.3.2 Body Temperature
Body temperature will be measured. The same method must be used for all measurements for 
each individual participant and should be the same for all participants.Â 
Â  059Y88
PRODUCT:   MK-8189  77
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
8.3.3.3 Orthostatic Vital Signs
Orthostatic VS (HR and BP) will also be obtained. Participants should be semi -recumbent for 
at least 10 minutes and then stand upright after the resting vitals for approximately  3minutes 
prior to measurement of orthostatic VS.
Electrocardiograms
12-L ead Safet y Electrocardiogram
Special care must be taken for proper lead placement b y qualified personnel. Skin should be 
clean and dry  prior to lead placement. Participants may  need to be shaved to ensure proper 
lead placement. Female participants may  need to remove interfering garments.
Participants should be resting in the semi -recumbent for at least 10 minutes prior to each 
ECG measurement.
The correction f ormula to be used for QTc is Fri dericia.
If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in 
place or mark the position of the electr odes for subsequent ECGs. To mark the position of the 
electrodes, 12 -lead electrode sites will be marked on the skin of each participant with an 
ECG skin marker pen to ensure reproducible electrode placement.
In all Panels, b aseline ( prior to Day  1 dosing )ECGs will be obtained in triplicate at least
1-2minutes apart as per the SoA .The mean of these measurements will be used as the 
baseline to calculate change from baseline for safety  evaluations (and for rechecks, if 
needed). 
In Panels A , Band D , postdose ECG measurements will be single measurements. In Panel C, 
postdose ECG measurements will be obtained in triplicate at least 1 -2 minutes apart as per 
the SoA.
During each treatment period, if a participant demonstrates an increase in QTc interval â‰¥60 
msec compared with mean predose baseline measurement, the ECG will be repeated twice 
within 10minutes (applies to Panel s
A, Band D only as Panel C will have triplicate post 
dose ECG evaluations) . The mean value of the QTc interval from the 3 ECGs will repr esent 
the value at that time point. I f the mean QTc interval increase from baseline for an y postdose 
time point is â‰¥60 msec, the participant will continue to be monitored b y repeat 12 -lead ECGs 
every  15 minutes for at least 1 hour or until the QTc is withi n 60 msec of baseline. If 
prolongation of the QTc interval â‰¥60 msec persists, a consultation with a study  cardiologist 
may be appropriate and the Sponsor should be notified.
If the mean QTc interval is ï‚³500 msec, the Sponsor should be notified, and the ECG s should 
be reviewed b y a cardiologist. The participant should be telemetry -monitored (until the QTc 
is <500 msec) or should be considered for transfer to a location where closer monitoring and 
definitive care ( e.g., a cardiac or intensive care unit) is available.Â 
Â  059Y88
PRODUCT:   MK-8189  78
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
If the participant has unstable hemod ynamics, or has an y clinicall y significant dysrh ythmias 
noted on telemetry , the participant should be immediatel y transferred to an acute care setting 
for definitive therap y.
If prolongation of the QTc is noted, concomitant medications that prolong QTc should be 
held until the QTc is within 60 msec of baseline and the QTc is <500 msec.
A study  cardiologist will be consulted b y the Principal I nvestigator as needed to review ECG 
tracings with abnormalities.
24-Hour Holter Assessment (Panel A ,Panel B and Panel D only)
For the entire 24- hour Holter recording duration, participant s should not wear metal jewelry  
such as watches, necklaces, and/or bracelets from the waist up. P articipant s must also not use 
electronic devices such as cell phones, computers/laptops, MP3 play ers, etc. during Holter 
recording. Holter recording will be turned on approximately  30minutes prior to trial drug 
administration in each trial period. Participants will not be allowed to shower/bath for the 
duration of the 24 -hour Holter assessment.
Holter data will be extracted (in triplicate) and analy zed by  a blinded core ECG laboratory  
according to a pre -specified algorithm. To minimize artifacts, participants must rest quietly  in 
a semi -recumbent positio n 
for ~10 minutes prior to the time points specified for extraction. 
No other study  assessments or procedures should occur during the resting period.
Please see Trial Procedures Manual for Holter -specific procedures provided by  the ECG
vendor .
Procedures for transfer , archiving, and review of ECGs will be specified b y the ECG vendor.
Pregnancy Testing
Female subjects of childbearing potential will be tested for serum and/or urine Î²-hCG at 
specific timepoints outlined in the SoA .  In the case of a positive or borderline serum Î² -hCG 
pregnancy  test at the pre -trial (screening) visit, the subject must not enter the trial; in the case 
of a positive or borderline urine Î²-hCG pregnancy test during the trial, a serum Î²-hCG
pregnancy  test will be required .  If the pregnancy  has been confirmed the subject must be 
discontinued from the trial immediately  and the pregnancy  must be reported to the Sponsor 
as outlined in Section 8.4.5.   
Clinical Safety Laboratory Assessments
â€¢Refer to Appendix 2for the list of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency .Â 
Â  059Y88
PRODUCT:   MK-8189  79
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
â€¢The investigator or medically  qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and rec ord any  clinically  
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not asso ciated with the 
underly ing disease, unless judged b y the investigator to be more severe than expected for 
the participant's condition.
â€¢All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the procedur esmanual and the SoA .
â€¢If laboratory  values from nonprotocol specified laboratory  assessments performed at the 
institutionâ€™s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
â€¢For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 14 day s after the last dose of stud y intervention , every  
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by the investigator .
Suicidal Ideation and Behavior Monitoring
8.3.7.1 Clinical Assessments for Suicidal Ideation and Behavior Monitoring
Suicidal ideation and behavior will be prospectively assessed during this study using the 
C-SSRS. The C -SSRS should be administere d by trained raters at the time points indicated in 
the S oA. In addition, C -SSRS will be administered at an y unscheduled visit where safet y 
assessments are performed. The C -SSRS will not be routinely  administered at visits with a 
sole purpose of PK sampling and/or witnessed study  intervention administration. Site staff
should review the con tents of the C -SSRS for complete ness. If the C -SSRS is administered 
by someone other than the investigator, consider providing the completed C -SSRS to the 
investigator for review, prior to their assessment of the participant and to fu rther inform their 
evaluation. The C-SSRS is not explicit about whether the participant specifically  has ideation 
at the time of screening. If a participant reports a prior history of ideation/behavior at 
screening, the assessor should also inquire and document if this is also present at the time of 
the screening visit.
Participant s who at an y time during this study report suicidal ideation or behavior that is 
considered to be an adverse event, either between visits or during visit interviews, must be 
assessed by the Investigator.  Participant s who report suicidal ideation with intent, with or 
without a plan or method (i.e., a positive re sponse to items 4 or 5 in the assessment of 
suicidal ideation on the C -SSRS) or suicidal behavior must be evaluated that day by a 
psychiatrist or other trained mental health professional who is a licensed psychologist, social 
worker or mental health nurse practitioner (or comparable professional qualification in 
countries outside of the United States).  Only  participant s whose suicidal ideation is passive, 
who expressly  deny any intent to act, and who, after evaluation, are not judged to be at Â 
Â  059Y88
PRODUCT:   MK-8189  80
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
serious risk for self -harm during the course of the study  may  continue in the study ; others 
must be discontinued from study  participat ion and receive appropriate clinical follow -up care 
to ensure their safety.  In addition, all AEs of suicidal ideation or behavior must be recorded 
as an Event of Clinical Interest (see Section 8.4.7).  Sites are to designate which health care 
professional s are to be responsible for acute care on -site and to specify  referral center(s) to be 
used for further evaluation .
Monitoring for Extrapyram idal Symptoms
The  investigator  or  qualified  designee  will  complete  the  BARS , AIMS and SAS   at  
times specif ied in the SoA. Additional assessments at unscheduled times outside of the SoA 
willbe conducted by study  staff if it is observed or a participant reports complaints of 
dystonia and or akathisia .
Assessment of Neuropsychological Effects
Fortheassessment ofthepsychological effects ,allparticipants will complete theVAS
attimes specified inSoA. Prior totheinitial administration of the VAS participant s will be 
trained bystudy  staff and will practice the assessment.
Inaddition, participant s with schi zophrenia will also complete the BPRS at timesspecified in 
SoA.
A General Neurological Exam will be performed at the Screening and Baseline visitsfor all
participants. A targeted Neurological Exam will be administered at times specified in the 
SoA. Details of the neurological examinations are in Appendix 11 and Appendix 12 .
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
asses sing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  the participant 
(or,when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
representative).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as o ther reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3 .
The investigator, who is a qualified ph ysician, will assess events that meet the definitio n of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .Â 
Â  059Y88
PRODUCT:   MK-8189  81
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable s afety  events that occur after the consent form is signed 
but before treatment allocation/randomization, must be reported b y the investigator for 
randomized participants only  if the event is the result of a protocol -specified intervention, 
including but not limited to washout or discontinuation of usual therap y, diet, placebo 
treatment, or a procedure.
From the time of treatment allocation/randomization through 14 day s following cessation of 
treatment, all AEs, SAEs and other reportable safety  events must be reported by  the 
investigator.
Additionally , any SAE brought to the attention of an investigator an y time outside of the time 
period specified in the previous paragraph also must be reported immediately to the Sponsor 
if the event is considered drug-related.
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study , and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be rec orded and 
reported to the Sponsor or designee within the time frames as indicated in Table 5 .Â 
Â  059Y88
PRODUCT:   MK-8189  82
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Table 5 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -Specified 
Follow -up PeriodReporting Time Period :
After the Protocol 
Specified Follow -up 
PeriodTimefram e to 
Report Event 
and Follow -up 
Information to 
SPONSOR:
Non-Serious 
Adverse Event 
(NSAE) Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -
in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE) 
including Cancer 
and OverdoseReport if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -
in treatmentReport all Report if:
-drug/vaccine related.
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported â€“
Follow  to 
completion/termination; 
report outcomeWithin 24 
hours of 
learning of 
event
Event of Clinical 
Interest (require 
regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-Potential DILI
-Require 
regulatory 
reportingNot required Within 24 
hours of 
learning of 
event
Event of Clinical 
Interest (Do not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within 5 
calendar days 
of learning of 
eventÂ 
Â  059Y88
PRODUCT:   MK-8189  83
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, events of clinical interest (ECI), 
cancer, and overdose will be followed until resolution, stabilization, until the event is 
otherwi se explained, or the participant is lost to follow -up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonserious AEs that occur in 
randomized participants for outcome. Further information on follow -up proced ures is given 
in Appendix 3.
Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safet y of participants an d the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs will be reported to regulatory  authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidelines for 
Good Clinical Practice [GCP] ).
Investigator safety  report s must be prepared for suspected unexpected serious adverse 
reactions (SUSAR s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if appropriate according to local requirements .
Pregnancy and Exposure During Breastfeeding
Although pr egnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the stud y are reportable to th e Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and sti llbirth must be reported as Â 
Â  059Y88
PRODUCT:   MK-8189  84
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Disease -related Events and/or Disease -related Outcomes Not Qualify ing as AEs or SAEs are
not applicable to this study . 
Events of Clinical Interest (ECI s)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical int erest for this study  include: 
1. An overdose of Sponsor's product, as defined in Section 8.5, that is not associated 
with clinical sy mptoms or abnormal laboratory  results.
2. An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X 
the upper limit of normal and, at the same time, an alkaline phosphatase lab value that 
is less than 2X the upper limit of normal, as determined by  way  of protocol -speci fied 
laboratory  testing or unscheduled laboratory  testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that must trigger 
an additional evalua tion for an underl ying etiology. The study  site guidance for 
assessment and follow up of these criteria can be found in the Investigator Study  File 
Binder (or equivalent).
It may  also be appropriate to conduct additional evaluation for an underl ying etiolo gy in the 
setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study  investigators 
and the Sponsor Clinical Director. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study.
3. Suicidal ideation and/or suicidal behavior as reported in the C -SSRS score s, TEAEs 
or an y self -injurious behavior
4. Dystonia
5. New or worsening t ardive dy skinesia
6. QTcF interval of â‰¥500 msec (the average of the three QTcFs will be used)Â 
Â  059Y88
PRODUCT:   MK-8189  85
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
8.5 Treatment of Overdose
The participant has taken (accidentally or intentionally) an y drug administ ered as part of the 
protocol that exceeds the dose as prescribed b y the protocol. I t is up to the investigator or the 
reporting ph ysician to decide whether a dose is to be considered an overdose, in consultation 
with the Sponsor.
8.6 Pharmacokinetics
The decision as to which plasma samples collected will be assay ed for evaluation of PK/ PD
will be collaborativel y determined by the Sponsor ( e.g., samples at lower doses may  not be 
assay ed if samples at higher doses reveal undetectable drug concentrations). If indicated, 
these samples may  also be assay ed and/or pooled for assay  in an exploratory manner for 
metabolites and/or additional PDmarkers .
Blood Collection for Plasma MK -8189
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
the procedures manual .
Urine Collection for MK -8189 and metabolite profiling
Sample collection, storage, and shipment instructions for urine samples will be provided in 
the procedures manual .
8.7 Pharmacodynamics
Pharmacod ynamic parameters , other than QTc and other ECG parameters, will not be 
evaluated in this study .
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from a ll participants as 
specified in the SoA:
ï‚·Blood for Genetic Analysis
Planned Genetic Analysis Sample Collection
The p lanned genetic a nalysis sample will be drawn for CYP2C9 genot yping and for planned 
analysis of the association between genetic variants in D NA and drug response. If the 
IRB/IEC does not approve of the planned anal ysis of the association between DNA variation 
and drug response, or if there is a local law or regulation prohibiting the same, data analysis 
will be limited to CYP2C9 . Leftover extra cted DNA will be stored for future biomedical 
researc h if the participant signs the future biomedical r esearch consent.Â 
Â  059Y88
PRODUCT:   MK-8189  86
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Sample collection, storage, and shipment instructions for planned genetic a nalysis samples 
will be provided in the procedures manual .
8.9 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
â€¢Leftover DNA for future research 
â€¢Leftover main study  plasma from MK -8189 and/or m etabolites assay stored for future 
research
8.10 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
Screening
Within a pproximately  4 weeks prior to treatment allocation/randomization, potential 
participants will be evaluated to determine that they fulfill the entry requirements as set forth 
in Sections 5 .1 and 5.2 .
Participants may  be rescreened after consultation with th e Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. Rescreen 
procedures cannot be conducted the day  prior to treatment allocation/randomization if there 
are Day  -1 procedures planned per protocol.
Treatment Period
Panel A: Healthy  participants that meet selection criteria for enrollment will participate in 
Panel A , 16 participant s in tota l. Participants will report to the CRU on Day -2 to undergo 
procedures in SoA.  
Panel B and Panel D : Participa nts with s chizophrenia thatmeet selection criteria for
enrollment willparticipate inPanel B or Panel D , 16 participants or 20 participants, 
respectivel y, in total. Participants must bewashed outfrom their antipsy choticmedication
foratleast 5 daysprior tothe Day  -1 Holter assessment. Participants willreport totheCRU
within a week of the start of their washout, minimally  on Day  -6.
Panel C: Participants with s chizophrenia thatmeet selection criteria forenrollment will
participate inPanel C, 12 participants in total. Participants will report to the CRU on Day  -1
to undergo procedures in SoA.  
On treatment day s between Day  1and Day 18(Panel A, B and C) or Day  1 and Day  15
(Panel D) , participants will be dosed onc e dail y with MK- 8189/placebo and have procedures Â 
Â  059Y88
PRODUCT:   MK-8189  87
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
complete d per the SoA.   Participants will remain in the unit through Day 21(Panel A, B, C) 
or Day  18(Panel D) procedures and discharged at the discretion of the investigator .
Discontinued Participants Continuing to be Monitored in the Study
At any  point if a participant discontinues from treatment but continues to be monitored in the 
study , a subset of study  procedures specified in the SoA may  be completed at the discretion 
of the investigator and with Sponsor agreement. The subset of study  procedures completed 
will be communicated in a PCL .
Posts tudy
After completion of treatment ,participants in Panel B and Panel D will resume the use of
their own antipsy chotic medication after theDay 18, 48 hour post-dose (Day 20-Panel B) or 
Day 15, 48 hour post -dose (Day  17- Panel D) PKsample hasbeen collected. A phone call 
should occur after 5- 7 day s after CRU discharge to check for any  side effects and medication 
compliance.
All participants will be required to return to clinic approximate ly 14 day s after the last dose 
of study  intervention for the poststudy  visit. I f the post study  visit occurs less than 14 day s 
after the last dose of study intervention, a subsequent follow -up telephone call should be 
made at 14 day s post the last dose of study  intervention to determine if any  AEs have 
occurred since the post study  clinic visit.
8.11 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study , the timing of the ECG extraction from the 24- hour Holter recording , and 
blood sample for MK- 8189 and ECG collection arethe critical procedure s.At any  postdose 
time point, these assessments will be collected close to the exact time point as possible .The 
PK sample should follow immediately  after the Holter extraction is complete.
These procedures will be performed in the following order (below) with regard to the 
prescribed time.  These procedures can be done prior to or after the time point.
1. Holter ECG assessment (extraction period )
2. Resting VS
3. Orthostatic VS
4. Blood for MK- 8189
As a bloo d sample for assessment of MK-8189 plasma concentration , 12-lead safet y ECGs, 
and resting and orthostatic VS are planned at the same timepoint ,the order of execution is as 
follows:
1. 12-l eadsafet yECGÂ 
Â  059Y88
PRODUCT:   MK-8189  88
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
2. Resting VS
3. Orthostatic VS
4. Blood for MK- 8189
All other procedures should be completed as close to the prescribed/scheduled time as 
possible. Study  procedures can be performed prior or after the prescribed/scheduled time.
The order of priorit y can be changed during the study  with joint agreement of the investig ator 
and the Sponsor Clinical Director.
Any nonscheduled procedures required for urgent evaluation of safet y concerns take 
precedence over all routine scheduled procedures.
The following variance in procedure collection times will be permitted.
â€¢Predose sta ndard safet y evaluations: 12-lead safety  ECG swithin 2 hours prior to dosing ; 
laboratory  safet y tests within approximately 48hrsprior to dosing
â€¢Postdose standard safet y evaluations: 12-lead safety  ECG ,and VS
a.Day 1 postdose through Day  18(Panels A, B and C) postdose or Day  1 postdose 
through Day  15 (Panel D) postdose may  be obtained +/ -15 min of the theoretical 
sampling time
b.Day 19 postdose through Day  21(Panels A, B and C) or Day  16 postdose through Day  
18 (Panel D) may be obtained +/ -30 min of the theoretical sampling time
â€¢Postdose laboratory  safety  tests on Day s 1 through 18 may  be obtained:
a.For blood: within -90 minutes from the theoretical sampling time
b.For urine: within -120 minutes from the theoretical sampling time.
â€¢Predose and Postdose ECG Holter extractions may  be obtained -15/+5 minutes from the 
theoretical sampling time.
â€¢PK collections: 
a.May be obtained -5/+10 minutes from the theoretical sampling time.
b.Must be obtained no more than +10 minutes after the end of the ECG Holter extraction
window at each theoretical timepoint .
c.Must NOT be taken prior to the end of the ECG Holter extraction window .Â 
Â  059Y88
PRODUCT:   MK-8189  89
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
d.Must be obtained no more than +15 minutes after the 12 -lead safet y ECG at each 
theoretical timepoint and must be collected following vital sign a ssessments. 
â€¢Study  intervention administration: +/-30 mins
8.12 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of MK- 8189 in humans, and the PK, PD, and safet y profiles of 
the compound are still being elucidated. This protocol is written with some flexibility  to 
accommodate the inherent dy namic nature of Phase 1 clinical studies. Modifications to the 
dose, dosing regimen, and/or clinical or laboratory procedures currentl y outlined may  be 
required t o achieve the scientific goals of the stud y objectives and/or to ensure appropriate 
safet y monitoring of the study participants.
As such, some alterations from the currentl y outlined dose and/or dosing regimen may be 
permitted based on newly available data , but the maximum daily  dose may  not exceed those 
currentl y outlined in the protocol.
ï‚·Repeat of or decrease in the dose and/or titration steps of the stud y intervention 
administered in an y given day /panel.
ï‚·Entire panel may  be omitted .
ï‚·Adjustment of the dosing interval ( e.g., divided doses [BID to QD, QD to BID, TID, or 
vice versa]) .
ï‚·Instructions to take study intervention with or without food or drink may also be modified 
based on newl y available data .
ï‚·Modification of the P K/PDsample processing and ship ping details based on newly 
available data.
ï‚·A single dose may be skipped, and dosing may continue at the same dose level or 
adjusted downwards. 
The PK/ PD sampling scheme currentl y outlined in the protocol may be modified during the 
study  based on newl y available PK or PD data ( e.g., to obtain data closer to the time of peak 
plasma concentrations). If indicated, these collected samples may also be assayed in an 
exploratory  manner for metabolites and/or additional PD markers.
Up to additional 50 mL  of blood may be drawn for safet y, PK, and/or PD analy ses. The total 
blood volume withdrawn from an y single participant will not exceed the maximum allowable 
volume during his/her participation in the entire study (Section 10.10).
The timing of procedures for assessment of safet y procedures ( e.g., VS, ECG, safet y 
laboratory  tests, etc.) may  be modified during the study  based on newl y available data. Â 
Â  059Y88
PRODUCT:   MK-8189  90
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Additional laboratory  safety  tests may  be added to blood samples previously  drawn to obtain 
additional safet y information. These changes will not increase the number of study  
procedures for a given participant during his/her participation in the entire study.
It is understood that the current stud y ma y emplo y some or none of the alterations described 
above. An y alter ation made to this protocol to meet the study  objectives must be detailed b y 
the Sponsor in a letter to the Study  File and forwarded to the investigator for retention. The 
letter may  be forwarded to the I RB/IEC at the discretion of the investigator .
9 STATIS TICAL ANALYSIS PLAN
9.1 Statistical Analysis Plan Summary
This section contains a brief summary  of the statistical anal yses for this trial. Full detail is in 
the Statistical Analy sis Plan (SAP) (Section 9.2).
Safety : Summary  statistics and plots will be genera ted for raw laboratory  safet y tests, 12-lead 
ECGs, and/or VS as well as for change from baseline, as deemed clinicall y appropriate.  
Depending on the safet y parameter, the difference from baseline will either be computed on 
the original scale (raw change f rom baseline) or on the log scale and back -transformed for 
reporting (percent change from baseline). For Panels A, B, and C, Day -1 8hr serves as a 
baseline for post- dose vital sign readings. For Panel D, D ay-1 8hr, 10hr, and 16 hr readings 
willserve as time-matched baseline sfor the corresponding post-dose vital sign readings.
For all panels, summary  statistics and plots will be generated for Barnes Akathisia Rating 
Scale ( BARS ), Abnormal I nvoluntary  Movement Scale (AIMS) and Simpson Angus Scale 
(SAS), Bond and Leader Visual Analogue Scale (VAS ), and Brief Ps ychiatric Rating Scale 
(BPRS ) as well as for change from baseline .  The difference from baseline will be computed 
on the o riginal sc ale (raw change from baseline) .Responses to the C -SSRS will be listed.
PK Summary : 
Panel A ( health y participants: Japanese and n on-Japanese) : Separatel y for each PK 
parameter, individual values of AUC0 -24hr, Cmax, and C24hr at each dose level (and day  
where applicable) will be natural log- transformed and evaluated with a linear mixed effects 
model containing a fixed effect for dose, population ( Japanese, Non -Japanese ), and 
population by  dose and a random effect for subject. 
Panels B and D (schizophrenia participants: monotherap y), Panel C (schizophrenia 
participants: add- on therapy ),:Separatel y for each panel and PK parameter, individual values 
of AUC0 -24hr, Cmax, and C24hr at each dose level (and day  where applicable) will be 
natural log- transformed and evaluated with a linear mixed effects model containing a fixed 
effect for dose and a random effect for subject.  
For each population and PK parameter , geometric means (GM) and corresponding 
ninety -five percent confidence intervals (CI) for each dose will be provided.Â 
Â  059Y88
PRODUCT:   MK-8189  91
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Cardiody namic Anal ysis:  
The exploratory  objective pertaining to QTc will be evaluated through development of a 
model describing the relationship between MK- 8189 plasma concentrations and QTc change 
from ba seline.  Separate models may  be evaluated for each population . Details of t he 
concentration- QTc analysiswill be specified in a separate modeling anal ysis plan 
(MAP). This MAP will be completed prior to unblinding and database lock.   Results of this 
analysis will be reported separately  from the CSR.
9.2 Responsibility for Analyses
The statistical anal ysis of the data obtained from this study  will be conducted by , or under the 
direct auspices of, the Early Clinical Development Statistics Department in collabora tion 
with the Quantitative Pharmacology  and Pharmacometrics Department and Translational 
Pharmacology  Department of the Sponsor.
If, after the stud y has begun, changes are made to the statistical anal ysis plan stated below, 
then these deviations to the pla n will be listed, along with an explanation as to why  they  
occurred, in the Clinical Study  Report.
9.3 Hypotheses/Estimation
Objectives:
To evaluate the safet y and tolerability  of rising multip le once -daily oral doses of MK -8189 in 
participants with schizophrenia (monotherap y and add -on)and healthy  Japanese and non -
Japanese participants
To estimate the pharmacokinetics for MK -8189 following multiple once -daily  oral doses in 
participants with schizophrenia (monotherap y and add -on)and in healthy  Japanese and 
non-Japanese participants
To evaluate the effect of MK -8189 concentrations on QTc interval and other ECG 
parameters
9.4 Analysis Endpoints
Primary  Endpoints
Safety :Primary  safet y endpoints will include all ty pes of adverse experience s, in addition to 
laboratory  safet y tests, 12-lead ECGs, and VS. Baseline is defined as day  1 predose (Day  -1 
for VS) reading . 
BARS , AIMS, SAS, VAS and BPRS for all participants. The Columbia Suicide Severit y 
Rating Scale (C -SSRS) will be used to sy stematically  and prospectivel y ascertain and 
document the occurrence of suicidal events (i.e., ideation and behavior). Responses on the 
C-SSRS are classified according to 11 prespecified categories as described in procedure 
manual .The most severe treatment -emergent ideation and behavior event reported at a visit Â 
Â  059Y88
PRODUCT:   MK-8189  92
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
will be used for analy sis and reporting. An event is considered treatment -emergent during the 
assessment phase if it newly  eme rged or is more severe compared to recent history  (i.e., 
protocol -defined recent history  prior to entering the trial as stated in the Inclusion/Exclusion 
criteria for suicidal ideation/behavior, up to and including the randomization visit).
Secondary  Endpo ints
Pharmacokinetics: The PKvariables MK- 8189 ( AUC0- 24hr, Cmax, C24hr, Tmax, CL, Vd 
andt1/2)areof secondary interest.
Exploratory  Endpoints
Cardiody namics: QTc change from baseline (Holter ECGs for Panels A, B, and D and 
triplicate 12- lead safet y ECG measurements for Panel C ), HR, RR interval, PR interval, and 
QRS duration .U and T wave morphology are of exploratory  interest
9.5 Analysis Populations
The following populations are defined for the analysis and reporting of data.  All participants
will be reported, and their data analy zed, according to the treatment(s) they actuall y received. 
All Participants as Treated (APasT): The All Participants as Treated Population consists of 
allparticipants who received at least one dose of treatment .  This population will be used for 
assessments of safety  and tolerability .
Per-Protocol (PP) : The Per -Protocol Population consists of t he set of data generated by the 
subset of participants who comply  with the protocol sufficiently  to ensure that these data wi ll 
be likely  to exhibit the effects of treatment, according to the underl ying scientific model. 
Compliance covers such considerations as exposure to treatment, availability of 
measurements and absence of important protocol deviations .  Important protocol deviations 
will be identified to the extent possible prior to unblinding by individuals responsible for data 
collection/compliance, and its analysis and interpretation.  An y participants or data values 
excluded from anal ysis will be identified, along with their reason for exclusion, in the CSR.  
At the end of the stud y, all participants who are compliant with the study procedure as 
aforementioned and have available data from at least one treatment (dose level) will be 
included in the Per -Protocol dataset. This population will be used for the PK and 
Concentration- QTc analyses.
9.6 Statistical Methods
Safety 
Summary  statistics and plots will be generated for raw laboratory  safet y tests, 12-lead ECGs, 
and/or VS as well as for change from baseline, as deemed clinic ally appropriate.  Depending 
on the safet y parameter, the difference from baseline will either be computed on the original 
scale (raw change from baseline) or on the log scale and back -transformed for reporting 
(percent change from baseline). Â 
Â  059Y88
PRODUCT:   MK-8189  93
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
For all pane ls, summary  statistics and plots will be generated for BARS , AIMS ,SAS, VAS , 
and BPRS as well as for change from baseline .  The difference from baseline will be 
computed on the original sc ale (raw change from baseline) .Responses to the C -SSRS will be 
listed.
Pharmacokinetics
Model -Based PK Summary  
The PK parameters in healthy  (Panel A),and schizophrenia ( Panels B, C , and D ), will be 
evaluated separately  as variability  in PK parameters in schizophrenia participants may  differ 
from those in the health y participants and these panels also differ in the day when the PK are 
collected. Furthermore , the PK parameters in Panel B andDwill be evaluated separatel y as 
these panels differ in the day  when the PK data are collected.
Panel A ( health y participants: Japanese and non -Japanese): Separatel y for each PK 
parameter, individual values of AUC0 -24hr, Cmax, and C24hr at each dose level (and day  
where applicable) will be natural log- transformed and evaluated with a linear mixed effects 
model containing a fixed effect for dose, population ( Japanese, Non -Japanese ), and 
population by  dose and a random effect for subject. Kenward and Roger's method will be 
used to calculate the denominator degrees of freedom for the fixed effects.   For each 
population, ninety -five percent CIsfor the least squares means for each dose will be 
constructed on the natural log scale and will reference the t -distribution. Exponentiating the 
least-squares means, and lower and upper limits of these CIswill y ield estimates for th e 
population GMs and CI sabout the GMs on the original scale.
Panels B and D (schizophrenia participants: monotherap y), Panel C (schizophrenia 
participants: add- on therapy ), ):Separately  for each panel and PK parameter, individual 
values of AUC0 -24hr, Cma x, and C24hr at each dose level (and day  where applicable) will 
be natural log -transformed and evaluated with a linear mixed effects model containing a 
fixed effect for dose ,and a random effect for subject.  Geometric means (GM) and 
corresponding 95% CIs for each dose will be provided.
Descriptive Statistics 
For each panel i ndividual values will be listed for each PK parameter AUC 0-24hr, Cmax, 
C24hr, Tmax, CL , Vd, and t1/2 by dose (and day  where applicable) , and the following (non-
model -based) descriptive statistics will be provided: N (number of participants with non-
missing data), arithmetic mean, standard deviation, arithmetic  percent CV (calculated as 
100x standard deviation/arithmetic mean), median, minimum, maximum, GM, and 
geometric percent CV (ca lculated as  100 x sqrt( exp(s2) -1), where s2is the observed 
variance on the natural log -scale).Â 
Â  059Y88
PRODUCT:   MK-8189  94
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
General
For the above PK analy ses, d ata will be examined for departures from the assumptions of the 
statistical model(s) as appropriate; e.g., heteroscedasticity , nonnormalit y of the error terms.  
Distribution- free methods may  be used if a serious departure from the assumptions of the 
models(s) is observed, or suitable data transformations may be applied.
Cardiody namic Anal ysis 
The exploratory  objective pertaining to QTc will be evaluated through development of a 
model describing the relationship between MK- 8189 plasma concentrations and QTc change 
from baseline.  Separate models may  be evaluated for each population. Details of t he 
concentration- QTc anal ysis will be specified in a separate modeling anal ysis plan 
(MAP). This MAP will be completed prior to unblinding and database lock.   Results of this 
analysis will be reported separately  from the CSR.
9.7 Interim Analyses
No interim anal ysis isplanned .
9.8 Multiplicity
No multiplicity  adjustments are needed, as there are no h ypotheses.
9.9 Sample Size and Power Calculations
Since there are no h ypotheses, no power calculations are provided. For evaluation of the 
relationship between QTc and plasm a concentrations, t he number of dose levels being 
evaluated and the number of subjects on each treatment is consistent with those deemed to be 
adequate in the Scientific White P aper on Concentration- QTc Modeling [Mehrotra, D. V., et 
al 2017] .Â 
Â  059Y88
PRODUCT:   MK-8189  95
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator- initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigativ e sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to asses s the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues Â 
Â  059Y88
PRODUCT:   MK-8189  96
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it condu ctsthat are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underp owered and the analyses complicated by statistical issues such as multiplicity.
MSDâ€™s policy on authorship is consistent with the re commendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should ref lect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will b e acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except 
changes required urgently to prot ect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the participant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All p articipation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or representative), ethics committee, and/or regulatory authorities will have 
access to confidential medical records t hat might identify the participant by name.
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics c omm ittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SDâ€™s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referral s. However, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants.Â 
Â  059Y88
PRODUCT:   MK-8189  97
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted abo ve, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be 
consist ent with local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SDâ€™s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulati ons, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accordance with 21
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this inf ormation on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Data Protection
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred t o the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authori zed personnel appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities.Â 
Â  059Y88
PRODUCT:   MK-8189  98
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2 Confidentiality of P articipant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  signing the consent form, the participant agrees 
to this process. If stud y documents will be photocopied during the process of verifying 
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining rec ords of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
Publication Policy
The results of this study  may  be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordance with 
standard editorial and ethical practice, the Sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual s ite data. I n this case, a 
coordinating investigator will be designated b y mutual agreement.
If publication activity is not directed b y the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary  information and to provide comments.  
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements.Â 
Â  059Y88
PRODUCT:   MK-8189  99
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whe ther the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information nec essary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue p articipation b y calling a central contact number for further 
information on appropriate study  locations and study  site contact information.
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study  or its results to those 
registries. 
Compliance with Law, Audit, and Debarmen
By signing this protocol, the investigator agrees to conduct the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally  
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations sponsored b y MSD, is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conduct ing or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsorâ€™s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the s tudy is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigatorâ€™s knowledge, threatened.Â 
Â  059Y88
PRODUCT:   MK-8189  100
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted t o the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
physicall y or electronically signing the CRF.
Detailed information regarding D ata Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of th e Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponso r.
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigatorâ€™s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.Â 
Â  059Y88
PRODUCT:   MK-8189  101
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor will 
promptly  notify  that study  siteâ€™s IRB/IEC.Â 
Â  059Y88
PRODUCT:   MK-8189  102
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.2 Appendix 2: Clinical Laboratory Tests
â€¢The tests detailed in Table 6will be performed b y the local laboratory .
â€¢Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5of the protocol.
â€¢Additional tests may  be performed at an y time during the stud y as determined necessary  
by the investigator or required by  local regulations.
â€¢Pregnancy  testing:
-Pregnancy  testing requirements for study  inclusion are described in Section 5.1.
-Pregnancy  testing (urine or serum as required b y local regulations) should be 
conducted at the end of relevant s ystemic exposure and correspond with the time 
frame for female participant contraception in Section 5.1.
-Additional serum or urine pregnancy  tests may  be performed, as determined 
necessary  by the investigator or required b y local regulation, to establish the 
absence of pregnancy  at any  time during the subject's participation in the study .
Table 6 Protocol -required Safet y Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hem atology Platelet Count WBC count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hem oglobin
Hem atocrit
Chemistry Blood Urea 
Nitrogen (BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -Oxaloacetic 
Transaminase (SGOT)Total bilirubin 
(and direct 
bilirubin, if total 
bilirubin is 
elevated above 
the upper limit 
of normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase (SGPT)Total Protein
Glucose (fasting) Calcium Alkaline phosphatase
Routine Urinalysis Specific gravity
pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by dipstick
Microscopic examination (if blood or protein is abnormal)Â 
Â  059Y88
PRODUCT:   MK-8189  103
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Laboratory 
AssessmentsParameters
Other Screening 
TestsFollicle -stimulating hormone (as needed in women of non childbearing potential 
only)
Urine alcoho l, cotinine (Panel A only) and drug screen (to include at minimum: 
amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiaz epines ; If 
the clinical site's drug screen evaluation routinely detects additional agents, the 
relevance of positive findings for exclusion wil l be discussed w ith the Sponsor. )
Serum or urine Î² human chorionic gonadotropin (Î² hCG) pregnancy test (as needed 
for WOCBP)
Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus 
antibody) 
â€¢WBC Differential: absolute or % acc eptab le per institutional standard.
â€¢Creatinine: GFR (measured or calculated) or creatinine clearance can be used in place of creatinine.
NOTES:
The investigator (or medically qualified designee) must document their review of each laboratory safety 
report.
Laboratory/a nalyte results that could unblind the study will not be reported to investigative sites or other 
blinded personnel until the study has been unblindedÂ 
Â  059Y88
PRODUCT:   MK-8189  104
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definition of AE
AE definition
â€¢An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
â€¢NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
â€¢NOTE: For purposes of AE definition, study intervention (also referred to as Sponsorâ€™s 
product) includes an y pharmaceutical product, biological product, vaccine, device, 
diagnostic agent, or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufact ured by , licensed by , 
provided b y, or distributed by the Sponsor for human use in this study.
Events meeting the AE definition
â€¢Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiol ogical scans, vital signs measurements), 
including those that worsen from baseline, or are considered clinicall y significant in the 
medical and scientific judgment of the investigator.
â€¢Exacerbation of a chronic or intermittent pre -existing condition includ ing either an 
increase in frequency  and/or intensity  of the condition.
â€¢New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
â€¢Signs, sy mptoms, or the clinical sequela e of a suspected drug- drug interaction.
â€¢Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
â€¢For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  â€œaccidental or intentional overdose without adverse effect.â€
â€¢Any new cancer or progression of existing cancer.Â 
Â  059Y88
PRODUCT:   MK-8189  105
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Events NOT meeting the AE d efinition
â€¢Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
â€¢Situations in which an untoward medical occurrence did not oc cur (social and/or 
convenience admission to a hospital).
â€¢Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
â€¢Surgery  planned prior to informed consent to treat a p re-existing condition that has not 
worsened.
â€¢Refe r to Section 8.4.6 for protocol -specific exceptions.
Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any unt oward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
â€¢ The term â€œ life-threatening â€in the definition of â€œseriousâ€ refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
â€¢Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary  measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participantâ€™s 
medical history .
d.Results in persistent or significant disability/incapacity
â€¢The term disability  means a substantial disruption of a personâ€™s ability  to conduct 
normal life functions.Â 
Â  059Y88
PRODUCT:   MK-8189  106
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
â€¢This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomit ing, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
â€¢In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
â€¢Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Example s of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.
Additional Events Reported in the Same Manner as SAE
Additional events that require reporting in the same manner as SAE
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to t he Sponsor in the same timeframe as SAEs to 
meet certain local requirements. Therefore, these events are considered serious by the 
Sponsor for collection purposes.
â€¢Is a new cancer (that is not a condition of the study)
â€¢Is associated with an overdose
Record ing AE and SAE
AE and SAE r ecording
â€¢When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory , and diagnostics reports) related to 
the event.
â€¢The investigator will record all r elevant AE/SAE information on the AE 
CRFs /worksheets at each examination.Â 
Â  059Y88
PRODUCT:   MK-8189  107
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
â€¢It is not acceptable for the investigator to send photocopies of the participantâ€™s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
â€¢There may  be instances when copies of medical records for certain cases are requested b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copies of the medical records before submission to the 
Sponsor.
â€¢The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of i ntensity
â€¢An event is defined as â€œseriousâ€ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
â€¢The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable s afety event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort, 
and not interfering with every day activities (for pediatric studies, awareness of
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies, definitely acting like something is wrong).
-Severe: An event that prevents normal everyday  activitie s. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  used for rating the 
intensity  of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely  distressed or unable to do usual activit ies).
Assessment of c ausality
â€¢Did the Sponsor â€™s product cause the AE?
â€¢The determination of the likelihood that the Sponsor â€™s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigatorâ€™s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.Â 
Â  059Y88
PRODUCT:   MK-8189  108
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
â€¢The following components are to be used to assess the relationship between the 
Sponsor â€™s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor â€™s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall yexposed to the 
Sponsor â€™s product such as: reliable history, acceptable compliance assessment (pill 
count, diary , etc.), expected pharmacologic effect, or measurement of drug/metabolite 
in bodily  specimen?
-Time Course: Did the AE follow in a reasonable tem poral sequence from 
administration of the Sponsor â€™s product? I s the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal product)?
-Likely Cause: Is the AE not reasonabl y explained by  another etiol ogy such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor â€™s product discontinued or dose/exposure/frequency  
reduced?
-If yes, did the AE resolve or improve?
-If yes, this is a positive dechallenge.
-If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability ; (2) the AE resolved/improved despite continuation of the Sponsor â€™s 
product; (3) the stud y is a single -dose dru g stud y; or (4) Sponsor â€™s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor â€™s product in this study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability , or (2) the study  is a single -dose drug study; or (3) Sponsor â€™s 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR â€™S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR â€™S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N Â 
Â  059Y88
PRODUCT:   MK-8189  109
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
ADVANCE BY THE SPONSOR CLINI CAL  DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC .
â€¢Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor â€™s product or drug class 
pharmacology  or toxicology ?
â€¢The assessme nt of relationship will be reported on the case report forms/worksheets b y 
an investigator who is a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.
â€¢Use the following scale of criteria as guida nce (not all criteria must be present to be 
indicative of a Sponsor â€™s product relationship).
-Yes, there is a reasonable possibility  of Sponso râ€™s product relationship:
-There is evidence of exposure to the Sponsor â€™s product. The temporal sequence of 
the AE o nset relative to the administration of the Sponsor â€™s product is reasonable. 
The AE is more likel y explained by the Sponsor â€™s product than by  another cause.
-No, there is not a re asonable possibility  of Sponsorâ€™ s product relationship:
-Participant did not rec eive the Sponsor â€™s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor â€™s product is not reasonable OR 
the AE is more likely  explained by  another cause than the Sponsorâ€™s product. 
(Also entered for a participant with overdose without an associated AE.)
â€¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
â€¢There may  be situations in which an SAE has occurred and the investigator h as minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
â€¢The investiga tor may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  assessment.
â€¢The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow-up of AE and SAE
â€¢The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.Â 
Â  059Y88
PRODUCT:   MK-8189  110
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
â€¢New or updated information will be recorded in the CRF.
â€¢The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electronic d ata 
collection t ool
â€¢The primary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
â€¢Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
â€¢If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
â€¢Reference Section 8.4.1  for reporting time requirements.
â€¢The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
â€¢ After the stud y is completed at a given site, the EDCtool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
â€¢If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by telephone (see next section).
â€¢Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
â€¢If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
â€¢In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
â€¢Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
â€¢Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent).Â 
Â  059Y88
PRODUCT:   MK-8189  111
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not a pplicable.Â 
Â  059Y88
PRODUCT:   MK-8189  112
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.5 Appendix 5: Contraceptiv e Guidance
Definitions 
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below):
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
â€¢ Premenarchal
â€¢Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnelâ€™s review of the participantâ€™s 
medical records, medical examination, or medical history interview.
â€¢Postmenopausal fem ale
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
â—¦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of 12 months of amenorrhea, confirmation with two 
FSH measurements in the postmenopausal range is required.
-Females on HRT and whose menopausal status is in doubt will be required to use one 
of the nonhormonal highly effective contraception met hods if they  wish to continue 
their HRT during the study andif HRT use is permitted per protocol . Otherwise, 
they must discontinue HRT to allow confirmation of postmenopausal status before 
study  enrollment.Â 
Â  059Y88
PRODUCT:   MK-8189  113
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
Contraception Requirements
Contraceptives allowe d during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correct ly.
â€¢Progestogen -only subdermal contraceptive implantb,c
â€¢IUSc,d
â€¢IUD
â€¢Bilateral tubal occlusion
â€¢Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional high ly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia can come from the site personnelâ€™s revie w of the participantâ€™s 
medical records, medical examination, or medical histo ry intervie w.
Sexual Abstinence
â€¢Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
aContraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for participants of clinical studies.
bIf locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to 
those which inhibit ovulation.
cMale condoms must be used in addition to the hormonal contraception.
dIUS is a prog estin releasing IUD.
Note: The follow ing are not acceptable methods of contraception:
-Periodic abstinence (calendar, symp tothermal, post -ovulation methods), withdraw al (coitus 
interruptus), spermicides only, and LAM.
-Male condom with cap, diaphragm, or sponge with spermicide.
-Male and female condom should not be used together (due to risk of failure with frictio n).Â 
Â  059Y88
PRODUCT:   MK-8189  114
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1. Definitions
a. Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition .1
b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d. DNA: Deox yribonucleic acid.
e. RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 9will be 
used in various experiments to understand:
â€¢The biology  of how drugs/vaccines work
â€¢Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
â€¢Other pathway s drugs/vaccines may  interact with
â€¢The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtai ned from study ing and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of n ovel treatments targeted to populations 
with the greatest need. All specimens will be used by the Sponsor or those working for or 
with the Sponsor.
3. Summary of Procedures for Future Biomedical Research .
a. Participants for Enrollment
All participants enrolled in the clinical study  will be considered for enrollment in the 
future biomedical research substudyÂ 
Â  059Y88
PRODUCT:   MK-8189  115
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
b. Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study  visit by  the investigator or his or her d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next possible Part icipant Visit. Consent forms 
signed b y the participant will be kept at the clinical study site under secure storage for 
regulatory  reasons.
A template of each stud y siteâ€™s approved informed consent will be stored in the 
Sponsorâ€™s clinical document reposito ry.
c. eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
d. Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtained a t a time when the participant is 
having blood drawn for other study  purposes.
4. Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is criti cal to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participan t characteristics like gender, age, medical history  and treatment outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain any personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube.Â 
Â  059Y88
PRODUCT:   MK-8189  116
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
5. Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by the Sponsor, or an additional third party  (eg, a university  investigator) designated b y 
the Sponsor. The investigator conducting the anal ysis will follow the Sponsorâ€™s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substu dy. Future biomedical r esearch 
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6. Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biomedical research and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contacting the principal investigator for the main study. If medical 
records for the main study are still available, the investigat or will contact the Sponsor 
using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens were collected from study participants 
specificall y for future biomedical r esearch, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Spo nsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required by regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participantâ€™s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to 20 y ears from the end of the main study . Specimens ma y be stored for 
longer if a regulatory  or governmental authorit y has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the study  site will b e shipped to a central laboratory  and then shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
study , the stud y site will ship directly to the Sponsor -designated biorepository . The 
specimens will be stor ed under strict supervision in a limited access facility which Â 
Â  059Y88
PRODUCT:   MK-8189  117
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
operates to assure the integrity of the specimens. Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database .
8. Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laborat ory studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misi nterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and participants. Pa rticipants will not be 
identified by  name in any published reports about this study  or in any  other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and trea ted o n Sponsor 
clinical studies for f uture biomedical r esearch.
11. Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situa tion, there is risk that the 
information, like all medical information, may  be misused.
12. Questions
Any questions related to the future biomedical research should be e mailed directly  to 
clinical.specimen.management@merck.com.Â 
Â  059Y88
PRODUCT:   MK-8189  118
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
13. References
1. National Cancer Ins titute [I nternet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
2. International Conference on Harmonization [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions-
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3. Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
4. Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/Â 
Â  059Y88
PRODUCT:   MK-8189  119
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.7 Appendix 7: Country -specific Requirements
Not applicable.Â 
Â  059Y88
PRODUCT:   MK-8189  120
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.8 Appendix 8: 12-Lead Electrocardiogram Abnormality Criteria
If criteria listed in table below differ from inclusion/exclusion criteria, the most conservative 
criteria should be used.
12-Lead Electrocardiogram Abnormality Criteria
Screen Failure CriteriaPotentially Significant Post -
Randomization Findings 
(clarification on action to take)
RHYTHM
Sinus Tachycardiaï€¾110 beats per minute 
(bpm)HR >110 bpm  and HR increase of â‰¥ 25 
bpm from  baseline
Sinus Bradycardia <40 bpmHR <40 bpm and HR decrease of â‰¥5 bpm 
from baseline
Sinus Pause/Arrest >2.0 seconds >2.0 seconds
Atrial premature complex ï€¾1 beat â‰¥3 beats
Ventricular premature complex All â‰¥3 beats
Ectopic Atrial Rhythm None None
Junctional RhythmJunctional Rhythm with 
HR <40 bpmJunctional Rhythm with HR <40 bpm
Idioventricular Rhythm All All
Atrial Fibrillation All All
Atrial Flutter All All
Supraventricular Tachycardia All All
Ventricular Tachycardia All All
AXIS
Left Axis DeviationRBBB with Left Anterior 
Hem iblock (LAHB)New  onset LAHB
Right Axis DeviationRBBB with Left Posterior 
Hem iblock (LPHB)New  onset LPHB
CONDUCTION
1st degree A- V Block PR â‰¥ 230 msPR â‰¥ 230 ms + increase of ï€¾15 m s; or PR 
increase of >25%
2nd degree A -V Block Mobitz Type II Mobitz Type II
3rd degree A -V Block All All
LBBB   All All
RBBB   RBBB with LAHB/LPHB 
as defined aboveNew  onset RBBB (not including rate -
related)Â 
Â  059Y88
PRODUCT:   MK-8189  121
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
12-Lead Electrocardiogram Abnormality Criteria
Screen Failure CriteriaPotentially Significant Post -
Randomization Findings 
(clarification on action to take)
Incomplete Right BBB 
(ICRBBB) (QRS<120 ms)No exclusion Nothing
Short PR/ Preexcitation syndrome Delta wave + PR <120 ms Delta wave + PR <120 ms
Other Intra -ventricular 
Conduction DelayQRS â‰¥130 m s QRS ï‚³130 ms + increase of ï‚³10 ms
QTc (B or F)
Male QTc â‰¥470 msQTc â‰¥500 ms or increase of â‰¥60 ms from 
baseline
Female QTc â‰¥480 msQTc â‰¥500 ms or increase of â‰¥60 ms from 
baseline
HYPERTROPHY
Atrial abnormalitiesDefinite evidence of P 
mitrale or P pulmonaleDefinite evidence of P mitrale or P 
pulmonale
Ventricular abnormalitiesVoltage criteria for LVH 
plus Strain PatternVoltage criteria for LVH plus Strain 
Pattern
MYOCARDIAL  INFARCTION
Acute or Recent All All
Old All All
ST/T MORPHOLOGY
ST elevation suggestive of 
Myocardial Injury In 2 or more contiguous 
leadsIn 2 or more contiguous leads
ST depression suggestive of
Myocardial Ischaemia In 2 or more contiguous  
leadsIn 2 or more contiguous  leads
T-wave Inversions suggestive of  
Myocardial Ischaemia In 2 or more contiguous  
leadsIn 2 or more contiguous leads
Non-specific ST -T changes 
(In 2 or more leads)No exclusion In 2 or more contiguous leads
PACEMAKER All All
Baseline is defined as Predose Day 1
ms=milliseconds, mm=millimeterÂ 
Â  059Y88
PRODUCT:   MK-8189  122
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory  values obtained at prestud y (screening) visit and/or predose evaluation:
A.If all protocol- specified laboratory  values are normal, the participant may  enter the stud y.
B.If a protocol specified laboratory  value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study .
C.If â‰¥1 protocol -specified laboratory  value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
1.The participant may  be excluded from the study ;
2.The participant may  be included in the study  if th e abnormal value(s) is not clinically  
significant (NCS) (the investigator must annotate the laboratory  value â€œNCSâ€ on the 
laboratory  safet y test source document).
3.The participant may  be included in the study  if the abnormalit y is consistent with a 
pre-existing medical condition which is not excluded per protocol ( e.g., elevated 
eosinophil count in a participant with asthma or seasonal allergies), the medical 
condition should be annotated on the laboratory  report .
OR
4.The abnormal test may  be repeated (refer items a. and b. below for continuation of 
algorithm for repeated values).
a.If the repeat test value is within the normal range, the participant may enter the study.
b.If the repeat test value is still abnormal, the study investigator will evaluate the 
potenti al participant with a complete history and physical examination, looking 
especiall y for diseases that could result in the abnormal laboratory value in question. If 
such diseases can be ruled out, and if the abnormal laboratory value is not clinically 
relev ant, then the participant may  enter the stud y.
D.If there is an y clinical uncertaint y regarding the significance of an abnormal value, the 
participant will be excluded from the stud y.Â 
Â  059Y88
PRODUCT:   MK-8189  123
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.10 Appendix 10: Blood Volume Table
All Panels Pre-trialTreatment 
Period Post-trialTotal 
CollectionsmL Per 
CollectionTotal 
mL/ Test
Laboratory safety tests
(included FSH and 
Î²-hCG )1 4 1 6 12.5 75.0
HIV/Hepatitis Screen 
(at the discretion of 
the investigator)1 1 8.5 8.5
Blood for Planned 
Genetic Analysis  1 1 8.5 8.5
Blood for MK-8189
(Panels A andB)43 43 4.0 172.0
Blood for MK -8189 
(Panel C)35 35 4.0 140.0
Blood for MK -8189 
(Panel D)49 49 4.0 196.0
Total Bloo d Volume Participant (Panels A andB)â€ 264.0 mL
Total Bloo d Volume Participant (Panel C)â€ 232.0 mL
Total Bloo d Volume Participant (Panel D)â€ 288.0 mL
â€ If additional PK and/or safety analysis is necessary, additional blood (up to 50mL) may be 
obtained.  Â 
Â  059Y88
PRODUCT:   MK-8189  124
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.11 Appendix 11: General (Full) Neurological Exam
The General Neurological Examination includes all the modules listed below and is 
intended to be a general screening examination.
MODULE 1 â€“ MENTAL STATUS EXAMINATION
A.General Level of Arousal: Generall y assess general level of alertness, attentiveness, and 
concentration throughout the interview. Regarding attentiveness, note evidence of 
impaired attention or concentration. For example, difficulty  remembering or following 
instructions or distractibility  may  be signs of inattention.
B.Thought Processes and Language: Generally  assess lo gic, relevance, organization and 
coherence of volunteerâ€™s use of language throughout the interview.
C.Orientation (time, place, person)
D.Attention/Concentration
Ask the subject to count backwards from 100 b y 7â€™s (â€œSerial 7â€™sâ€) or ask to recite months 
backwards or spell a 5 unique letter word (e.g. â€œWORL Dâ€) backwards.  
Note : to avoid learning effects, switch between tests throughout the study
E.Memory :   Test registration of 3 objects; then test immediate recall 5 minutes later.
Grade : NORMAL or IMPAIRED and describe abnormality (for each, A to E, 
above).  Normal performance on Serial 7â€™s is getting to 65 with no more than one error. Â 
Â  059Y88
PRODUCT:   MK-8189  125
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
MODULE 2 â€“ CRANIAL NERVE ASSESSMENT
A. IIâ€“Visual Fields and acuity
B. II, IIIâ€“Pupil Size and Reactivity
C. III, IV, VIâ€“Extraocular Movements (range of motion, smooth pursuit, saccades, 
nystagmus)
1.Observe for n ystagmus during ey e movements, increased ny stagmus at the end of gaze 
or other oculomotor changes (mild ny stagmus at extremes of gaze is normal). Note 
direction of nystagmus
D. V â€“Facial Sensation, Jaw Strength
E. VIIâ€“Muscles of Facial Expression (wrinkle brow, squeeze ey es shut, smile)
F. VIII â€“Auditory  Acuity  (assessed using a bed -side screening test e.g. b y rubbing fingers 
on each side of subjectâ€™s head or by whispering numbers)
G. IXâ€“ Gag reflex
H. X â€“Swallow 
I.XIâ€“Shoulder shrug
J. Tongue Protrusion (midline)
Score : left and right (except for G, H, J)
Grade : NORMAL or IMPAIRED and describe abnormalityÂ 
Â  059Y88
PRODUCT:   MK-8189  126
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
MODULE 3 - MOTOR SYSTEM
A.Muscle Tone
1.Askthe volunteer to relax.
2.Flex and extend the volunteerâ€™s elbows and at the knees (bilaterally). 
3.There is a small, continuous resistance to passive movement.
4.Observe for involuntary  movements (e.g., tremor, tics, fasciculations). Observe for 
resistance to passive movement; observe for decreased (flaccid) or increased 
(rigid/spastic) tone.
Score :  left and right
Grade : NORMAL, INCREASED or DECREASED
B.Muscle Strength
1.Ask the subject to stand up from sitting without using hands
Grade: NORMAL, IMPAIRED and describe abnormality
2. Test proximal limb strength b y having the volunteer flex and extend the knees and 
elbows against your resistance.
Test bilaterall y, and compare one side to the other.
Score :  left and right
Grade : 5/5: normal; 
4/5: move ment against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activityÂ 
Â  059Y88
PRODUCT:   MK-8189  127
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
3.Test distal limb strength by having the volunteer conduct dorsiflexion and plantar 
flexion of the volunteerâ€™s feet; finger abduction and handgrip strength against your 
resistance.
Test bilaterall y, and compare one side to the other.
Score :  left and right
Grade : 5/5: normal; 
4/5: movement against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activity
C.Pronator Drift
1.Ask the volunteer to hold bo th arms straight forward with, palms up and eyes closed for 
~10-15 seconds as tolerated; watch for how well the arm position is maintained .
2.Instruct the volunteer to keep both arms still while y ou tap them briskly  downward. The 
volunteer should normally be able to maintain extension and supination. I nability  to 
maintain extension and supination (and drift into pronation) indicates an upper motor 
neuron deficit.
Score :  left and right
Grade : NORMAL or IMPAIRED and describe abnormalityÂ 
Â  059Y88
PRODUCT:   MK-8189  128
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
MODULE 4 - REFLEXES
A.Biceps
B.Knee
Note :Other deep tendon reflexes may be tested at Investigator's discretion (e.g. elbow, 
wrist or Achilles tendon)
Score : left and right
Grade : NORMAL, INCREASED, DECREASED or ABSENT
C.Babinski
Score : left and right
Grade : NORMAL or ABNORMALÂ 
Â  059Y88
PRODUCT:   MK-8189  129
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
MODULE 5 - COORDINATION AND GAIT
A.Rapid, Rhy thmic Alternating Movements
1.Testing each hand separately , ask the volunteer to tap the distal thumb with the tip of 
each finger, in sequence, as fast as possible. 
Score : left and right
Grade : NORMAL or IMPAIRED
Reminder : If the rapid alternate movements are disturbed, the subject will be asked to 
strike his hand on the thigh, raise the hand, turn it over and then strike the back of the 
hand down on the same place.  (This test is impaired in cerebellar disease, extra 
pyramidal disease and upper MN weakness.)
B.Point- to-Point Movements
1.Ask the volunteer to touch y our index finger and their nose alternatel y several times.  
Move y our finger about as the volunteer performs this task.
Score : left and right
Grade : NORMAL or IMPAIRED
Reminder : If the point -to-point testing is disturbed, the subject will be asked to place 
one heel on the opposite knee and then run it down the shin to the big toe.  Repeat this 
for both sides.  (Impaired tests in dicate cerebellar disease.)
C.Romberg
1. Ask the volunteer to stand with both feet together and ey es closed for 20 to 
30seconds without support.
2.Be prepared to catch the volunteer if they  are unstable.
Grade : NORMAL or IMPAIRED
D.Gait
1.Ask the volunteer to walk across the room, turn and come back (assess posture, 
balance, swinging of arms and movement of the legs).
Grade : NORMAL or IMPAIRED and describe abnormality
2.Ask the volunteer to walk heel -to-toe in a straight line (tandem gait).
Grade : NOR MAL or IMPAIRED and describe abnormalityÂ 
Â  059Y88
PRODUCT:   MK-8189  130
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
MODULE 6 - SENSORY
A.Light touch sense :  cotton wisp on skin of forearms and legs, bilaterall y.
B.Pin prick: safety  pin touched lightl y to skin of forearms and legs, bilaterally.
C.Temperature : warm or cool object touched to skin of forearms and legs, bilaterally.
D.Vibration:  tuning fork vibration detection in hands, feet bilaterally.
E.Position sense :  perception of thumb and toe movement, bilaterally.
F.Stereognosis :  (identify  common objects placed in hand, e.g., coin, key ).
Score : left and right
Grade : NORMAL OR IMPAIRED and describe abnormality (for each A to F)Â 
Â  059Y88
PRODUCT:   MK-8189  131
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.12 Appendix 12: Targeted Neurological Exam
The Targeted Neurological Examination , which is intended to focus on tests where drug 
effects can be seen, includes the following tests only :
MODULE 1 â€“ MENTAL STATUS EXAMINATION
A.General Level of Arousal: Generall y assess general level of alertness, attentiveness, and 
concentration throughout the interview. Regarding attentiveness, note evidence of 
impaired attention or concentration. For example difficulty  remembering or following  
instructions or distractibility  may  be signs of inattention)
MODULE 2 â€“ CRANIAL NERVE ASSESSMENT
B. II, III â€“Pupil Size and Reactivity
C. III, IV, VI â€“ Extraocular Mov ements (range of motion, smooth pursuit, saccades, 
nystagmus)
1.Observe for n ystagmus during ey e movements, increased ny stagmus at the end of 
gaze or other oculomotor changes (mild n ystagmus at extremes of gaze is 
normal). Note direction of nystagmus
MODULE 3 - MOTOR SYSTEM
B.Muscle Tone
1.Ask the volunteer to relax.
2.Flex and extend the volunteerâ€™s elbows ( may also move wrists simultaneously ) and at 
the knees (bilaterally). When testing the upper limbs, do this again while the subject 
makes large repetitive movements with the opposite arm (e.g. patting the palm of the 
hand on the knee).
3.There is a small, co ntinuous resistance to passive movement.
Score :  left and right
Grade: NORMAL, IMPAIRED, or DECREASED and describe abnormalityÂ 
Â  059Y88
PRODUCT:   MK-8189  132
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
MODULE 5 - COORDINATION AND GAIT
A.Rapid, Rhy thmic Alternating Movements
1.Testing each hand separately , ask the volunteer to tap the distal thumb with the tip of 
each finger, in sequence, as fast as possible. 
Score : left and right
Grade : NORMAL or IMPAIRED
Reminder : If the rapid alternate movements are disturbed, the subject will be asked to 
strike his hand on the thigh, raise the hand, turn it over and then strike the back of the 
hand down on the same place.  (This test is impaired in cerebellar disease, extra 
pyramidal disease and upper MN weakness.)
D.Gait
2.Ask the volunteer to walk heel -to-toe in a straight line (tandem gait).
Grade : NORMAL or IMPAIRED and describe abnormality
MODULE 6 - SENSORY
A.Light touch sense :  cotton wisp on skin of forearms and legs, bilaterall y.Â 
Â  059Y88
PRODUCT:   MK-8189  133
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
10.13 Appendix 13: Abbreviations
Abbreviation Expanded Term
AAP atypical anti -psychotics
AE adverse event 
AIMS Abnormal Involuntary Movement Scale
BARS Barnes Akathisia Rating Scale
BPRS Brief Psychiatric Rating Scale
CRF case report form 
CRU clinical research unit
C-SSRS Columbia -Suicide Severity Rating Scale 
DILI drug-induced liver injury
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection 
EPS extrapyramidal symptoms
FDAAA Food and Drug Administration Amendments Act
FSH Follicle stimulating hormone 
GCP Good Clinical Practice 
IB Investigatorâ€™s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IND Investigational New Drug 
IRB Institutional Review Board 
NOAEL no observed adverse effect level 
PANSS positive and negative symptoms scale
PK pharmacokinetic
RNA ribonucleic acid
SAE serious adverse event 
SAS Simpson Angus Scale
SoA schedule of activities
SUSAR suspected unexpected serious adverse reaction
UDS urine drug screen
VAS Visual Analogue Scale
WONCBP woman/ women of non -childbearing potential
WOCBP woman/ women of childbearing potential Â 
Â  059Y88
PRODUCT:   MK-8189  134
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
11 REFERENCES
[Bender, A. T. and Beavo, J. 
A. 2006]Bender AT, Beavo JA. Cyclic nucleotide 
phosphodiesterases: molecular regulation 
to clinical use. Pharmacol Rev 
2006;58:488- 520.03RW09
[Department of Public Health 
2006]Department of Public Health. Guidelines 
for the use of at ypical antipsychotics in 
adults. Gasper JJ, Tsai C, editors. San 
Francisco (CA): Department of Public 
Health (SFDPH). 2006 Oct. 18 p.04X0BL
[Eli L illy 1996] US PI : ZYPREZA (olanzapine) Tablet for 
Oral use, ZYPREXA ZYDI S (olanzapine) 
Tablet, Orall y Disintegrating for Oral use, 
ZYPREXA IntraMuscular (ol anzapine) 
Injection, Powder, For Solution for 
Intramuscular use: 1996.03RVZ7
[Garnett, C., et al 2017] Garnett C, Bonate PL, Dang Q, Ferber G, 
Huang D, Liu J, et al. Scientific white 
paper on concentration- QTc modeling. J 
Pharmacokinet Pharmacody n. In pr ess 
2017. Erratum in: J Pharmacokinet 
Pharmacod yn. 2018 Jan 12.04WXDG
[Grauer, S. M., et al 2009] Grauer SM, Pulito VL , Navarra RL, Kell y 
MP, Kelley  C, Graf R, et al. 
Phosphodiesterase 10A inhibitor activity  
in preclinical models of the positive, 
cogniti ve, and negative sy mptoms of 
schizophrenia. J Pharmacol Exp Ther 
2009;331(2):574 -90.03RW0C
[Janssen Pharmaceutical Ltd 
1993]US PI : RISPERDALÂ®(risperidone) 
tablets, RI SPERDALÂ®(risperidone) oral 
solution, RI SPERDALÂ®M -
TABÂ®(risperidone) orally distegrating 
tablets: 1993.03RVZ5
[Mehrotra, D. V., et al 2017] Mehrotra DV, Fan L, Liu F, Tsai K. 
Enabling robust assessment of QTc 
prolongation in earl y phase clinical trials. 
Pharm Stat. 2017;16:218 -27.04XCJJÂ 
Â  059Y88
PRODUCT:   MK-8189  135
PROTOCOL/AMENDMENT N O.:  007 -06  
MK-8189 -007-06FINAL PROTOCOL 09-SEP-2019
[Novartis Pharmaceuticals 
1989]US PI : CLOZARILÂ®(clozapine) Tablets: 
1989.03RVZ3
[Pfizer 2010] U.S. Prescrbing Information: GEODON 
(ziprasidone HCl) capsules; GEODON 
(ziprasidone mesy late) injection for 
intramuscular use: 2010.00VN40
[Schmidt, C. J., et al 2008] Schmidt CJ, Chapin DS, Cianf rogna J, 
Corman ML , Hajos M, Harms JF, et al. 
Preclinical characterization of selective 
phosphodiesterase 10A inhibitors: a new 
therapeutic approach to the treatment of 
schizophrenia. J Pharmacol Exp Ther 
2008;325(2):681 -90.03RW0F
[Seeger, T. F., et al 2 003] Seeger TF, Bartlett B, Coskran TM, Culp 
JS, James L C, Krull DL, et al. 
Immunohistochemical localization of 
PDE10A in the rat brain. Brain Res 
2003;985:113- 26.03RW0G
[U.S. Prescribing Information 
2017]U.S. Prescribing Information: 
SEROQUEL  (quetiapine fumarate) tablets, 
for oral use: 2017.04QZNG
[U.S. Prescribing Information 
2017]U.S. Prescribing Information: ABILIFY 
DISCMELT (aripiprazole) orally 
disintegrating tablets and ABILIFY 
(aripiprazole) tablets, oral solution, 
injection for intramuscular use onl y: 2017.04QZNDÂ 
Â  059Y88